{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from tqdm import tqdm \n",
    "from xml.etree import ElementTree as ET\n",
    "from datetime import datetime\n",
    "import re\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def nctid2path(id):\n",
    "    part = id[:7] + 'xxxx'\n",
    "    name = id + '.xml'\n",
    "    return f'../../raw_data/{part}/{name}'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "All_data = []\n",
    "for i in range(10):\n",
    "    All_data.append(pd.read_csv(f'../../preprocess_data/All_data_part{i}.csv', index_col=0, low_memory=False))\n",
    "    # print(len(All_data[i].columns))\n",
    "    \n",
    "All = pd.concat(All_data)\n",
    "All"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>status</th>\n",
       "      <th>why_stop</th>\n",
       "      <th>label</th>\n",
       "      <th>phase</th>\n",
       "      <th>diseases</th>\n",
       "      <th>icdcodes</th>\n",
       "      <th>drugs</th>\n",
       "      <th>smiless</th>\n",
       "      <th>criteria</th>\n",
       "      <th>complete_year</th>\n",
       "      <th>start_year</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nctid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000102</th>\n",
       "      <td>completed</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 1/phase 2</td>\n",
       "      <td>['congenital adrenal hyperplasia']</td>\n",
       "      <td>[\"['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', ...</td>\n",
       "      <td>['nifedipine']</td>\n",
       "      <td>['COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-]...</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000110</th>\n",
       "      <td>completed</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['obesity']</td>\n",
       "      <td>[\"['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99....</td>\n",
       "      <td>['dietary fat']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000114</th>\n",
       "      <td>completed</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 3</td>\n",
       "      <td>['retinitis pigmentosa']</td>\n",
       "      <td>[]</td>\n",
       "      <td>['vitamin e', 'vitamin a']</td>\n",
       "      <td>['CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2...</td>\n",
       "      <td>\\n        Men and nonpregnant women between ag...</td>\n",
       "      <td>1987.0</td>\n",
       "      <td>1984.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000115</th>\n",
       "      <td>completed</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 2</td>\n",
       "      <td>['macular edema, cystoid']</td>\n",
       "      <td>[]</td>\n",
       "      <td>['acetazolamide']</td>\n",
       "      <td>['CC(=O)NC1=NN=C(S1)S(N)(=O)=O']</td>\n",
       "      <td>\\n        Males and females 8 years of age or ...</td>\n",
       "      <td>1994.0</td>\n",
       "      <td>1990.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000117</th>\n",
       "      <td>completed</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 3</td>\n",
       "      <td>['optic neuritis']</td>\n",
       "      <td>[\"['H46.8', 'H46.9']\"]</td>\n",
       "      <td>['immunoglobulin']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        To be eligible, patients must have a...</td>\n",
       "      <td>1997.0</td>\n",
       "      <td>1995.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263959</th>\n",
       "      <td>recruiting</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 2</td>\n",
       "      <td>['chronic hepatitis b']</td>\n",
       "      <td>[\"['B18.0', 'B18.1', 'B18.2', 'B18.8', 'B18.9']\"]</td>\n",
       "      <td>['gst-hg131', 'placebo to match gst-hg131']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>2024.0</td>\n",
       "      <td>2023.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263998</th>\n",
       "      <td>not yet recruiting</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 1</td>\n",
       "      <td>['xerophthalmia']</td>\n",
       "      <td>[]</td>\n",
       "      <td>['ncp112', 'ncp112 placebo']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>2025.0</td>\n",
       "      <td>2024.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264141</th>\n",
       "      <td>recruiting</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 2</td>\n",
       "      <td>['recurrent acute rhinosinusitis']</td>\n",
       "      <td>[]</td>\n",
       "      <td>['nitric oxide releasing solution']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>2024.0</td>\n",
       "      <td>2024.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264180</th>\n",
       "      <td>not yet recruiting</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 3</td>\n",
       "      <td>['advanced melanoma']</td>\n",
       "      <td>[\"['K74.02', 'G47.22', 'H35.3133', 'H35.3134',...</td>\n",
       "      <td>['single-agent chemotherapy']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...</td>\n",
       "      <td>2029.0</td>\n",
       "      <td>2024.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>not yet recruiting</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1</td>\n",
       "      <td>phase 2</td>\n",
       "      <td>['heart failure', 'worsening heart failure (wh...</td>\n",
       "      <td>[\"['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I...</td>\n",
       "      <td>['placebo', 'r2r01']</td>\n",
       "      <td>[]</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "      <td>2025.0</td>\n",
       "      <td>2024.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>171992 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                         status why_stop  label            phase  \\\n",
       "nctid                                                              \n",
       "NCT00000102           completed      NaN     -1  phase 1/phase 2   \n",
       "NCT00000110           completed      NaN     -1              NaN   \n",
       "NCT00000114           completed      NaN     -1          phase 3   \n",
       "NCT00000115           completed      NaN     -1          phase 2   \n",
       "NCT00000117           completed      NaN     -1          phase 3   \n",
       "...                         ...      ...    ...              ...   \n",
       "NCT06263959          recruiting      NaN     -1          phase 2   \n",
       "NCT06263998  not yet recruiting      NaN     -1          phase 1   \n",
       "NCT06264141          recruiting      NaN     -1          phase 2   \n",
       "NCT06264180  not yet recruiting      NaN     -1          phase 3   \n",
       "NCT06264310  not yet recruiting      NaN     -1          phase 2   \n",
       "\n",
       "                                                      diseases  \\\n",
       "nctid                                                            \n",
       "NCT00000102                 ['congenital adrenal hyperplasia']   \n",
       "NCT00000110                                        ['obesity']   \n",
       "NCT00000114                           ['retinitis pigmentosa']   \n",
       "NCT00000115                         ['macular edema, cystoid']   \n",
       "NCT00000117                                 ['optic neuritis']   \n",
       "...                                                        ...   \n",
       "NCT06263959                            ['chronic hepatitis b']   \n",
       "NCT06263998                                  ['xerophthalmia']   \n",
       "NCT06264141                 ['recurrent acute rhinosinusitis']   \n",
       "NCT06264180                              ['advanced melanoma']   \n",
       "NCT06264310  ['heart failure', 'worsening heart failure (wh...   \n",
       "\n",
       "                                                      icdcodes  \\\n",
       "nctid                                                            \n",
       "NCT00000102  [\"['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', ...   \n",
       "NCT00000110  [\"['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99....   \n",
       "NCT00000114                                                 []   \n",
       "NCT00000115                                                 []   \n",
       "NCT00000117                             [\"['H46.8', 'H46.9']\"]   \n",
       "...                                                        ...   \n",
       "NCT06263959  [\"['B18.0', 'B18.1', 'B18.2', 'B18.8', 'B18.9']\"]   \n",
       "NCT06263998                                                 []   \n",
       "NCT06264141                                                 []   \n",
       "NCT06264180  [\"['K74.02', 'G47.22', 'H35.3133', 'H35.3134',...   \n",
       "NCT06264310  [\"['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I...   \n",
       "\n",
       "                                                   drugs  \\\n",
       "nctid                                                      \n",
       "NCT00000102                               ['nifedipine']   \n",
       "NCT00000110                              ['dietary fat']   \n",
       "NCT00000114                   ['vitamin e', 'vitamin a']   \n",
       "NCT00000115                            ['acetazolamide']   \n",
       "NCT00000117                           ['immunoglobulin']   \n",
       "...                                                  ...   \n",
       "NCT06263959  ['gst-hg131', 'placebo to match gst-hg131']   \n",
       "NCT06263998                 ['ncp112', 'ncp112 placebo']   \n",
       "NCT06264141          ['nitric oxide releasing solution']   \n",
       "NCT06264180                ['single-agent chemotherapy']   \n",
       "NCT06264310                         ['placebo', 'r2r01']   \n",
       "\n",
       "                                                       smiless  \\\n",
       "nctid                                                            \n",
       "NCT00000102  ['COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-]...   \n",
       "NCT00000110                                                 []   \n",
       "NCT00000114  ['CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2...   \n",
       "NCT00000115                   ['CC(=O)NC1=NN=C(S1)S(N)(=O)=O']   \n",
       "NCT00000117                                                 []   \n",
       "...                                                        ...   \n",
       "NCT06263959                                                 []   \n",
       "NCT06263998                                                 []   \n",
       "NCT06264141                                                 []   \n",
       "NCT06264180                                                 []   \n",
       "NCT06264310                                                 []   \n",
       "\n",
       "                                                      criteria  complete_year  \\\n",
       "nctid                                                                           \n",
       "NCT00000102  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...            NaN   \n",
       "NCT00000110  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...            NaN   \n",
       "NCT00000114  \\n        Men and nonpregnant women between ag...         1987.0   \n",
       "NCT00000115  \\n        Males and females 8 years of age or ...         1994.0   \n",
       "NCT00000117  \\n        To be eligible, patients must have a...         1997.0   \n",
       "...                                                        ...            ...   \n",
       "NCT06263959  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...         2024.0   \n",
       "NCT06263998  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...         2025.0   \n",
       "NCT06264141  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...         2024.0   \n",
       "NCT06264180  \\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...         2029.0   \n",
       "NCT06264310  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...         2025.0   \n",
       "\n",
       "             start_year  \n",
       "nctid                    \n",
       "NCT00000102         NaN  \n",
       "NCT00000110         NaN  \n",
       "NCT00000114      1984.0  \n",
       "NCT00000115      1990.0  \n",
       "NCT00000117      1995.0  \n",
       "...                 ...  \n",
       "NCT06263959      2023.0  \n",
       "NCT06263998      2024.0  \n",
       "NCT06264141      2024.0  \n",
       "NCT06264180      2024.0  \n",
       "NCT06264310      2024.0  \n",
       "\n",
       "[171992 rows x 11 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "raw_data = pd.read_csv('raw_data.csv', index_col=0)\n",
    "raw_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## description-summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>brief_summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000102</th>\n",
       "      <td>\\n      This protocol is designed to assess bo...</td>\n",
       "      <td>\\n      This study will test the ability of ex...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000105</th>\n",
       "      <td>\\n      Patients will receive each vaccine onc...</td>\n",
       "      <td>\\n      The purpose of this study is to learn ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000113</th>\n",
       "      <td>\\n      Myopia (nearsightedness) is an importa...</td>\n",
       "      <td>\\n      To evaluate whether progressive additi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000114</th>\n",
       "      <td>\\n      Retinitis pigmentosa (RP) is a group o...</td>\n",
       "      <td>\\n      To determine whether supplements of vi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000115</th>\n",
       "      <td>\\n      Uveitis, an intraocular inflammatory d...</td>\n",
       "      <td>\\n      To test the efficacy of acetazolamide ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264258</th>\n",
       "      <td>\\n      Youth with T1D who comply with inclusi...</td>\n",
       "      <td>\\n      The goal of this study is to evaluate ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264271</th>\n",
       "      <td>\\n      Education on carbohydrate counting and...</td>\n",
       "      <td>\\n      The study aims to elucidate whether pa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>\\n      This is a Phase 2, Double-Blind, Place...</td>\n",
       "      <td>\\n      This Study Aims to Evaluate the Safety...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264323</th>\n",
       "      <td>\\n      QUALITY ASSURANCE PLAN:\\r\\n\\r\\n      M...</td>\n",
       "      <td>\\n      A prospective cohort study with 9 mont...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264336</th>\n",
       "      <td>\\n      Multiple sclerosis (MS) is an immune-m...</td>\n",
       "      <td>\\n      Nearly 1 million individuals in the Un...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>326273 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          detailed_description  \\\n",
       "NCT00000102  \\n      This protocol is designed to assess bo...   \n",
       "NCT00000105  \\n      Patients will receive each vaccine onc...   \n",
       "NCT00000113  \\n      Myopia (nearsightedness) is an importa...   \n",
       "NCT00000114  \\n      Retinitis pigmentosa (RP) is a group o...   \n",
       "NCT00000115  \\n      Uveitis, an intraocular inflammatory d...   \n",
       "...                                                        ...   \n",
       "NCT06264258  \\n      Youth with T1D who comply with inclusi...   \n",
       "NCT06264271  \\n      Education on carbohydrate counting and...   \n",
       "NCT06264310  \\n      This is a Phase 2, Double-Blind, Place...   \n",
       "NCT06264323  \\n      QUALITY ASSURANCE PLAN:\\r\\n\\r\\n      M...   \n",
       "NCT06264336  \\n      Multiple sclerosis (MS) is an immune-m...   \n",
       "\n",
       "                                                 brief_summary  \n",
       "NCT00000102  \\n      This study will test the ability of ex...  \n",
       "NCT00000105  \\n      The purpose of this study is to learn ...  \n",
       "NCT00000113  \\n      To evaluate whether progressive additi...  \n",
       "NCT00000114  \\n      To determine whether supplements of vi...  \n",
       "NCT00000115  \\n      To test the efficacy of acetazolamide ...  \n",
       "...                                                        ...  \n",
       "NCT06264258  \\n      The goal of this study is to evaluate ...  \n",
       "NCT06264271  \\n      The study aims to elucidate whether pa...  \n",
       "NCT06264310  \\n      This Study Aims to Evaluate the Safety...  \n",
       "NCT06264323  \\n      A prospective cohort study with 9 mont...  \n",
       "NCT06264336  \\n      Nearly 1 million individuals in the Un...  \n",
       "\n",
       "[326273 rows x 2 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description_summary = All[['detailed_description/textblock', 'brief_summary/textblock']].dropna()\n",
    "description_summary.rename(columns={'detailed_description/textblock': 'detailed_description', 'brief_summary/textblock': 'brief_summary'}, inplace=True)\n",
    "description_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train Set: 293645 Test Set: 32628\n"
     ]
    }
   ],
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "\n",
    "train_set, test_set = train_test_split(description_summary, test_size=0.1, random_state=99)\n",
    "print(f'Train Set: {len(train_set)} Test Set: {len(test_set)}')\n",
    "train_set.to_csv('description-summary/train.csv')\n",
    "test_set.to_csv('description-summary/test.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Adervse Event Rate prediction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(0, 220, 0, 220, 0.0, 0.0)\n"
     ]
    }
   ],
   "source": [
    "def xmlfile2adverseevent(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    try:\n",
    "        serious_event = root.findall('clinical_results/reported_events/serious_events/category_list/category')#/measure/analyzed_list/analyzed/count_list')\n",
    "        for title in serious_event:\n",
    "            if title.find('title').text == 'Total':\n",
    "                event = title.findall('event_list/event')\n",
    "                for e in event:\n",
    "                    if 'serious' in e.find('sub_title').text and 'Total' in e.find('sub_title').text:\n",
    "                        count = e.findall('counts')\n",
    "                        serious_adverse_affected = 0\n",
    "                        serious_adverse_atrisk = 0\n",
    "                        for group in count:\n",
    "                            serious_adverse_affected += eval(group.attrib['subjects_affected'])\n",
    "                            serious_adverse_atrisk += eval(group.attrib['subjects_at_risk'])\n",
    "\n",
    "                    elif 'mortality' in e.find('sub_title').text and 'Total' in e.find('sub_title').text:\n",
    "                        count = e.findall('counts')\n",
    "                        mortality_affected = 0\n",
    "                        mortality_atrisk = 0\n",
    "                        for group in count:\n",
    "                            mortality_affected += eval(group.attrib['subjects_affected'])\n",
    "                            mortality_atrisk += eval(group.attrib['subjects_at_risk'])\n",
    "        return serious_adverse_affected, serious_adverse_atrisk, mortality_affected, mortality_atrisk, serious_adverse_affected / serious_adverse_atrisk, mortality_affected / mortality_atrisk\n",
    "    \n",
    "    except:\n",
    "        return None, None, None, None, None, None\n",
    "\n",
    "xml_file = \"../../raw_data/NCT0356xxxx/NCT03569748.xml\"\n",
    "result = xmlfile2adverseevent(xml_file)\n",
    "print(result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "57199it [02:03, 34.70it/s] "
     ]
    }
   ],
   "source": [
    "adverse_list = []\n",
    "\n",
    "# 480403 lines\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "        \n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        \n",
    "        adverse_affected, adverse_risk, mortality_affected, mortality_risk, adverse_event_rate, mortality_rate = xmlfile2adverseevent(xml_path)\n",
    "        if adverse_affected is not None:\n",
    "            adverse_list.append((nct_id, adverse_affected, adverse_risk, mortality_affected, mortality_risk, adverse_event_rate, mortality_rate))    \n",
    "\n",
    "adverse_df = pd.DataFrame(adverse_list, columns=['ntcid', 'serious_adverse_affected', 'serious_adverse_atrisk', 'mortality_affected', 'mortality_atrisk', 'serious_adverse_rate', 'mortality_rate'])\n",
    "adverse_df = adverse_df.set_index('ntcid')\n",
    "print(adverse_df)\n",
    "adverse_df.to_csv('adverse-event-rate-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Participants dropout rate Forecasting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "483239it [15:52, 507.14it/s] \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "             started  completed  not_completed  droupout_rate\n",
      "ntcid                                                        \n",
      "NCT00000125     1636       1159            477       0.291565\n",
      "NCT00000134      279        279              0       0.000000\n",
      "NCT00000135      209        168             41       0.196172\n",
      "NCT00000136      234        234              0       0.000000\n",
      "NCT00000142       64         64              0       0.000000\n",
      "...              ...        ...            ...            ...\n",
      "NCT06002347       23         20              3       0.130435\n",
      "NCT06033079      536        536              0       0.000000\n",
      "NCT06076681       40         40              0       0.000000\n",
      "NCT06076694       80         77              3       0.037500\n",
      "NCT06097676       51         48              3       0.058824\n",
      "\n",
      "[62058 rows x 4 columns]\n"
     ]
    }
   ],
   "source": [
    "# 提取\n",
    "def xmlfile2participantflow(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    try:\n",
    "        participant_flow = root.findall('clinical_results/participant_flow/period_list/period/milestone_list/milestone')#/measure/analyzed_list/analyzed/count_list')\n",
    "        for child in participant_flow:\n",
    "            \n",
    "            if child.find('title').text == 'STARTED':\n",
    "                started = 0\n",
    "                for perid in child.findall('participants_list/participants'):\n",
    "                    started += eval(perid.attrib['count'])\n",
    "            elif child.find('title').text == 'COMPLETED':\n",
    "                completed = 0\n",
    "                for perid in child.findall('participants_list/participants'):\n",
    "                    completed += eval(perid.attrib['count'])\n",
    "            elif child.find('title').text == 'NOT COMPLETED':\n",
    "                not_completed = 0\n",
    "                for perid in child.findall('participants_list/participants'):\n",
    "                    not_completed += eval(perid.attrib['count'])\n",
    "\n",
    "        not_complete_percent = not_completed / started    \n",
    "    except:\n",
    "        started, completed, not_completed, not_complete_percent = -1, -1, -1, -1\n",
    "    \n",
    "    return started, completed, not_completed, not_complete_percent\n",
    "\n",
    "flow_list = []\n",
    "\n",
    "# 480403 lines\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "        \n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        \n",
    "        started, completed, not_completed, not_complete_percent = xmlfile2participantflow(xml_path)\n",
    "        if started != -1:\n",
    "            # print(started, completed, not_completed, complete_percent)\n",
    "            flow_list.append((nct_id, started, completed, not_completed, not_complete_percent))    \n",
    "\n",
    "participantsflow_df = pd.DataFrame(flow_list, columns=['ntcid', 'started', 'completed', 'not_completed', 'droupout_rate'])\n",
    "participantsflow_df = participantsflow_df.set_index('ntcid')\n",
    "print(participantsflow_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "participantsflow_df.to_csv('participant-flow-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: ylabel='droupout_rate'>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.boxplot(data = participantsflow_df, y='droupout_rate')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trial Duration Prediction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_date(date_str):\n",
    "    try:\n",
    "        output = datetime.strptime(date_str, \"%B %d, %Y\")\n",
    "    except:\n",
    "        try:\n",
    "            output = datetime.strptime(date_str, \"%B %Y\")\n",
    "        except Exception as e:\n",
    "            print(e)\n",
    "            raise e\n",
    "    return output\n",
    "\n",
    "def calculate_duration(start_date, completion_date):\n",
    "    # Unit: days\n",
    "    if start_date and completion_date:\n",
    "        start_date = parse_date(start_date)\n",
    "        completion_date = parse_date(completion_date)\n",
    "        duration = (completion_date - start_date).days\n",
    "    else:\n",
    "        duration = -1\n",
    "\n",
    "    return duration\n",
    "\n",
    "def xmlfile2date(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    try:\n",
    "        start_date = root.find('start_date').text\n",
    "    except:\n",
    "        start_date = ''\n",
    "    try:\n",
    "        completion_date = root.find('primary_completion_date').text\n",
    "        type = root.find('primary_completion_date').attrib['type']\n",
    "    except:\n",
    "        try:\n",
    "            completion_date = root.find('completion_date').text \n",
    "            type = (root.find('completion_date').attrib['type'] == \"Actual\")\n",
    "        except:\n",
    "            completion_date = ''\n",
    "            type = False\n",
    "\n",
    "    return start_date, completion_date, type\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "483239it [14:42, 547.79it/s] \n"
     ]
    }
   ],
   "source": [
    "date_list = []\n",
    "\n",
    "# 480403 lines\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "        \n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        \n",
    "        start_date, completion_date, type = xmlfile2date(xml_path)\n",
    "\n",
    "        if type:\n",
    "            if start_date and completion_date:\n",
    "                duration = calculate_duration(start_date, completion_date)\n",
    "            else:\n",
    "                duration = -1\n",
    "        \n",
    "            date_list.append((nct_id, start_date, completion_date, duration))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                    start_date    completion_date  time_day\n",
      "ntcid                                                      \n",
      "NCT00000105          July 2002         March 2012      3531\n",
      "NCT00000113     September 1997       October 2001      1491\n",
      "NCT00000114           May 1984          June 1987      1126\n",
      "NCT00000115      December 1990          June 1994      1278\n",
      "NCT00000116           May 1996     September 2002      2314\n",
      "...                        ...                ...       ...\n",
      "NCT06264297  February 20, 2023       January 2027      1411\n",
      "NCT06264310         March 2024       January 2025       306\n",
      "NCT06264323  September 1, 2017       May 30, 2018       271\n",
      "NCT06264336      March 1, 2024  December 31, 2024       305\n",
      "NCT06264349     March 15, 2024       May 15, 2025       426\n",
      "\n",
      "[468178 rows x 3 columns]\n"
     ]
    }
   ],
   "source": [
    "# 483239  lines\n",
    "date_df = pd.DataFrame(date_list, columns=['ntcid', 'start_date', 'completion_date', 'time_day'])\n",
    "date_df = date_df.set_index('ntcid')\n",
    "print(date_df)\n",
    "\n",
    "# date_df.to_csv('data/ntcid_time_all.csv', index=False, sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>start_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>time_day</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ntcid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000105</th>\n",
       "      <td>July 2002</td>\n",
       "      <td>March 2012</td>\n",
       "      <td>3531</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000113</th>\n",
       "      <td>September 1997</td>\n",
       "      <td>October 2001</td>\n",
       "      <td>1491</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000114</th>\n",
       "      <td>May 1984</td>\n",
       "      <td>June 1987</td>\n",
       "      <td>1126</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000115</th>\n",
       "      <td>December 1990</td>\n",
       "      <td>June 1994</td>\n",
       "      <td>1278</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000116</th>\n",
       "      <td>May 1996</td>\n",
       "      <td>September 2002</td>\n",
       "      <td>2314</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264297</th>\n",
       "      <td>February 20, 2023</td>\n",
       "      <td>January 2027</td>\n",
       "      <td>1411</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>March 2024</td>\n",
       "      <td>January 2025</td>\n",
       "      <td>306</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264323</th>\n",
       "      <td>September 1, 2017</td>\n",
       "      <td>May 30, 2018</td>\n",
       "      <td>271</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264336</th>\n",
       "      <td>March 1, 2024</td>\n",
       "      <td>December 31, 2024</td>\n",
       "      <td>305</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264349</th>\n",
       "      <td>March 15, 2024</td>\n",
       "      <td>May 15, 2025</td>\n",
       "      <td>426</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>462610 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                    start_date    completion_date  time_day\n",
       "ntcid                                                      \n",
       "NCT00000105          July 2002         March 2012      3531\n",
       "NCT00000113     September 1997       October 2001      1491\n",
       "NCT00000114           May 1984          June 1987      1126\n",
       "NCT00000115      December 1990          June 1994      1278\n",
       "NCT00000116           May 1996     September 2002      2314\n",
       "...                        ...                ...       ...\n",
       "NCT06264297  February 20, 2023       January 2027      1411\n",
       "NCT06264310         March 2024       January 2025       306\n",
       "NCT06264323  September 1, 2017       May 30, 2018       271\n",
       "NCT06264336      March 1, 2024  December 31, 2024       305\n",
       "NCT06264349     March 15, 2024       May 15, 2025       426\n",
       "\n",
       "[462610 rows x 3 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Filter out unusable time data.\n",
    "# 469937 lines\n",
    "date_df = date_df[date_df['time_day'] > 0]\n",
    "date_df\n",
    "# date_df.to_csv('trial-duration-prediction/ntcid_duration_time.csv', index=False, sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Medium time_day: 669.0\n",
      "Average time_day: 932.4504312487841\n",
      "Minimum time_day: 1\n",
      "Maximum time_day: 42217\n",
      "Standard Deviation of time_day: 1082.6610761928803\n"
     ]
    }
   ],
   "source": [
    "# Analysis\n",
    "medium_time_day = date_df['time_day'].median()\n",
    "average_time_day = date_df['time_day'].mean()\n",
    "minimum_time_day = date_df['time_day'].min()\n",
    "maximum_time_day = date_df['time_day'].max()\n",
    "std_time_day = date_df['time_day'].std()\n",
    "\n",
    "print(\"Medium time_day:\", medium_time_day)\n",
    "print(\"Average time_day:\", average_time_day)\n",
    "print(\"Minimum time_day:\", minimum_time_day)\n",
    "print(\"Maximum time_day:\", maximum_time_day)\n",
    "print(\"Standard Deviation of time_day:\", std_time_day)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "     month  count\n",
      "0        0   4720\n",
      "1        1  10905\n",
      "2        2  11684\n",
      "3        3  12078\n",
      "4        4  11331\n",
      "..     ...    ...\n",
      "560   1252      2\n",
      "561   1266      1\n",
      "562   1270      1\n",
      "563   1339      1\n",
      "564   1407      1\n",
      "\n",
      "[565 rows x 2 columns]\n"
     ]
    }
   ],
   "source": [
    "date_df['month'] = date_df['time_day'] // 30\n",
    "frequency_month = date_df['month'].value_counts().sort_index().reset_index()\n",
    "print(frequency_month)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_data = frequency_month[frequency_month['month'] <= 72]\n",
    "\n",
    "plt.figure(figsize=(10, 6))\n",
    "\n",
    "plt.scatter(plot_data['month'], plot_data['count'], s=10, c='blue')\n",
    "\n",
    "plt.xlabel('Month')\n",
    "plt.ylabel('Frequency')\n",
    "plt.title('Frequency of Months (Limited to 72)')\n",
    "plt.grid(True)  # Add grid\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>icdcodes</th>\n",
       "      <th>drugs</th>\n",
       "      <th>criteria</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nctid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000102</th>\n",
       "      <td>[\"['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', ...</td>\n",
       "      <td>['nifedipine']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000110</th>\n",
       "      <td>[\"['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99....</td>\n",
       "      <td>['dietary fat']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000114</th>\n",
       "      <td>[]</td>\n",
       "      <td>['vitamin e', 'vitamin a']</td>\n",
       "      <td>\\n        Men and nonpregnant women between ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000115</th>\n",
       "      <td>[]</td>\n",
       "      <td>['acetazolamide']</td>\n",
       "      <td>\\n        Males and females 8 years of age or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000117</th>\n",
       "      <td>[\"['H46.8', 'H46.9']\"]</td>\n",
       "      <td>['immunoglobulin']</td>\n",
       "      <td>\\n        To be eligible, patients must have a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263959</th>\n",
       "      <td>[\"['B18.0', 'B18.1', 'B18.2', 'B18.8', 'B18.9']\"]</td>\n",
       "      <td>['gst-hg131', 'placebo to match gst-hg131']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263998</th>\n",
       "      <td>[]</td>\n",
       "      <td>['ncp112', 'ncp112 placebo']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264141</th>\n",
       "      <td>[]</td>\n",
       "      <td>['nitric oxide releasing solution']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264180</th>\n",
       "      <td>[\"['K74.02', 'G47.22', 'H35.3133', 'H35.3134',...</td>\n",
       "      <td>['single-agent chemotherapy']</td>\n",
       "      <td>\\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>[\"['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I...</td>\n",
       "      <td>['placebo', 'r2r01']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>171992 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                      icdcodes  \\\n",
       "nctid                                                            \n",
       "NCT00000102  [\"['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', ...   \n",
       "NCT00000110  [\"['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99....   \n",
       "NCT00000114                                                 []   \n",
       "NCT00000115                                                 []   \n",
       "NCT00000117                             [\"['H46.8', 'H46.9']\"]   \n",
       "...                                                        ...   \n",
       "NCT06263959  [\"['B18.0', 'B18.1', 'B18.2', 'B18.8', 'B18.9']\"]   \n",
       "NCT06263998                                                 []   \n",
       "NCT06264141                                                 []   \n",
       "NCT06264180  [\"['K74.02', 'G47.22', 'H35.3133', 'H35.3134',...   \n",
       "NCT06264310  [\"['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I...   \n",
       "\n",
       "                                                   drugs  \\\n",
       "nctid                                                      \n",
       "NCT00000102                               ['nifedipine']   \n",
       "NCT00000110                              ['dietary fat']   \n",
       "NCT00000114                   ['vitamin e', 'vitamin a']   \n",
       "NCT00000115                            ['acetazolamide']   \n",
       "NCT00000117                           ['immunoglobulin']   \n",
       "...                                                  ...   \n",
       "NCT06263959  ['gst-hg131', 'placebo to match gst-hg131']   \n",
       "NCT06263998                 ['ncp112', 'ncp112 placebo']   \n",
       "NCT06264141          ['nitric oxide releasing solution']   \n",
       "NCT06264180                ['single-agent chemotherapy']   \n",
       "NCT06264310                         ['placebo', 'r2r01']   \n",
       "\n",
       "                                                      criteria  \n",
       "nctid                                                           \n",
       "NCT00000102  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT00000110  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT00000114  \\n        Men and nonpregnant women between ag...  \n",
       "NCT00000115  \\n        Males and females 8 years of age or ...  \n",
       "NCT00000117  \\n        To be eligible, patients must have a...  \n",
       "...                                                        ...  \n",
       "NCT06263959  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT06263998  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT06264141  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT06264180  \\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...  \n",
       "NCT06264310  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "\n",
       "[171992 rows x 3 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duration_prediction_input = raw_data[['icdcodes', 'drugs', 'criteria']]\n",
    "duration_prediction_input"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "icdcodes     0\n",
       "drugs        0\n",
       "criteria    28\n",
       "dtype: int64"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duration_prediction_input.isna().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "166587"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# 取交集\n",
    "cross_index = list(set(duration_prediction_input.index.to_list()).intersection(set(date_df.index.to_list())))\n",
    "len(cross_index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['NCT01887340',\n",
       " 'NCT00449449',\n",
       " 'NCT00852670',\n",
       " 'NCT04326283',\n",
       " 'NCT05910983',\n",
       " 'NCT02849743',\n",
       " 'NCT02647268',\n",
       " 'NCT02671552',\n",
       " 'NCT01912534',\n",
       " 'NCT03284853',\n",
       " 'NCT01957176',\n",
       " 'NCT03474198',\n",
       " 'NCT02728050',\n",
       " 'NCT00810667',\n",
       " 'NCT02133482',\n",
       " 'NCT05738759',\n",
       " 'NCT01399580',\n",
       " 'NCT06028828',\n",
       " 'NCT04372628',\n",
       " 'NCT02213029',\n",
       " 'NCT00461786',\n",
       " 'NCT00777933',\n",
       " 'NCT00116025',\n",
       " 'NCT01672333',\n",
       " 'NCT01024075',\n",
       " 'NCT01881217',\n",
       " 'NCT04317703',\n",
       " 'NCT03335852',\n",
       " 'NCT00452803',\n",
       " 'NCT03343080',\n",
       " 'NCT00181558',\n",
       " 'NCT00592488',\n",
       " 'NCT00781443',\n",
       " 'NCT03031262',\n",
       " 'NCT05588609',\n",
       " 'NCT02570997',\n",
       " 'NCT00038701',\n",
       " 'NCT01314898',\n",
       " 'NCT00599196',\n",
       " 'NCT01633359',\n",
       " 'NCT02344511',\n",
       " 'NCT02620683',\n",
       " 'NCT00139880',\n",
       " 'NCT00246441',\n",
       " 'NCT00523211',\n",
       " 'NCT00665626',\n",
       " 'NCT05330078',\n",
       " 'NCT01393340',\n",
       " 'NCT04328844',\n",
       " 'NCT00685529',\n",
       " 'NCT00972283',\n",
       " 'NCT01963663',\n",
       " 'NCT02373280',\n",
       " 'NCT06145321',\n",
       " 'NCT02479204',\n",
       " 'NCT02357225',\n",
       " 'NCT03629600',\n",
       " 'NCT01762670',\n",
       " 'NCT03403517',\n",
       " 'NCT02485106',\n",
       " 'NCT03420079',\n",
       " 'NCT01235546',\n",
       " 'NCT06229288',\n",
       " 'NCT01008280',\n",
       " 'NCT04585035',\n",
       " 'NCT02557854',\n",
       " 'NCT03709940',\n",
       " 'NCT00367133',\n",
       " 'NCT01421667',\n",
       " 'NCT05491330',\n",
       " 'NCT00175890',\n",
       " 'NCT02517021',\n",
       " 'NCT02594735',\n",
       " 'NCT00959907',\n",
       " 'NCT00285727',\n",
       " 'NCT01423292',\n",
       " 'NCT03153852',\n",
       " 'NCT03014882',\n",
       " 'NCT02389790',\n",
       " 'NCT05792254',\n",
       " 'NCT03684772',\n",
       " 'NCT04240054',\n",
       " 'NCT00841854',\n",
       " 'NCT01781572',\n",
       " 'NCT06014528',\n",
       " 'NCT00126243',\n",
       " 'NCT01936363',\n",
       " 'NCT01434498',\n",
       " 'NCT03403712',\n",
       " 'NCT05907057',\n",
       " 'NCT00440440',\n",
       " 'NCT00814866',\n",
       " 'NCT00377520',\n",
       " 'NCT01144195',\n",
       " 'NCT02944955',\n",
       " 'NCT00412971',\n",
       " 'NCT02194088',\n",
       " 'NCT01448096',\n",
       " 'NCT01505166',\n",
       " 'NCT03596762',\n",
       " 'NCT01668550',\n",
       " 'NCT05022147',\n",
       " 'NCT03780959',\n",
       " 'NCT01352208',\n",
       " 'NCT03150628',\n",
       " 'NCT00599755',\n",
       " 'NCT00666029',\n",
       " 'NCT04083079',\n",
       " 'NCT04858958',\n",
       " 'NCT00533949',\n",
       " 'NCT01564784',\n",
       " 'NCT03273322',\n",
       " 'NCT06109948',\n",
       " 'NCT05856695',\n",
       " 'NCT00858338',\n",
       " 'NCT02488642',\n",
       " 'NCT00533728',\n",
       " 'NCT05186818',\n",
       " 'NCT00442390',\n",
       " 'NCT05628103',\n",
       " 'NCT01177150',\n",
       " 'NCT03578575',\n",
       " 'NCT04952051',\n",
       " 'NCT03625518',\n",
       " 'NCT06066853',\n",
       " 'NCT02108756',\n",
       " 'NCT00788372',\n",
       " 'NCT00096070',\n",
       " 'NCT04903197',\n",
       " 'NCT05663827',\n",
       " 'NCT04201561',\n",
       " 'NCT02477813',\n",
       " 'NCT02222714',\n",
       " 'NCT04190966',\n",
       " 'NCT02787317',\n",
       " 'NCT02679131',\n",
       " 'NCT02737709',\n",
       " 'NCT06054984',\n",
       " 'NCT00338936',\n",
       " 'NCT00093145',\n",
       " 'NCT00218660',\n",
       " 'NCT00494234',\n",
       " 'NCT03396380',\n",
       " 'NCT05387265',\n",
       " 'NCT05328258',\n",
       " 'NCT02681887',\n",
       " 'NCT05414461',\n",
       " 'NCT00000197',\n",
       " 'NCT03254628',\n",
       " 'NCT00846040',\n",
       " 'NCT03383146',\n",
       " 'NCT04490681',\n",
       " 'NCT01570634',\n",
       " 'NCT01139346',\n",
       " 'NCT03288545',\n",
       " 'NCT01471288',\n",
       " 'NCT01022749',\n",
       " 'NCT04071366',\n",
       " 'NCT04339426',\n",
       " 'NCT00334490',\n",
       " 'NCT05336266',\n",
       " 'NCT01160614',\n",
       " 'NCT00369044',\n",
       " 'NCT02047227',\n",
       " 'NCT00895830',\n",
       " 'NCT01321827',\n",
       " 'NCT01686802',\n",
       " 'NCT00621530',\n",
       " 'NCT05895370',\n",
       " 'NCT05385523',\n",
       " 'NCT01523002',\n",
       " 'NCT02183142',\n",
       " 'NCT01416883',\n",
       " 'NCT00136786',\n",
       " 'NCT00180635',\n",
       " 'NCT02503826',\n",
       " 'NCT04499339',\n",
       " 'NCT01469351',\n",
       " 'NCT00521014',\n",
       " 'NCT04016818',\n",
       " 'NCT02179645',\n",
       " 'NCT00775944',\n",
       " 'NCT00126399',\n",
       " 'NCT05905133',\n",
       " 'NCT01046994',\n",
       " 'NCT00749047',\n",
       " 'NCT05536141',\n",
       " 'NCT02844179',\n",
       " 'NCT00485615',\n",
       " 'NCT02198846',\n",
       " 'NCT00104663',\n",
       " 'NCT05923411',\n",
       " 'NCT02808975',\n",
       " 'NCT05506930',\n",
       " 'NCT02100930',\n",
       " 'NCT01512446',\n",
       " 'NCT03893825',\n",
       " 'NCT03938792',\n",
       " 'NCT00583258',\n",
       " 'NCT00406874',\n",
       " 'NCT00467467',\n",
       " 'NCT01294410',\n",
       " 'NCT04724187',\n",
       " 'NCT01618825',\n",
       " 'NCT01397006',\n",
       " 'NCT02758431',\n",
       " 'NCT00674713',\n",
       " 'NCT03466645',\n",
       " 'NCT03547141',\n",
       " 'NCT01431820',\n",
       " 'NCT00287482',\n",
       " 'NCT04585334',\n",
       " 'NCT01239797',\n",
       " 'NCT00364832',\n",
       " 'NCT01318551',\n",
       " 'NCT05549726',\n",
       " 'NCT00859274',\n",
       " 'NCT00986765',\n",
       " 'NCT00570531',\n",
       " 'NCT05481177',\n",
       " 'NCT05056974',\n",
       " 'NCT03353831',\n",
       " 'NCT00577148',\n",
       " 'NCT03086213',\n",
       " 'NCT03347292',\n",
       " 'NCT04805671',\n",
       " 'NCT00006377',\n",
       " 'NCT05210790',\n",
       " 'NCT00050232',\n",
       " 'NCT00006465',\n",
       " 'NCT02693444',\n",
       " 'NCT03978000',\n",
       " 'NCT05412160',\n",
       " 'NCT02255435',\n",
       " 'NCT01251211',\n",
       " 'NCT00969046',\n",
       " 'NCT01714713',\n",
       " 'NCT03928847',\n",
       " 'NCT03172052',\n",
       " 'NCT03688230',\n",
       " 'NCT00606515',\n",
       " 'NCT03122444',\n",
       " 'NCT04859062',\n",
       " 'NCT00215163',\n",
       " 'NCT00766116',\n",
       " 'NCT01169597',\n",
       " 'NCT04299971',\n",
       " 'NCT01220869',\n",
       " 'NCT05915546',\n",
       " 'NCT00024323',\n",
       " 'NCT01275144',\n",
       " 'NCT03368131',\n",
       " 'NCT01554969',\n",
       " 'NCT03552770',\n",
       " 'NCT02401191',\n",
       " 'NCT02311205',\n",
       " 'NCT00070200',\n",
       " 'NCT00593463',\n",
       " 'NCT02586649',\n",
       " 'NCT01093534',\n",
       " 'NCT00099905',\n",
       " 'NCT05888857',\n",
       " 'NCT04777383',\n",
       " 'NCT01519297',\n",
       " 'NCT04385407',\n",
       " 'NCT01934049',\n",
       " 'NCT02637167',\n",
       " 'NCT00628732',\n",
       " 'NCT06148311',\n",
       " 'NCT00003115',\n",
       " 'NCT00284752',\n",
       " 'NCT05807945',\n",
       " 'NCT02500199',\n",
       " 'NCT04868760',\n",
       " 'NCT05104099',\n",
       " 'NCT01098656',\n",
       " 'NCT00545454',\n",
       " 'NCT05238597',\n",
       " 'NCT05168280',\n",
       " 'NCT02236793',\n",
       " 'NCT01148771',\n",
       " 'NCT01347424',\n",
       " 'NCT02852395',\n",
       " 'NCT00405808',\n",
       " 'NCT02023164',\n",
       " 'NCT00517296',\n",
       " 'NCT04616183',\n",
       " 'NCT06239155',\n",
       " 'NCT05210946',\n",
       " 'NCT02410512',\n",
       " 'NCT03582722',\n",
       " 'NCT04216771',\n",
       " 'NCT05222152',\n",
       " 'NCT03517943',\n",
       " 'NCT00277303',\n",
       " 'NCT01784614',\n",
       " 'NCT05574712',\n",
       " 'NCT01690624',\n",
       " 'NCT01147887',\n",
       " 'NCT05139043',\n",
       " 'NCT03753477',\n",
       " 'NCT02809378',\n",
       " 'NCT00870194',\n",
       " 'NCT01176201',\n",
       " 'NCT00463008',\n",
       " 'NCT00968877',\n",
       " 'NCT05116007',\n",
       " 'NCT01532336',\n",
       " 'NCT00039481',\n",
       " 'NCT05608369',\n",
       " 'NCT01745848',\n",
       " 'NCT02962921',\n",
       " 'NCT00286221',\n",
       " 'NCT01018017',\n",
       " 'NCT03220841',\n",
       " 'NCT03568721',\n",
       " 'NCT02370095',\n",
       " 'NCT00204529',\n",
       " 'NCT00183612',\n",
       " 'NCT01782027',\n",
       " 'NCT02187783',\n",
       " 'NCT04316585',\n",
       " 'NCT00080327',\n",
       " 'NCT04360785',\n",
       " 'NCT04361851',\n",
       " 'NCT02719977',\n",
       " 'NCT02840409',\n",
       " 'NCT02821026',\n",
       " 'NCT00060385',\n",
       " 'NCT02739100',\n",
       " 'NCT01854268',\n",
       " 'NCT02207491',\n",
       " 'NCT01222845',\n",
       " 'NCT01499849',\n",
       " 'NCT03303677',\n",
       " 'NCT05285696',\n",
       " 'NCT01711970',\n",
       " 'NCT02149225',\n",
       " 'NCT00413335',\n",
       " 'NCT04827134',\n",
       " 'NCT00514618',\n",
       " 'NCT04870359',\n",
       " 'NCT00261365',\n",
       " 'NCT01287494',\n",
       " 'NCT01683266',\n",
       " 'NCT00083226',\n",
       " 'NCT03181815',\n",
       " 'NCT03139604',\n",
       " 'NCT00518635',\n",
       " 'NCT00044928',\n",
       " 'NCT05287386',\n",
       " 'NCT00490035',\n",
       " 'NCT04468425',\n",
       " 'NCT01306617',\n",
       " 'NCT03376503',\n",
       " 'NCT02683265',\n",
       " 'NCT05856305',\n",
       " 'NCT00351910',\n",
       " 'NCT02032290',\n",
       " 'NCT01286987',\n",
       " 'NCT01864824',\n",
       " 'NCT02258607',\n",
       " 'NCT02054936',\n",
       " 'NCT04002687',\n",
       " 'NCT01415505',\n",
       " 'NCT05635305',\n",
       " 'NCT00164151',\n",
       " 'NCT00383136',\n",
       " 'NCT05047913',\n",
       " 'NCT02434718',\n",
       " 'NCT04736173',\n",
       " 'NCT03199053',\n",
       " 'NCT00842400',\n",
       " 'NCT04373421',\n",
       " 'NCT00111670',\n",
       " 'NCT05376644',\n",
       " 'NCT00564993',\n",
       " 'NCT01452737',\n",
       " 'NCT02904772',\n",
       " 'NCT03349619',\n",
       " 'NCT00181571',\n",
       " 'NCT00893451',\n",
       " 'NCT02139124',\n",
       " 'NCT03872453',\n",
       " 'NCT00192101',\n",
       " 'NCT01289327',\n",
       " 'NCT02509117',\n",
       " 'NCT06246968',\n",
       " 'NCT00866073',\n",
       " 'NCT02775539',\n",
       " 'NCT03500731',\n",
       " 'NCT02598505',\n",
       " 'NCT00027248',\n",
       " 'NCT01500005',\n",
       " 'NCT00162097',\n",
       " 'NCT04717700',\n",
       " 'NCT03830957',\n",
       " 'NCT02376283',\n",
       " 'NCT02669784',\n",
       " 'NCT00692354',\n",
       " 'NCT04914676',\n",
       " 'NCT03811054',\n",
       " 'NCT01555814',\n",
       " 'NCT02145091',\n",
       " 'NCT02264418',\n",
       " 'NCT05047523',\n",
       " 'NCT02117128',\n",
       " 'NCT03631654',\n",
       " 'NCT01241123',\n",
       " 'NCT02805842',\n",
       " 'NCT03988387',\n",
       " 'NCT02544997',\n",
       " 'NCT05471687',\n",
       " 'NCT00244361',\n",
       " 'NCT02102243',\n",
       " 'NCT00136994',\n",
       " 'NCT03984838',\n",
       " 'NCT02461186',\n",
       " 'NCT00591383',\n",
       " 'NCT04694586',\n",
       " 'NCT04976751',\n",
       " 'NCT05339685',\n",
       " 'NCT01243619',\n",
       " 'NCT01516918',\n",
       " 'NCT05040880',\n",
       " 'NCT05604131',\n",
       " 'NCT05984121',\n",
       " 'NCT00732927',\n",
       " 'NCT02452177',\n",
       " 'NCT00746863',\n",
       " 'NCT01861054',\n",
       " 'NCT00546520',\n",
       " 'NCT03137082',\n",
       " 'NCT01988402',\n",
       " 'NCT02831491',\n",
       " 'NCT03086473',\n",
       " 'NCT01876849',\n",
       " 'NCT03526848',\n",
       " 'NCT03303950',\n",
       " 'NCT00473915',\n",
       " 'NCT05458193',\n",
       " 'NCT05227300',\n",
       " 'NCT00779051',\n",
       " 'NCT00795574',\n",
       " 'NCT00021502',\n",
       " 'NCT00571298',\n",
       " 'NCT05343819',\n",
       " 'NCT03782233',\n",
       " 'NCT04066491',\n",
       " 'NCT04607148',\n",
       " 'NCT02015208',\n",
       " 'NCT03883802',\n",
       " 'NCT03276676',\n",
       " 'NCT02152956',\n",
       " 'NCT02069834',\n",
       " 'NCT03157388',\n",
       " 'NCT02173392',\n",
       " 'NCT05381142',\n",
       " 'NCT00183729',\n",
       " 'NCT00323791',\n",
       " 'NCT05938946',\n",
       " 'NCT06013995',\n",
       " 'NCT02314819',\n",
       " 'NCT00703976',\n",
       " 'NCT03719898',\n",
       " 'NCT02536417',\n",
       " 'NCT03122665',\n",
       " 'NCT05263505',\n",
       " 'NCT04922983',\n",
       " 'NCT02490345',\n",
       " 'NCT02110264',\n",
       " 'NCT02563327',\n",
       " 'NCT01762163',\n",
       " 'NCT05758818',\n",
       " 'NCT00647166',\n",
       " 'NCT04509700',\n",
       " 'NCT00452673',\n",
       " 'NCT03511066',\n",
       " 'NCT00790478',\n",
       " 'NCT00725855',\n",
       " 'NCT00688493',\n",
       " 'NCT01864798',\n",
       " 'NCT02950948',\n",
       " 'NCT02388152',\n",
       " 'NCT01111851',\n",
       " 'NCT04952857',\n",
       " 'NCT03813056',\n",
       " 'NCT00002911',\n",
       " 'NCT02470780',\n",
       " 'NCT02838329',\n",
       " 'NCT04405999',\n",
       " 'NCT00342563',\n",
       " 'NCT04126707',\n",
       " 'NCT02917863',\n",
       " 'NCT00017368',\n",
       " 'NCT02130635',\n",
       " 'NCT03152591',\n",
       " 'NCT04200729',\n",
       " 'NCT02682758',\n",
       " 'NCT02565576',\n",
       " 'NCT04394975',\n",
       " 'NCT05389852',\n",
       " 'NCT01469468',\n",
       " 'NCT02070653',\n",
       " 'NCT01757119',\n",
       " 'NCT01802866',\n",
       " 'NCT05672316',\n",
       " 'NCT00005080',\n",
       " 'NCT02593383',\n",
       " 'NCT00462501',\n",
       " 'NCT04232345',\n",
       " 'NCT04620369',\n",
       " 'NCT01587222',\n",
       " 'NCT05641896',\n",
       " 'NCT04360681',\n",
       " 'NCT04532749',\n",
       " 'NCT05028218',\n",
       " 'NCT01091103',\n",
       " 'NCT00948064',\n",
       " 'NCT03326726',\n",
       " 'NCT01691209',\n",
       " 'NCT00058461',\n",
       " 'NCT04708496',\n",
       " 'NCT04220775',\n",
       " 'NCT00177177',\n",
       " 'NCT01808313',\n",
       " 'NCT04732598',\n",
       " 'NCT03783182',\n",
       " 'NCT02303405',\n",
       " 'NCT01761994',\n",
       " 'NCT02301390',\n",
       " 'NCT03782740',\n",
       " 'NCT02400931',\n",
       " 'NCT01377623',\n",
       " 'NCT03024515',\n",
       " 'NCT04646330',\n",
       " 'NCT00121524',\n",
       " 'NCT00596453',\n",
       " 'NCT02807428',\n",
       " 'NCT03160118',\n",
       " 'NCT02987998',\n",
       " 'NCT00066638',\n",
       " 'NCT05078047',\n",
       " 'NCT03353298',\n",
       " 'NCT05718258',\n",
       " 'NCT01295892',\n",
       " 'NCT04238143',\n",
       " 'NCT00316173',\n",
       " 'NCT05422534',\n",
       " 'NCT01905501',\n",
       " 'NCT02010918',\n",
       " 'NCT06128148',\n",
       " 'NCT00694759',\n",
       " 'NCT05805839',\n",
       " 'NCT05825781',\n",
       " 'NCT01169090',\n",
       " 'NCT01337531',\n",
       " 'NCT04655586',\n",
       " 'NCT03700515',\n",
       " 'NCT00425750',\n",
       " 'NCT00949182',\n",
       " 'NCT04556617',\n",
       " 'NCT01848873',\n",
       " 'NCT05911295',\n",
       " 'NCT00910455',\n",
       " 'NCT02826044',\n",
       " 'NCT00326391',\n",
       " 'NCT06196697',\n",
       " 'NCT01901224',\n",
       " 'NCT00580931',\n",
       " 'NCT01883648',\n",
       " 'NCT05417594',\n",
       " 'NCT02939989',\n",
       " 'NCT01573910',\n",
       " 'NCT03163381',\n",
       " 'NCT00748969',\n",
       " 'NCT00045630',\n",
       " 'NCT02601898',\n",
       " 'NCT00099320',\n",
       " 'NCT00981682',\n",
       " 'NCT00678769',\n",
       " 'NCT05580601',\n",
       " 'NCT00921167',\n",
       " 'NCT00770341',\n",
       " 'NCT05695027',\n",
       " 'NCT01456585',\n",
       " 'NCT02571816',\n",
       " 'NCT00796211',\n",
       " 'NCT00222105',\n",
       " 'NCT01682564',\n",
       " 'NCT05847205',\n",
       " 'NCT01824303',\n",
       " 'NCT01514344',\n",
       " 'NCT02183012',\n",
       " 'NCT05248893',\n",
       " 'NCT00419380',\n",
       " 'NCT02628587',\n",
       " 'NCT03098355',\n",
       " 'NCT00964548',\n",
       " 'NCT01508000',\n",
       " 'NCT01656629',\n",
       " 'NCT00639574',\n",
       " 'NCT00905229',\n",
       " 'NCT00598013',\n",
       " 'NCT00913952',\n",
       " 'NCT01859182',\n",
       " 'NCT00989014',\n",
       " 'NCT04292184',\n",
       " 'NCT05822544',\n",
       " 'NCT01857362',\n",
       " 'NCT05694871',\n",
       " 'NCT05485012',\n",
       " 'NCT00573378',\n",
       " 'NCT01381055',\n",
       " 'NCT00157482',\n",
       " 'NCT03993353',\n",
       " 'NCT03156725',\n",
       " 'NCT04147806',\n",
       " 'NCT05232279',\n",
       " 'NCT02374060',\n",
       " 'NCT00259168',\n",
       " 'NCT04903002',\n",
       " 'NCT01913067',\n",
       " 'NCT05467826',\n",
       " 'NCT04399980',\n",
       " 'NCT02011659',\n",
       " 'NCT02068092',\n",
       " 'NCT02145039',\n",
       " 'NCT03774355',\n",
       " 'NCT04111978',\n",
       " 'NCT00086515',\n",
       " 'NCT04944017',\n",
       " 'NCT00005799',\n",
       " 'NCT02103894',\n",
       " 'NCT02826161',\n",
       " 'NCT00484341',\n",
       " 'NCT01452659',\n",
       " 'NCT02269228',\n",
       " 'NCT06048341',\n",
       " 'NCT02626884',\n",
       " 'NCT01129375',\n",
       " 'NCT01379274',\n",
       " 'NCT00674921',\n",
       " 'NCT01304901',\n",
       " 'NCT05946005',\n",
       " 'NCT02058446',\n",
       " 'NCT00096018',\n",
       " 'NCT01168596',\n",
       " 'NCT01497977',\n",
       " 'NCT00495365',\n",
       " 'NCT02852434',\n",
       " 'NCT02871297',\n",
       " 'NCT02076919',\n",
       " 'NCT00167674',\n",
       " 'NCT01617746',\n",
       " 'NCT03289871',\n",
       " 'NCT01211665',\n",
       " 'NCT02219633',\n",
       " 'NCT03909412',\n",
       " 'NCT01920945',\n",
       " 'NCT00667095',\n",
       " 'NCT02722369',\n",
       " 'NCT04042623',\n",
       " 'NCT03988634',\n",
       " 'NCT00835679',\n",
       " 'NCT04386642',\n",
       " 'NCT06146413',\n",
       " 'NCT03420911',\n",
       " 'NCT02014714',\n",
       " 'NCT04321278',\n",
       " 'NCT05443984',\n",
       " 'NCT00988715',\n",
       " 'NCT06233474',\n",
       " 'NCT02347085',\n",
       " 'NCT01183390',\n",
       " 'NCT03082534',\n",
       " 'NCT00387777',\n",
       " 'NCT06126315',\n",
       " 'NCT05548283',\n",
       " 'NCT00710697',\n",
       " 'NCT00688688',\n",
       " 'NCT02630706',\n",
       " 'NCT01306578',\n",
       " 'NCT01188694',\n",
       " 'NCT00532818',\n",
       " 'NCT00005637',\n",
       " 'NCT04899427',\n",
       " 'NCT00004868',\n",
       " 'NCT02413008',\n",
       " 'NCT01877655',\n",
       " 'NCT02119221',\n",
       " 'NCT00062101',\n",
       " 'NCT05929729',\n",
       " 'NCT03344692',\n",
       " 'NCT00640510',\n",
       " 'NCT04956302',\n",
       " 'NCT02355743',\n",
       " 'NCT02946814',\n",
       " 'NCT05080543',\n",
       " 'NCT01383759',\n",
       " 'NCT03268590',\n",
       " 'NCT05516758',\n",
       " 'NCT01171313',\n",
       " 'NCT04134884',\n",
       " 'NCT04566978',\n",
       " 'NCT02374047',\n",
       " 'NCT02918370',\n",
       " 'NCT05286164',\n",
       " 'NCT04424966',\n",
       " 'NCT00785460',\n",
       " 'NCT00788099',\n",
       " 'NCT02797548',\n",
       " 'NCT01356407',\n",
       " 'NCT04485195',\n",
       " 'NCT04867252',\n",
       " 'NCT05574049',\n",
       " 'NCT03159559',\n",
       " 'NCT06180057',\n",
       " 'NCT01087008',\n",
       " 'NCT00525785',\n",
       " 'NCT03936829',\n",
       " 'NCT04400760',\n",
       " 'NCT00944333',\n",
       " 'NCT02586441',\n",
       " 'NCT05688111',\n",
       " 'NCT00974246',\n",
       " 'NCT04772456',\n",
       " 'NCT05439148',\n",
       " 'NCT01544283',\n",
       " 'NCT02495662',\n",
       " 'NCT01393626',\n",
       " 'NCT01015066',\n",
       " 'NCT02461589',\n",
       " 'NCT02888990',\n",
       " 'NCT04460560',\n",
       " 'NCT01468636',\n",
       " 'NCT04616534',\n",
       " 'NCT01076543',\n",
       " 'NCT05679908',\n",
       " 'NCT04680767',\n",
       " 'NCT03245658',\n",
       " 'NCT01048008',\n",
       " 'NCT00004744',\n",
       " 'NCT05204173',\n",
       " 'NCT05532696',\n",
       " 'NCT03968562',\n",
       " 'NCT01560624',\n",
       " 'NCT00609765',\n",
       " 'NCT01057862',\n",
       " 'NCT00250796',\n",
       " 'NCT00403949',\n",
       " 'NCT00768274',\n",
       " 'NCT00814307',\n",
       " 'NCT03898583',\n",
       " 'NCT01917006',\n",
       " 'NCT02677896',\n",
       " 'NCT03425656',\n",
       " 'NCT06223048',\n",
       " 'NCT00547989',\n",
       " 'NCT02011958',\n",
       " 'NCT01535508',\n",
       " 'NCT02538848',\n",
       " 'NCT02261090',\n",
       " 'NCT04338321',\n",
       " 'NCT01237808',\n",
       " 'NCT02324257',\n",
       " 'NCT03922750',\n",
       " 'NCT03850691',\n",
       " 'NCT05045378',\n",
       " 'NCT02173301',\n",
       " 'NCT05717621',\n",
       " 'NCT03415711',\n",
       " 'NCT06239623',\n",
       " 'NCT00322699',\n",
       " 'NCT00315601',\n",
       " 'NCT03257670',\n",
       " 'NCT01037140',\n",
       " 'NCT01180660',\n",
       " 'NCT00238368',\n",
       " 'NCT01900184',\n",
       " 'NCT03832426',\n",
       " 'NCT05799053',\n",
       " 'NCT00443703',\n",
       " 'NCT02214615',\n",
       " 'NCT01483469',\n",
       " 'NCT01213693',\n",
       " 'NCT01900093',\n",
       " 'NCT02533375',\n",
       " 'NCT01767857',\n",
       " 'NCT05350943',\n",
       " 'NCT00370552',\n",
       " 'NCT00115336',\n",
       " 'NCT00738101',\n",
       " 'NCT05214495',\n",
       " 'NCT04493138',\n",
       " 'NCT02691910',\n",
       " 'NCT01723722',\n",
       " 'NCT03564288',\n",
       " 'NCT00197613',\n",
       " 'NCT00316849',\n",
       " 'NCT05589753',\n",
       " 'NCT05769010',\n",
       " 'NCT03834051',\n",
       " 'NCT00983944',\n",
       " 'NCT03469583',\n",
       " 'NCT02005666',\n",
       " 'NCT04296266',\n",
       " 'NCT01369329',\n",
       " 'NCT02815397',\n",
       " 'NCT03878927',\n",
       " 'NCT01176565',\n",
       " 'NCT00106613',\n",
       " 'NCT03904368',\n",
       " 'NCT02390258',\n",
       " 'NCT03245333',\n",
       " 'NCT02981277',\n",
       " 'NCT04483206',\n",
       " 'NCT04573946',\n",
       " 'NCT00381264',\n",
       " 'NCT02115113',\n",
       " 'NCT02392871',\n",
       " 'NCT00005961',\n",
       " 'NCT02720770',\n",
       " 'NCT03061981',\n",
       " 'NCT01779167',\n",
       " 'NCT04142151',\n",
       " 'NCT04858074',\n",
       " 'NCT00871507',\n",
       " 'NCT00376636',\n",
       " 'NCT06021145',\n",
       " 'NCT05409417',\n",
       " 'NCT03583307',\n",
       " 'NCT02776033',\n",
       " 'NCT01427907',\n",
       " 'NCT02985177',\n",
       " 'NCT04255069',\n",
       " 'NCT05621759',\n",
       " 'NCT03586674',\n",
       " 'NCT00652106',\n",
       " 'NCT00728923',\n",
       " 'NCT02615730',\n",
       " 'NCT03592693',\n",
       " 'NCT05664971',\n",
       " 'NCT02614456',\n",
       " 'NCT00669877',\n",
       " 'NCT02924272',\n",
       " 'NCT01859702',\n",
       " 'NCT00642850',\n",
       " 'NCT01976845',\n",
       " 'NCT00116064',\n",
       " 'NCT00754767',\n",
       " 'NCT00720512',\n",
       " 'NCT00762034',\n",
       " 'NCT00210548',\n",
       " 'NCT01845194',\n",
       " 'NCT05945147',\n",
       " 'NCT02268422',\n",
       " 'NCT05817851',\n",
       " 'NCT00777673',\n",
       " 'NCT01329406',\n",
       " 'NCT01195766',\n",
       " 'NCT01536717',\n",
       " 'NCT00805480',\n",
       " 'NCT03304873',\n",
       " 'NCT02187094',\n",
       " 'NCT01999322',\n",
       " 'NCT04486716',\n",
       " 'NCT06087289',\n",
       " 'NCT04588922',\n",
       " 'NCT04023253',\n",
       " 'NCT06182358',\n",
       " 'NCT06198907',\n",
       " 'NCT00847860',\n",
       " 'NCT01585428',\n",
       " 'NCT00965978',\n",
       " 'NCT02475070',\n",
       " 'NCT03903809',\n",
       " 'NCT00919503',\n",
       " 'NCT00924989',\n",
       " 'NCT02853643',\n",
       " 'NCT03941535',\n",
       " 'NCT01028222',\n",
       " 'NCT01538511',\n",
       " 'NCT00686543',\n",
       " 'NCT01302249',\n",
       " 'NCT01720550',\n",
       " 'NCT03237728',\n",
       " 'NCT04686448',\n",
       " 'NCT05477797',\n",
       " 'NCT02088073',\n",
       " 'NCT05307978',\n",
       " 'NCT00938145',\n",
       " 'NCT00135824',\n",
       " 'NCT00518271',\n",
       " 'NCT02318303',\n",
       " 'NCT02886962',\n",
       " 'NCT01484080',\n",
       " 'NCT00799058',\n",
       " 'NCT02242188',\n",
       " 'NCT01754402',\n",
       " 'NCT00021814',\n",
       " 'NCT04826588',\n",
       " 'NCT02895061',\n",
       " 'NCT03197714',\n",
       " 'NCT03046979',\n",
       " 'NCT05255523',\n",
       " 'NCT00877006',\n",
       " 'NCT01924000',\n",
       " 'NCT01012141',\n",
       " 'NCT05542342',\n",
       " 'NCT03080831',\n",
       " 'NCT05840510',\n",
       " 'NCT06112223',\n",
       " 'NCT01027559',\n",
       " 'NCT03377257',\n",
       " 'NCT04551911',\n",
       " 'NCT00163189',\n",
       " 'NCT01745458',\n",
       " 'NCT00060632',\n",
       " 'NCT00436267',\n",
       " 'NCT00252356',\n",
       " 'NCT01342289',\n",
       " 'NCT02414048',\n",
       " 'NCT00279162',\n",
       " 'NCT00310895',\n",
       " 'NCT04943757',\n",
       " 'NCT04903743',\n",
       " 'NCT02274974',\n",
       " 'NCT01486810',\n",
       " 'NCT02092701',\n",
       " 'NCT03489239',\n",
       " 'NCT05285592',\n",
       " 'NCT02825147',\n",
       " 'NCT04583254',\n",
       " 'NCT00471640',\n",
       " 'NCT03453034',\n",
       " 'NCT00514293',\n",
       " 'NCT01145534',\n",
       " 'NCT05405192',\n",
       " 'NCT03739619',\n",
       " 'NCT01977859',\n",
       " 'NCT00329628',\n",
       " 'NCT04107727',\n",
       " 'NCT00662363',\n",
       " 'NCT00049361',\n",
       " 'NCT00541099',\n",
       " 'NCT01454440',\n",
       " 'NCT00317512',\n",
       " 'NCT05440227',\n",
       " 'NCT02840552',\n",
       " 'NCT03057704',\n",
       " 'NCT03847467',\n",
       " 'NCT00502346',\n",
       " 'NCT03043443',\n",
       " 'NCT06176248',\n",
       " 'NCT01397500',\n",
       " 'NCT01085630',\n",
       " 'NCT01875250',\n",
       " 'NCT00819741',\n",
       " 'NCT03994380',\n",
       " 'NCT03410693',\n",
       " 'NCT03522129',\n",
       " 'NCT03633461',\n",
       " 'NCT04400487',\n",
       " 'NCT00357734',\n",
       " 'NCT03226392',\n",
       " 'NCT03435692',\n",
       " 'NCT01158885',\n",
       " 'NCT04286789',\n",
       " 'NCT01224236',\n",
       " 'NCT02194985',\n",
       " 'NCT03239600',\n",
       " 'NCT00875160',\n",
       " 'NCT01135459',\n",
       " 'NCT00422331',\n",
       " 'NCT04346862',\n",
       " 'NCT02777749',\n",
       " 'NCT02925559',\n",
       " 'NCT03217812',\n",
       " 'NCT01064284',\n",
       " 'NCT03208465',\n",
       " 'NCT00972374',\n",
       " 'NCT03571828',\n",
       " 'NCT00735969',\n",
       " 'NCT04206553',\n",
       " 'NCT05327803',\n",
       " 'NCT01586091',\n",
       " 'NCT05906537',\n",
       " 'NCT01440309',\n",
       " 'NCT00542685',\n",
       " 'NCT05005182',\n",
       " 'NCT00040417',\n",
       " 'NCT05517837',\n",
       " 'NCT01575769',\n",
       " 'NCT02295774',\n",
       " 'NCT05378737',\n",
       " 'NCT00624923',\n",
       " 'NCT02185339',\n",
       " 'NCT02600429',\n",
       " 'NCT00032799',\n",
       " ...]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cross_index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>start_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>time_day</th>\n",
       "      <th>month</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ntcid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT01887340</th>\n",
       "      <td>June 2013</td>\n",
       "      <td>June 2016</td>\n",
       "      <td>1096</td>\n",
       "      <td>36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00449449</th>\n",
       "      <td>September 2003</td>\n",
       "      <td>September 2006</td>\n",
       "      <td>1096</td>\n",
       "      <td>36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00852670</th>\n",
       "      <td>October 2008</td>\n",
       "      <td>July 2009</td>\n",
       "      <td>273</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04326283</th>\n",
       "      <td>April 2, 2020</td>\n",
       "      <td>April 28, 2023</td>\n",
       "      <td>1121</td>\n",
       "      <td>37</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05910983</th>\n",
       "      <td>December 1, 2023</td>\n",
       "      <td>May 1, 2024</td>\n",
       "      <td>152</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00604019</th>\n",
       "      <td>March 2003</td>\n",
       "      <td>August 2009</td>\n",
       "      <td>2345</td>\n",
       "      <td>78</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02782481</th>\n",
       "      <td>August 2016</td>\n",
       "      <td>October 15, 2018</td>\n",
       "      <td>805</td>\n",
       "      <td>26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02384889</th>\n",
       "      <td>April 2015</td>\n",
       "      <td>October 7, 2019</td>\n",
       "      <td>1650</td>\n",
       "      <td>55</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04261465</th>\n",
       "      <td>December 1, 2019</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>366</td>\n",
       "      <td>12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01033305</th>\n",
       "      <td>March 2010</td>\n",
       "      <td>August 2011</td>\n",
       "      <td>518</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>166587 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                   start_date   completion_date  time_day  month\n",
       "ntcid                                                           \n",
       "NCT01887340         June 2013         June 2016      1096     36\n",
       "NCT00449449    September 2003    September 2006      1096     36\n",
       "NCT00852670      October 2008         July 2009       273      9\n",
       "NCT04326283     April 2, 2020    April 28, 2023      1121     37\n",
       "NCT05910983  December 1, 2023       May 1, 2024       152      5\n",
       "...                       ...               ...       ...    ...\n",
       "NCT00604019        March 2003       August 2009      2345     78\n",
       "NCT02782481       August 2016  October 15, 2018       805     26\n",
       "NCT02384889        April 2015   October 7, 2019      1650     55\n",
       "NCT04261465  December 1, 2019  December 1, 2020       366     12\n",
       "NCT01033305        March 2010       August 2011       518     17\n",
       "\n",
       "[166587 rows x 4 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duration_prediction_output = date_df.loc[cross_index]\n",
    "duration_prediction_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>icdcodes</th>\n",
       "      <th>drugs</th>\n",
       "      <th>criteria</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nctid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT01887340</th>\n",
       "      <td>[]</td>\n",
       "      <td>['carboplatin', 'etoposide', 'cisplatin']</td>\n",
       "      <td>\\n        Inclusion Criteria shared:\\r\\n\\r\\n  ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00449449</th>\n",
       "      <td>[\"['N46.8', 'N46.9', 'N97.9', 'N97.0', 'N97.1'...</td>\n",
       "      <td>['pertubation with lidocain solution']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00852670</th>\n",
       "      <td>[\"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1'...</td>\n",
       "      <td>['act-128800', 'placebo']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04326283</th>\n",
       "      <td>[\"['G12.21']\"]</td>\n",
       "      <td>['trametinib (0.5 mg)', 'trametinib (1 mg)', '...</td>\n",
       "      <td>\\n        Main inclusion criteria:\\r\\n\\r\\n    ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05910983</th>\n",
       "      <td>[\"['N32.81']\"]</td>\n",
       "      <td>['intravesical botox injection']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00604019</th>\n",
       "      <td>[\"['T81.12XS', 'R65.20', 'R65.21', 'T81.12XA',...</td>\n",
       "      <td>['dopamine', 'norepinephrine']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02782481</th>\n",
       "      <td>[\"['G20.A2', 'G20.B2', 'G20.A1', 'G20.B1']\"]</td>\n",
       "      <td>['nd0612', 'placebo']</td>\n",
       "      <td>\\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02384889</th>\n",
       "      <td>[\"['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10...</td>\n",
       "      <td>['difluoromethylornithine', 'placebo']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04261465</th>\n",
       "      <td>[]</td>\n",
       "      <td>['olaparib', 'paclitaxel', 'carboplatin']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01033305</th>\n",
       "      <td>[]</td>\n",
       "      <td>['cycol™', 'placebo']</td>\n",
       "      <td>\\n        Inclusion Criteria:\\r\\n\\r\\n         ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>166587 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                      icdcodes  \\\n",
       "nctid                                                            \n",
       "NCT01887340                                                 []   \n",
       "NCT00449449  [\"['N46.8', 'N46.9', 'N97.9', 'N97.0', 'N97.1'...   \n",
       "NCT00852670  [\"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1'...   \n",
       "NCT04326283                                     [\"['G12.21']\"]   \n",
       "NCT05910983                                     [\"['N32.81']\"]   \n",
       "...                                                        ...   \n",
       "NCT00604019  [\"['T81.12XS', 'R65.20', 'R65.21', 'T81.12XA',...   \n",
       "NCT02782481       [\"['G20.A2', 'G20.B2', 'G20.A1', 'G20.B1']\"]   \n",
       "NCT02384889  [\"['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10...   \n",
       "NCT04261465                                                 []   \n",
       "NCT01033305                                                 []   \n",
       "\n",
       "                                                         drugs  \\\n",
       "nctid                                                            \n",
       "NCT01887340          ['carboplatin', 'etoposide', 'cisplatin']   \n",
       "NCT00449449             ['pertubation with lidocain solution']   \n",
       "NCT00852670                          ['act-128800', 'placebo']   \n",
       "NCT04326283  ['trametinib (0.5 mg)', 'trametinib (1 mg)', '...   \n",
       "NCT05910983                   ['intravesical botox injection']   \n",
       "...                                                        ...   \n",
       "NCT00604019                     ['dopamine', 'norepinephrine']   \n",
       "NCT02782481                              ['nd0612', 'placebo']   \n",
       "NCT02384889             ['difluoromethylornithine', 'placebo']   \n",
       "NCT04261465          ['olaparib', 'paclitaxel', 'carboplatin']   \n",
       "NCT01033305                              ['cycol™', 'placebo']   \n",
       "\n",
       "                                                      criteria  \n",
       "nctid                                                           \n",
       "NCT01887340  \\n        Inclusion Criteria shared:\\r\\n\\r\\n  ...  \n",
       "NCT00449449  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT00852670  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT04326283  \\n        Main inclusion criteria:\\r\\n\\r\\n    ...  \n",
       "NCT05910983  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "...                                                        ...  \n",
       "NCT00604019  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT02782481  \\n        Key Inclusion Criteria:\\r\\n\\r\\n     ...  \n",
       "NCT02384889  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT04261465  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "NCT01033305  \\n        Inclusion Criteria:\\r\\n\\r\\n         ...  \n",
       "\n",
       "[166587 rows x 3 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duration_prediction_input = duration_prediction_input.loc[cross_index]\n",
    "duration_prediction_input"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# duration_prediction_input.to_csv(f'trial-duration-prediction/input.csv')\n",
    "date_df.set_index('ntcid')\n",
    "date_df.to_csv(f'trial-duration-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## drug repurpose"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 171992/171992 [15:41<00:00, 182.61it/s]\n"
     ]
    }
   ],
   "source": [
    "start, complete = [], []\n",
    "for i in tqdm(raw_data.index):\n",
    "    xml_file = nctid2path(i)\n",
    "    # print(xml_file)\n",
    "    start_date, completion_date, type = xmlfile2date(xml_file)\n",
    "    # print(start_date, completion_date)\n",
    "    if start_date != '':\n",
    "        start_date = parse_date(start_date).year\n",
    "        # print(start_date.year)\n",
    "    else:\n",
    "        start_date = None\n",
    "    if completion_date != '':\n",
    "        completion_date = parse_date(completion_date).year\n",
    "        # print(completion_date.year)\n",
    "    else:\n",
    "        completion_date = None\n",
    "    start.append(start_date)\n",
    "    complete.append(completion_date)\n",
    "    # print(start_date, completion_date)\n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "raw_data['complete_year'] = complete\n",
    "raw_data['start_year'] = start\n",
    "raw_data.to_csv('raw_data.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train Set: 62043 Test Set: 104049\n"
     ]
    }
   ],
   "source": [
    "year = 2019\n",
    "test_part = raw_data[['diseases','icdcodes','drugs','smiless']][raw_data['complete_year'].apply(lambda x: year >= x if x is not None else False)]\n",
    "train_part = raw_data[['diseases','icdcodes','drugs','smiless']][raw_data['complete_year'].apply(lambda x: year < x if x is not None else False)]\n",
    "print(f'Train Set: {len(train_part.dropna())} Test Set: {len(test_part.dropna())}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 62043/62043 [00:04<00:00, 14692.67it/s]\n"
     ]
    }
   ],
   "source": [
    "train_drug_dict = {}\n",
    "train_drug_disease = {}\n",
    "for i in tqdm(train_part.index):\n",
    "    drugs = train_part.loc[i, 'drugs']\n",
    "    drugs = drugs if isinstance(drugs, list) else eval(drugs)\n",
    "    diseases = train_part.loc[i, 'diseases']\n",
    "    diseases = diseases if isinstance(diseases, list) else eval(diseases)\n",
    "    if isinstance(drugs, list):\n",
    "        for drug in drugs:\n",
    "            if drug in train_drug_dict:\n",
    "                train_drug_dict[drug] += 1\n",
    "                if isinstance(train_drug_disease[drug], list):\n",
    "                    if isinstance(diseases, list):\n",
    "                        train_drug_disease[drug].extend(diseases)\n",
    "                    else:\n",
    "                        train_drug_disease[drug].append(diseases)\n",
    "                else:\n",
    "                    train_drug_disease[drug] = diseases if isinstance(diseases, list) else [diseases]\n",
    "            else:\n",
    "                train_drug_dict[drug] = 1\n",
    "                train_drug_disease[drug] = diseases if isinstance(diseases, list) else [diseases]\n",
    "            train_drug_disease[drug] = list(set(train_drug_disease[drug]))\n",
    "    else:\n",
    "        print(drugs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train total pair: 206724\n"
     ]
    }
   ],
   "source": [
    "train_drug_twice = []\n",
    "total_pair = 0\n",
    "for k, v in train_drug_dict.items():\n",
    "    if v >= 2:\n",
    "        train_drug_twice.append(k)\n",
    "    total_pair += len(train_drug_disease[k])\n",
    "print(f\"Train total pair: {total_pair}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/95628 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 95628/95628 [00:05<00:00, 16033.98it/s]\n"
     ]
    }
   ],
   "source": [
    "test_drug_dict = {}\n",
    "test_drug_disease = {}\n",
    "for i in tqdm(test_part.index):\n",
    "    drugs = test_part.loc[i, 'drugs']\n",
    "    drugs = drugs if isinstance(drugs, list) else eval(drugs)\n",
    "    diseases = test_part.loc[i, 'diseases']\n",
    "    diseases = diseases if isinstance(diseases, list) else eval(diseases)\n",
    "    # print(diseases)\n",
    "    if isinstance(drugs, list):\n",
    "        for drug in drugs:\n",
    "            if drug in test_drug_dict:\n",
    "                test_drug_dict[drug] += 1\n",
    "                if isinstance(test_drug_disease[drug], list):\n",
    "                    if isinstance(diseases, list):\n",
    "                        test_drug_disease[drug].extend(diseases)\n",
    "                    else:\n",
    "                        test_drug_disease[drug].append(diseases)\n",
    "                else:\n",
    "                    test_drug_disease[drug] =  diseases if isinstance(diseases, list) else [diseases]\n",
    "            else:\n",
    "                test_drug_dict[drug] = 1\n",
    "                test_drug_disease[drug] = diseases if isinstance(diseases, list) else [diseases]\n",
    "\n",
    "            test_drug_disease[drug] = list(set(test_drug_disease[drug]))\n",
    "    else:\n",
    "        print(drugs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Test total pair: 99289\n"
     ]
    }
   ],
   "source": [
    "drop_k = []\n",
    "save_k = []\n",
    "total_pair = 0\n",
    "for k, v in test_drug_dict.items():\n",
    "    if k in train_drug_dict.keys():\n",
    "        save_k.append(k)\n",
    "        total_pair += len(test_drug_disease[k])\n",
    "    else:\n",
    "        drop_k.append(k)\n",
    "\n",
    "print(f\"Test total pair: {total_pair}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trial Approval Prediction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "trail approval 是否是status？"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "approval_input = raw_data[['icdcodes', 'drugs', 'criteria']]\n",
    "approval_output = raw_data[['status']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "def str2binary(value):\n",
    "    if value == 'Completed':\n",
    "        return 1\n",
    "    elif value == 'Terminated':\n",
    "        return 0\n",
    "    else:\n",
    "        return -1\n",
    "    \n",
    "# approval_output['label'] = approval_output['status'].apply(str2binary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "def xml2approval(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    try:\n",
    "        status = root.find('overall_status').text\n",
    "    except:\n",
    "        status = ''\n",
    "    return status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "483239it [16:24, 490.71it/s] \n"
     ]
    }
   ],
   "source": [
    "approval_output = []\n",
    "\n",
    "with open('../../data/all_xml', 'r') as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f'../../{xml_path.strip()}'\n",
    "        nct_id = re.search(r'/([^/]+)\\.xml$', xml_path).group(1)\n",
    "        status = xml2approval(xml_path)\n",
    "        if str2binary(status) != -1:\n",
    "            approval_output.append((nct_id, status, str2binary(status)))\n",
    "        \n",
    "approval_output_df = pd.DataFrame(approval_output, columns=['ntcid', 'status', 'label']).set_index('ntcid')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "label\n",
       "1    263381\n",
       "0     28014\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "approval_output_df['label'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# approval_input.to_csv('trial-approval-prediction/input.csv')\n",
    "approval_output_df.to_csv('trial-approval-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trial Failure Reason Prediction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "选择 why_stopped? 还是只筛出trial_outcom_v1.csv的"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "failure_input = raw_data[['icdcodes', 'drugs', 'criteria']][raw_data['status']!='completed']\n",
    "failure_output = raw_data['why_stop'][raw_data['status']!='completed']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "why_stop\n",
       "\\n    slow accrual\\r\\n                                                                                                                                         294\n",
       "\\n    sponsor decision\\r\\n                                                                                                                                     236\n",
       "\\n    low accrual\\r\\n                                                                                                                                          202\n",
       "\\n    lack of funding\\r\\n                                                                                                                                      178\n",
       "\\n    lack of enrollment\\r\\n                                                                                                                                   114\n",
       "                                                                                                                                                              ... \n",
       "\\n    b3301002 was discontinued on 18 april 2012 for strategic reasons.there were no safety concerns\\r\\n    leading to discontinuation of this study.\\r\\n        1\n",
       "\\n    study stopped due to early stopping rule\\r\\n                                                                                                               1\n",
       "\\n    pi has passed away. requested by department to terminate study.\\r\\n                                                                                        1\n",
       "\\n    due to unforseen recruiting difficulties, the study was closed.\\r\\n                                                                                        1\n",
       "\\n    investigators no longer wanted to pursue this research topic\\r\\n                                                                                           1\n",
       "Name: count, Length: 13586, dtype: int64"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "raw_data['why_stop'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>trialOutcome</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>studyid</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000102</th>\n",
       "      <td>Completed, Outcome unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000105</th>\n",
       "      <td>Terminated, Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000172</th>\n",
       "      <td>Completed, Positive outcome/primary endpoint(s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000173</th>\n",
       "      <td>Completed, Positive outcome/primary endpoint(s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000174</th>\n",
       "      <td>Completed, Negative outcome/primary endpoint(s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03733301</th>\n",
       "      <td>Completed, Positive outcome/primary endpoint(s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03733574</th>\n",
       "      <td>Completed, Outcome unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03735446</th>\n",
       "      <td>Terminated, Business decision - Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03736044</th>\n",
       "      <td>Completed, Outcome unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03736473</th>\n",
       "      <td>Completed, Outcome unknown</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>51291 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                  trialOutcome\n",
       "studyid                                                       \n",
       "NCT00000102                         Completed, Outcome unknown\n",
       "NCT00000105                                  Terminated, Other\n",
       "NCT00000172  Completed, Positive outcome/primary endpoint(s...\n",
       "NCT00000173  Completed, Positive outcome/primary endpoint(s...\n",
       "NCT00000174  Completed, Negative outcome/primary endpoint(s...\n",
       "...                                                        ...\n",
       "NCT03733301  Completed, Positive outcome/primary endpoint(s...\n",
       "NCT03733574                         Completed, Outcome unknown\n",
       "NCT03735446              Terminated, Business decision - Other\n",
       "NCT03736044                         Completed, Outcome unknown\n",
       "NCT03736473                         Completed, Outcome unknown\n",
       "\n",
       "[51291 rows x 1 columns]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trial_outcome_v1 = pd.read_csv('data/IQVIA/trial_outcomes_v1.csv', index_col=0)\n",
    "trial_outcome_v1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "trialOutcome\n",
       "Completed, Positive outcome/primary endpoint(s) met          16067\n",
       "Completed, Outcome unknown                                    9162\n",
       "Completed, Outcome indeterminate                              4478\n",
       "Terminated, Poor enrollment                                   4088\n",
       "Completed, Negative outcome/primary endpoint(s) not met       3767\n",
       "Terminated, Unknown                                           3103\n",
       "Terminated, Planned but never initiated                       2562\n",
       "Terminated, Other                                             2000\n",
       "Terminated, Lack of efficacy                                  1682\n",
       "Terminated, Business decision - Other                         1448\n",
       "Terminated, Safety/adverse effects                             921\n",
       "Terminated, Lack of funding                                    752\n",
       "Terminated, Business decision - Pipeline reprioritization      691\n",
       "Terminated, Business decision - Drug strategy shift            315\n",
       "Completed, Early positive outcome                              255\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trial_outcome_v1['trialOutcome'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "trialOutcome\n",
       "Completed, Outcome indeterminate                             4478\n",
       "Terminated, Poor enrollment                                  4088\n",
       "Completed, Negative outcome/primary endpoint(s) not met      3767\n",
       "Terminated, Unknown                                          3103\n",
       "Terminated, Planned but never initiated                      2562\n",
       "Terminated, Other                                            2000\n",
       "Terminated, Lack of efficacy                                 1682\n",
       "Terminated, Business decision - Other                        1448\n",
       "Terminated, Safety/adverse effects                            921\n",
       "Terminated, Lack of funding                                   752\n",
       "Terminated, Business decision - Pipeline reprioritization     691\n",
       "Terminated, Business decision - Drug strategy shift           315\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# 选择trial outcome v1 里的 Completed, Positive outcome/primary endpoint(s) met / Completed, Outcome unknown / Completed, Outcome indeterminate / \n",
    "#                         Completed, Early positive outcome 除去 \n",
    "# Completed, Negative outcome/primary endpoint(s) not met 保留\n",
    "## completed 里的 p-n\n",
    "def Choose_completed(value):\n",
    "    delete = ['Completed, Positive outcome/primary endpoint(s) met', 'Completed, Outcome unknown', ' Completed, Outcome indeterminate', 'Completed, Early positive outcome']\n",
    "    if value in delete:\n",
    "        return False\n",
    "    else:\n",
    "        return True\n",
    "failure_output = trial_outcome_v1[trial_outcome_v1['trialOutcome'].apply(Choose_completed)]\n",
    "failure_output['trialOutcome'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_14127/3494840454.py:1: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  failure_output['label'] = failure_output['trialOutcome'].astype('category').cat.codes\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "label\n",
       "1     4478\n",
       "9     4088\n",
       "0     3767\n",
       "11    3103\n",
       "8     2562\n",
       "7     2000\n",
       "5     1682\n",
       "3     1448\n",
       "10     921\n",
       "6      752\n",
       "4      691\n",
       "2      315\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "failure_output['label'] = failure_output['trialOutcome'].astype('category').cat.codes\n",
    "failure_output['label'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10820"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# 取交集\n",
    "cross_index = list(set(failure_output.index.to_list()).intersection((failure_input.index.to_list())))\n",
    "len(cross_index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "failure_input = failure_input.loc[cross_index]\n",
    "failure_input.to_csv('trial-failure-reason-prediction/input.csv')\n",
    "failure_output = failure_output.loc[cross_index]\n",
    "failure_output.to_csv('trial-failure-reason-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patient-Trial Matching"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "没有找到patient单独的信息，只有一些分组后group的信息"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Eligibility Criteria Design"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "trial summary/objective 选择 哪个  是否要选择completed的部分"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "def xmlfile2text(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    try:\n",
    "        brief_title = root.find('brief_title').text\n",
    "    except:\n",
    "        brief_title = ''\n",
    "    try:\n",
    "        brief_summary = root.find('brief_summary/textblock').text\n",
    "    except:\n",
    "        brief_summary = ''\n",
    "    try:\n",
    "        detailed_description = root.find('detailed_description/textblock').text \n",
    "    except:\n",
    "        detailed_description = ''\n",
    "    try:\n",
    "        criteria = root.find('eligibility/criteria/textblock').text\n",
    "    except:\n",
    "        criteria = ''\n",
    "    try:\n",
    "        status = root.find('overall_status').text\n",
    "    except:\n",
    "        status = None\n",
    "    try:\n",
    "        phase = root.find('phase').text\n",
    "    except:\n",
    "        phase = None\n",
    "    \n",
    "    # print(brief_title, brief_summary, detailed_description, criteria, status, phase)\n",
    "\n",
    "    return brief_title, brief_summary, detailed_description, criteria, phase, status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "483239it [1:16:35, 105.15it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                    start_date    completion_date  time_day  month\n",
      "ntcid                                                             \n",
      "NCT00000105          July 2002         March 2012      3531    117\n",
      "NCT00000113     September 1997       October 2001      1491     49\n",
      "NCT00000114           May 1984          June 1987      1126     37\n",
      "NCT00000115      December 1990          June 1994      1278     42\n",
      "NCT00000116           May 1996     September 2002      2314     77\n",
      "...                        ...                ...       ...    ...\n",
      "NCT06264297  February 20, 2023       January 2027      1411     47\n",
      "NCT06264310         March 2024       January 2025       306     10\n",
      "NCT06264323  September 1, 2017       May 30, 2018       271      9\n",
      "NCT06264336      March 1, 2024  December 31, 2024       305     10\n",
      "NCT06264349     March 15, 2024       May 15, 2025       426     14\n",
      "\n",
      "[469937 rows x 4 columns]\n"
     ]
    }
   ],
   "source": [
    "text_list = []\n",
    "\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "        \n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        \n",
    "        brief_title, brief_summary, detailed_description, criteria, phase, status = xmlfile2text(xml_path)\n",
    "\n",
    "        text_list.append((nct_id, brief_title, brief_summary, detailed_description, criteria, phase, status))\n",
    "\n",
    "text_df = pd.DataFrame(text_list, columns=['ntcid', 'brief_title', 'brief_summary', 'detailed_description', 'criteria', 'phase', 'status'])\n",
    "text_df = text_df.set_index('ntcid')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "text_df.to_csv('eligibility-criteria-design/input.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Drug Dose Prediction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "dose information "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(['4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.', '2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.', 'Placebo administered orally once daily in combination with TCS.'], 'Phase 3')\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "483239it [24:47, 324.93it/s] \n"
     ]
    }
   ],
   "source": [
    "def xml2dose(xml_file):\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    phase = root.find('phase').text\n",
    "\n",
    "    interventions = [i for i in root.findall('intervention')]\n",
    "    arm_group_label = set([j.text for i in interventions if i.find('intervention_type').text=='Drug' for j in i.findall('arm_group_label') ])\n",
    "    arm_group = [i for i in root.findall('arm_group')]\n",
    "    description = [i.find('description').text for i in arm_group if i.find('arm_group_label').text in arm_group_label]\n",
    "    assert len(arm_group_label) == len(description)\n",
    "    return description, phase\n",
    "\n",
    "xml_file = \"../../raw_data/NCT0373xxxx/NCT03733301.xml\"\n",
    "result = xml2dose(xml_file)\n",
    "print(result)\n",
    "\n",
    "\n",
    "dose_description_list = []\n",
    "\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "\n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\\n\",\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        try:\n",
    "            dose_description, phase = xml2dose(xml_path)\n",
    "            if dose_description is not None:\n",
    "                dose_description_list.append((nct_id, dose_description, phase))\n",
    "        except:\n",
    "            continue\n",
    "\n",
    "dose_description_df = pd.DataFrame(dose_description_list, columns=['ntcid', 'dose_description', 'phase'])\n",
    "dose_description_df = dose_description_df.set_index('ntcid')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "dose = dose_description_df[dose_description_df['phase'] == 'Phase 2']\n",
    "# dose.to_csv('drug-dose-prediction/output_phase2.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "dose = pd.read_csv(f'drug-dose-prediction/output.csv', index_col=0)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>dose_description</th>\n",
       "      <th>phase</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nctid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000249</th>\n",
       "      <td>['Subject inhaled 20% N2O for 40 minutes with ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000250</th>\n",
       "      <td>['Subjects will immerse forearm in lukewarm wa...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000251</th>\n",
       "      <td>['Subjects inhale 30% N2O', 'Subjects inhale 0...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000252</th>\n",
       "      <td>['Subjects will inhale 0% N2O', 'Subjects will...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000271</th>\n",
       "      <td>['Participants were treated with desipramine, ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263491</th>\n",
       "      <td>['If participants show that they have no MRD, ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263543</th>\n",
       "      <td>['SG will be administered on Days 1 and 8 of c...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263959</th>\n",
       "      <td>['Patiants on stable nucleos(t)ide analog (NA)...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264141</th>\n",
       "      <td>['Nasal spray with nitric oxide releasing solu...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>['8 study subjects will receive placebo once d...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>35983 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              dose_description    phase\n",
       "nctid                                                                  \n",
       "NCT00000249  ['Subject inhaled 20% N2O for 40 minutes with ...  Phase 2\n",
       "NCT00000250  ['Subjects will immerse forearm in lukewarm wa...  Phase 2\n",
       "NCT00000251  ['Subjects inhale 30% N2O', 'Subjects inhale 0...  Phase 2\n",
       "NCT00000252  ['Subjects will inhale 0% N2O', 'Subjects will...  Phase 2\n",
       "NCT00000271  ['Participants were treated with desipramine, ...  Phase 2\n",
       "...                                                        ...      ...\n",
       "NCT06263491  ['If participants show that they have no MRD, ...  Phase 2\n",
       "NCT06263543  ['SG will be administered on Days 1 and 8 of c...  Phase 2\n",
       "NCT06263959  ['Patiants on stable nucleos(t)ide analog (NA)...  Phase 2\n",
       "NCT06264141  ['Nasal spray with nitric oxide releasing solu...  Phase 2\n",
       "NCT06264310  ['8 study subjects will receive placebo once d...  Phase 2\n",
       "\n",
       "[35983 rows x 2 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dose"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def select_dose_description(value):\n",
    "    if type(value)==list and len(value) > 0:\n",
    "        return True\n",
    "    elif type(value)==str and len(eval(value)) >0: \n",
    "        return True\n",
    "    else:\n",
    "        return False\n",
    "dose = dose[dose['dose_description'].apply(select_dose_description)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "dose.to_csv('drug-dose-prediction/output.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0, 12.0, 40.0]\n",
      "[30.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0]\n",
      "[1.0]\n",
      "[40.0, 12.0, 40.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[1.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 3.0]\n",
      "[]\n",
      "[500.0, 750.0]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 1.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.15]\n",
      "[]\n",
      "[15.0]\n",
      "[0.24]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 8.5]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0, 10.0, 5.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 1.5]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[100.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.04, 0.08, 0.12, 0.16]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.25, 15.0]\n",
      "[]\n",
      "[0.3]\n",
      "[45.0, 60.0, 60.0, 1.0, 60.0, 60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.5, 10.0, 15.0, 0.2, 3.5, 10.0, 15.0, 0.2]\n",
      "[0.25, 0.25]\n",
      "[10.0, 10.0]\n",
      "[50.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05, 0.1, 0.2]\n",
      "[]\n",
      "[16.0, 200.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.125, 0.125]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[3.0, 24.0]\n",
      "[]\n",
      "[1.0]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05, 0.1]\n",
      "[0.075]\n",
      "[]\n",
      "[]\n",
      "[28.0, 12.0, 0.025, 0.05, 33.0]\n",
      "[20.0]\n",
      "[20.0, 175.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.75, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0, 6.0, 6.0, 6.0]\n",
      "[7.5, 7.5]\n",
      "[]\n",
      "[0.06]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 2.0, 2.5]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[0.7, 0.7, 0.7]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[0.3, 10.0, 3.0, 10.0, 10.0, 10.0, 0.3, 0.3, 3.0, 3.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[6.25, 15.0]\n",
      "[1.5, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.1, 0.015, 0.015]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0, 2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 15.0, 15.0]\n",
      "[7.5]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[175.0, 90.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[1.2, 1.2, 1.2, 1.2, 1.2]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[20.0, 50.0, 20.0, 50.0, 20.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[0.075, 0.025, 0.05, 0.025, 0.0375]\n",
      "[0.15, 0.15]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 8.0, 10.0, 10.0, 20.0]\n",
      "[3.2]\n",
      "[]\n",
      "[]\n",
      "[0.3]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.772, 2.244]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 4.5]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 4.0]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0, 10.0]\n",
      "[0.15, 0.2, 0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[60.0]\n",
      "[]\n",
      "[20.0, 75.0, 100.0, 50.0, 5.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 1.3, 3.0]\n",
      "[25.0]\n",
      "[8.0, 4.0]\n",
      "[40.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 4.0, 2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1]\n",
      "[5.0, 5.0, 5.0, 5.0]\n",
      "[0.4, 0.4, 2.0, 1.0, 0.5, 0.25, 0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[0.05, 0.1]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[30.0, 60.0, 120.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 5.0]\n",
      "[10.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0, 4.0]\n",
      "[5.0]\n",
      "[60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 3.0, 4.0, 3.0]\n",
      "[]\n",
      "[6.0, 9.0, 6.0, 9.0]\n",
      "[4.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[12.0, 12.0, 12.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0, 60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0, 15.0]\n",
      "[0.7, 1.0]\n",
      "[]\n",
      "[]\n",
      "[500.0, 100.0, 500.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 120.0, 60.0, 120.0]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[5.0, 20.0]\n",
      "[]\n",
      "[5.0]\n",
      "[5.0]\n",
      "[3.0, 24.0, 2.5]\n",
      "[2.5, 10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[12.0, 12.0]\n",
      "[15.0]\n",
      "[15.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[100.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0, 2.0, 4.0, 8.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 0.03, 2.0, 0.03]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 5.0, 6.0, 15.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0, 10.0, 10.0, 15.0, 10.0]\n",
      "[]\n",
      "[0.16, 5.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 8.0, 6.0]\n",
      "[]\n",
      "[0.15, 0.15, 0.15]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.48]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 6.0, 9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[]\n",
      "[6.0, 8.0, 6.0]\n",
      "[6.0, 15.0]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.875, 3.5, 3.5, 3.5, 3.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[20.0]\n",
      "[20.0, 24.0, 25.0, 29.0, 30.0, 34.0]\n",
      "[9.0]\n",
      "[]\n",
      "[]\n",
      "[110.0, 110.0]\n",
      "[]\n",
      "[7.5, 120.0]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 10.0, 5.0, 1.5, 10.0, 5.0, 1.5, 0.1]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[0.375, 8.0, 0.375]\n",
      "[4.0, 4.0, 8.0, 20.0, 10.0, 10.0, 20.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[5.0]\n",
      "[6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 6.0, 2.0, 6.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[2.5]\n",
      "[2.0, 8.0, 6.0, 4.0, 2.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[15.0, 10.0, 10.0, 10.0, 10.0, 15.0]\n",
      "[]\n",
      "[0.5, 0.5, 0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[0.3, 0.6, 1.2, 2.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.75, 1.0, 1.25]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0, 50.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[0.05, 0.005, 0.1, 0.01]\n",
      "[]\n",
      "[50.0, 50.0, 0.0, 0.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[7.5, 10.0, 5.0, 12.5, 2.5, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[80.0]\n",
      "[2.5]\n",
      "[]\n",
      "[9.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[1.5, 15.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[15.0, 15.0, 20.0, 8.0, 15.0, 8.0]\n",
      "[5.0]\n",
      "[60.0, 60.0]\n",
      "[0.8]\n",
      "[3.6]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0, 3.0, 10.0]\n",
      "[]\n",
      "[60.0, 60.0, 60.0, 60.0, 60.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 1.5, 5.0, 1.5, 0.01]\n",
      "[]\n",
      "[6.5, 0.5, 2.0, 2.0, 2.0, 0.5, 2.0, 2.0, 2.0]\n",
      "[6.0, 4.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0, 15.0, 15.0, 15.0]\n",
      "[]\n",
      "[20.0, 10.0, 20.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.4, 4.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0, 0.5, 1.5, 2.0]\n",
      "[12.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[30.0, 10.0, 10.0, 3.0]\n",
      "[1.0, 2.0, 1.0, 4.0, 1.0, 8.0, 1.0, 12.0, 1.0, 16.0, 1.0, 1.0, 2.0, 1.0, 4.0, 1.0, 8.0, 1.0, 12.0, 1.0, 16.0, 1.0, 1.2, 2.0, 1.2, 4.0, 1.2, 8.0, 1.2, 12.0, 1.2, 16.0, 1.2, 1.2, 2.0, 1.2, 4.0, 1.2, 8.0, 1.2, 12.0, 1.2, 16.0, 1.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.2, 0.1, 0.2, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5]\n",
      "[4.0]\n",
      "[10.0]\n",
      "[]\n",
      "[0.15, 0.15]\n",
      "[]\n",
      "[0.9, 0.2, 0.9, 0.2, 0.5, 0.9, 0.2, 1.0, 0.9, 0.2, 2.0, 0.9, 0.2, 4.0, 0.1, 0.03, 0.1, 0.03, 0.5, 0.1, 0.03, 1.0, 0.1, 0.03, 2.0, 0.1, 0.03, 4.0]\n",
      "[0.9, 0.2, 0.5, 0.9, 0.2, 1.0, 0.9, 0.2, 2.0, 0.9, 0.2, 4.0, 0.9, 0.2, 8.0, 0.1, 0.03, 0.5, 0.1, 0.03, 1.0, 0.1, 0.03, 2.0, 0.1, 0.03, 4.0, 0.1, 0.03, 8.0]\n",
      "[15.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[1.5, 0.75, 1.5]\n",
      "[5.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0]\n",
      "[]\n",
      "[0.35]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.2]\n",
      "[]\n",
      "[5.0]\n",
      "[10.0, 30.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.9, 0.2, 0.9, 0.2, 0.5, 0.9, 0.2, 1.0, 0.9, 0.2, 2.0, 0.9, 0.2, 4.0, 0.1, 0.04, 0.1, 0.04, 0.5, 0.1, 0.04, 1.0, 0.1, 0.04, 2.0, 0.1, 0.04, 4.0]\n",
      "[15.0]\n",
      "[0.012]\n",
      "[0.9, 0.2, 0.5, 0.9, 0.2, 1.0, 0.9, 0.2, 2.0, 0.9, 0.2, 4.0, 0.9, 0.2, 0.8, 0.1, 0.4, 0.5, 0.1, 0.4, 1.0, 0.1, 0.4, 2.0, 0.1, 0.4, 4.0, 0.1, 0.4, 8.0]\n",
      "[20.0, 40.0, 80.0, 10.0, 10.0, 20.0, 40.0]\n",
      "[1.0, 2.5]\n",
      "[]\n",
      "[0.25, 2.5, 5.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[35.0]\n",
      "[20.0, 30.0, 40.0, 50.0, 60.0]\n",
      "[5.0, 10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[1.5]\n",
      "[0.3, 10.0, 0.1, 0.3, 1.5, 0.03, 0.3, 10.0, 0.1, 0.3, 1.5, 0.03]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[0.15, 0.5, 1.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 1.0, 0.4, 2.0, 1.0, 0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[0.1, 1.0, 1.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0]\n",
      "[]\n",
      "[6.0]\n",
      "[10.0, 15.0, 7.5, 15.0, 7.5, 10.0, 10.0, 15.0, 7.5]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 6.0]\n",
      "[]\n",
      "[3.3]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0, 15.0]\n",
      "[5.0]\n",
      "[]\n",
      "[10.0, 30.0]\n",
      "[60.0, 90.0]\n",
      "[]\n",
      "[0.47, 1.67, 3.34, 40.78, 0.47]\n",
      "[5.0]\n",
      "[60.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 1.0, 3.0, 2.5, 6.0]\n",
      "[9.0, 9.0, 27.0, 9.0, 9.0, 9.0, 9.0, 9.0, 9.0, 9.0, 9.0, 9.0]\n",
      "[]\n",
      "[7.5, 5.0]\n",
      "[]\n",
      "[0.2, 0.2]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0, 15.0, 15.0]\n",
      "[]\n",
      "[5.0, 10.0, 10.0]\n",
      "[]\n",
      "[0.5, 2.0]\n",
      "[240.0]\n",
      "[]\n",
      "[]\n",
      "[0.04]\n",
      "[]\n",
      "[15.0]\n",
      "[0.04]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0, 5.0, 7.0]\n",
      "[15.0, 75.0, 15.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.2]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[3.6]\n",
      "[]\n",
      "[3.6, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 3.0, 1.0, 10.0, 10.0, 10.0, 30.0, 30.0, 10.0, 30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0, 20.0]\n",
      "[1.7, 1.4, 3.9, 3.1]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 12.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.1, 1.7, 7.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.0625, 0.125]\n",
      "[8.0, 6.0, 6.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0, 10.0, 10.0, 15.0, 10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[0.16, 0.64, 0.16, 0.64]\n",
      "[10.0, 50.0, 30.0, 10.0, 50.0, 30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[5.0, 10.0, 20.0, 10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.045]\n",
      "[10.0, 20.0, 10.0, 20.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[0.02, 0.1]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 40.0]\n",
      "[]\n",
      "[30.0, 15.0, 30.0, 15.0, 30.0, 15.0]\n",
      "[]\n",
      "[0.7, 0.7, 1.0, 1.0, 1.5, 1.5, 2.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[0.14, 0.17, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 1.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.51, 0.17, 0.76, 0.17]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[60.0, 30.0]\n",
      "[1.0, 0.8, 50.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[4.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[3.0, 10.0, 3.0]\n",
      "[]\n",
      "[20.0, 1.0, 3.0, 6.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[2.5, 1.0, 5.0]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 5.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0, 0.16]\n",
      "[]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 6.0]\n",
      "[6.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0, 20.0]\n",
      "[5.0, 6.0, 6.0, 3.0]\n",
      "[]\n",
      "[8.0, 2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0, 5.0]\n",
      "[20.0, 20.0, 40.0, 80.0, 20.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[1.5, 3.0, 4.5]\n",
      "[3.2]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[15.0]\n",
      "[15.0]\n",
      "[]\n",
      "[50.0, 10.0]\n",
      "[1.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[0.1, 0.15, 0.2, 0.075]\n",
      "[]\n",
      "[]\n",
      "[15.0, 10.0]\n",
      "[]\n",
      "[5.0, 10.0, 5.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.4, 0.25, 0.1]\n",
      "[]\n",
      "[5.0]\n",
      "[0.2, 0.2, 1.0, 0.1]\n",
      "[1.0, 1.0]\n",
      "[0.024, 0.04]\n",
      "[30.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 1.0, 0.3, 15.0]\n",
      "[10.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0, 12.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[8.0]\n",
      "[0.9, 0.9]\n",
      "[7.5]\n",
      "[]\n",
      "[20.0, 40.0]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[10.0, 0.5, 10.0, 0.5]\n",
      "[11.0, 8.3, 11.0]\n",
      "[]\n",
      "[3.0, 10.0]\n",
      "[3.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[0.001, 0.003, 0.01, 0.03, 0.1]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[8.0, 12.0, 12.0, 12.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0, 20.0, 10.0, 40.0, 10.0, 20.0, 20.0, 10.0, 40.0]\n",
      "[60.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 10.0, 10.0, 10.0, 20.0]\n",
      "[2.0]\n",
      "[1.8, 1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[0.3, 1.0, 3.0]\n",
      "[4.0, 6.0]\n",
      "[5.0, 1.25, 10.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 4.0, 4.0, 4.0, 2.0, 4.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 1.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[160.0, 10.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[0.2, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[15.0, 6.0, 8.0]\n",
      "[0.15]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0, 7.5]\n",
      "[1.5, 1.0, 0.7]\n",
      "[4.0, 2.0, 8.0, 6.0, 8.0, 6.0, 4.0, 2.0, 8.0, 6.0, 4.0, 2.0, 8.0, 6.0]\n",
      "[20.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[5.0]\n",
      "[1.0]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[2.24, 3.14]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.8, 1.5, 1.2]\n",
      "[]\n",
      "[2.5]\n",
      "[10.0, 15.0, 15.0]\n",
      "[]\n",
      "[11.0, 11.0]\n",
      "[18.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.25]\n",
      "[10.0, 40.0, 80.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0, 6.0, 6.0, 2.0, 6.0, 6.0]\n",
      "[]\n",
      "[40.0, 80.0]\n",
      "[]\n",
      "[15.0]\n",
      "[100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.6, 11.2]\n",
      "[]\n",
      "[15.0]\n",
      "[0.5]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0, 15.0, 15.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[1.0]\n",
      "[5.0]\n",
      "[10.0, 20.0, 10.0, 2.5, 2.5]\n",
      "[10.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[2.0, 2.0]\n",
      "[2.0, 2.0, 2.0]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[]\n",
      "[5.6]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[5.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 9.0, 9.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5]\n",
      "[28.0, 14.0, 0.03]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 10.0, 60.0, 0.8, 5.0, 10.0, 5.0, 10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[7.5, 7.5, 7.5]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[0.5]\n",
      "[6.0, 2.0]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 10.0, 10.0, 10.0, 20.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 2.0, 1.8, 1.8, 1.3, 1.3, 1.5, 2.0, 1.5, 1.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[0.08, 0.14, 0.08, 0.14]\n",
      "[1.5, 2.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[14.0, 14.0]\n",
      "[20.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.3, 2.1, 0.5, 3.5]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 4.0, 6.0, 8.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 6.0, 10.0]\n",
      "[3.2]\n",
      "[3.2]\n",
      "[]\n",
      "[10.0]\n",
      "[4.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0]\n",
      "[9.0]\n",
      "[]\n",
      "[]\n",
      "[90.0]\n",
      "[0.25]\n",
      "[8.0, 25.0, 6.0, 25.0, 8.0, 25.0, 6.0, 25.0]\n",
      "[]\n",
      "[15.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[4.0, 7.5, 6.0]\n",
      "[10.0]\n",
      "[3.6]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[0.15, 0.15]\n",
      "[9.0]\n",
      "[]\n",
      "[5.6, 11.2, 11.2, 11.2]\n",
      "[1.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 4.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.0]\n",
      "[]\n",
      "[5.0]\n",
      "[10.0]\n",
      "[45.0, 45.0]\n",
      "[]\n",
      "[]\n",
      "[2.772]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[20.0, 20.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 4.0, 2.0]\n",
      "[]\n",
      "[2.0]\n",
      "[7.5, 9.4]\n",
      "[9.4]\n",
      "[]\n",
      "[2.2, 2.2, 2.2, 2.2, 2.5, 2.5]\n",
      "[2.0, 2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[25.0, 200.0, 5.0, 80.0, 200.0, 5.0, 80.0]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[15.0, 20.0]\n",
      "[6.0, 4.8, 3.6]\n",
      "[10.0]\n",
      "[1.0]\n",
      "[]\n",
      "[3.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[25.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 1.0, 0.5, 0.25, 0.125]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0, 10.0, 10.0]\n",
      "[0.03, 0.06, 0.06]\n",
      "[]\n",
      "[5.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[10.0, 5.0]\n",
      "[6.0]\n",
      "[7.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[6.0, 6.0, 10.0]\n",
      "[9.0]\n",
      "[7.5]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 6.0, 15.0]\n",
      "[0.25]\n",
      "[7.0, 14.0, 7.0, 14.0]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[9.0]\n",
      "[1.8]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[30.0, 10.0, 60.0, 20.0]\n",
      "[]\n",
      "[60.0]\n",
      "[2.0]\n",
      "[3.0, 3.0]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 5.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[12.5]\n",
      "[6.0, 9.0]\n",
      "[]\n",
      "[20.0, 5.0, 35.0]\n",
      "[6.0]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0, 20.0, 20.0, 25.0, 25.0, 30.0, 30.0, 35.0, 35.0, 40.0, 40.0, 45.0, 45.0, 50.0, 50.0, 55.0, 55.0]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[50.0, 30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[11.0]\n",
      "[1.0, 10.0]\n",
      "[]\n",
      "[6.0]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[15.0, 0.06, 0.06]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[1.5]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[0.25, 4.2, 0.2]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 5.0]\n",
      "[]\n",
      "[6.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.25]\n",
      "[]\n",
      "[10.0, 30.0, 45.0]\n",
      "[40.0, 20.0]\n",
      "[3.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0, 4.0, 4.0]\n",
      "[0.9]\n",
      "[]\n",
      "[3.14]\n",
      "[]\n",
      "[8.0, 8.0, 6.0]\n",
      "[1.8, 2.4, 1.2]\n",
      "[]\n",
      "[4.0, 0.375, 4.0, 0.375]\n",
      "[]\n",
      "[3.0, 6.0]\n",
      "[]\n",
      "[55.0]\n",
      "[]\n",
      "[0.9, 0.9, 0.9]\n",
      "[]\n",
      "[2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.9]\n",
      "[]\n",
      "[]\n",
      "[0.6]\n",
      "[]\n",
      "[10.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 6.0, 8.0, 6.0, 6.0]\n",
      "[]\n",
      "[1.0, 1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.6, 3.6, 3.6]\n",
      "[60.0, 60.0]\n",
      "[15.0]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[]\n",
      "[1.6]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[12.0]\n",
      "[]\n",
      "[5.0, 6.0]\n",
      "[]\n",
      "[6.4, 6.4]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.015, 0.015]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[12.0, 5.0]\n",
      "[]\n",
      "[3.75, 5.0]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[0.1, 1.0, 0.5, 1.0, 0.1, 0.5]\n",
      "[]\n",
      "[]\n",
      "[0.005, 0.0125, 0.011, 0.025, 0.027, 0.0625, 0.054, 0.125, 0.108, 0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[20.0, 30.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[0.1, 0.2, 0.3, 0.4, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 8.0, 6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[5.0, 20.0]\n",
      "[0.1, 0.3, 0.5, 0.75, 1.0, 1.5]\n",
      "[60.0, 0.6, 1.0]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[66.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 2.0, 9.0, 3.0, 12.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[1.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[0.16, 0.32]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[10.0, 10.0, 10.0, 10.0, 3.0, 5.0, 10.0, 3.0, 10.0, 5.0, 10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[10.0]\n",
      "[16.0]\n",
      "[15.0]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.075, 0.1, 0.15, 0.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 60.0, 80.0]\n",
      "[10.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 25.0]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[120.0, 60.0]\n",
      "[4.0]\n",
      "[]\n",
      "[10.0]\n",
      "[6.0, 4.0, 6.0, 4.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 5.0]\n",
      "[]\n",
      "[0.5]\n",
      "[10.0, 10.0]\n",
      "[1.0]\n",
      "[]\n",
      "[10.0, 0.5]\n",
      "[1.0, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 2.3]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[5.0, 2.5, 1.25, 0.15, 3.0, 0.15, 1.2, 0.15, 0.4, 0.15, 0.15, 5.0, 5.0, 0.4, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.4, 3.6, 3.6]\n",
      "[]\n",
      "[]\n",
      "[2.0, 10.0, 2.0, 2.0, 10.0, 10.0]\n",
      "[150.0, 50.0, 100.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[60.0, 55.0, 65.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 5.0]\n",
      "[3.0]\n",
      "[5.0, 5.0]\n",
      "[15.0]\n",
      "[]\n",
      "[12.0]\n",
      "[150.0, 50.0]\n",
      "[8.0]\n",
      "[0.9, 0.6, 0.9, 1.2, 1.5]\n",
      "[7.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[50.0, 5.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.4, 9.4, 9.4, 7.5, 9.4, 9.4, 7.5, 7.5, 7.5, 9.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 10.0, 15.0]\n",
      "[]\n",
      "[0.1, 0.3, 0.5, 1.0, 1.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 15.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[8.3, 25.0, 16.7, 50.0, 33.3, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.125, 0.5, 0.25, 0.0625]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.4]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0, 15.0, 15.0, 15.0]\n",
      "[1.0, 1.0, 0.5, 0.25, 0.125]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[7.5, 5.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 2.5, 2.5, 5.0, 2.5]\n",
      "[]\n",
      "[]\n",
      "[2.5, 5.0, 10.0, 5.0, 10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[15.0, 10.0, 15.0]\n",
      "[]\n",
      "[5.0, 20.0]\n",
      "[1.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[3.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[35.0, 20.0, 20.0]\n",
      "[5.0, 10.0, 3.2, 9.6]\n",
      "[]\n",
      "[]\n",
      "[0.3, 0.3]\n",
      "[]\n",
      "[]\n",
      "[0.41, 0.71]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[4.0, 2.0, 6.0, 8.0, 6.0, 6.0]\n",
      "[]\n",
      "[100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.4, 2.2, 4.4, 6.6]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0, 0.015, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 3.0, 5.0, 8.0, 8.0, 3.0, 8.0, 3.0, 5.0, 8.0, 3.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 5.0, 2.5, 10.0]\n",
      "[]\n",
      "[3.0]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.6, 4.0, 2.0, 6.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[400.0, 400.0]\n",
      "[2.5]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[0.12, 0.12]\n",
      "[70.0, 0.067, 70.0, 0.067]\n",
      "[3.0, 10.0, 30.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 7.0]\n",
      "[0.5]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[0.9]\n",
      "[]\n",
      "[7.0, 5.0, 7.0, 7.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 5.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 4.5]\n",
      "[]\n",
      "[6.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 30.0, 15.0, 30.0]\n",
      "[]\n",
      "[2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[60.0, 60.0]\n",
      "[]\n",
      "[0.15, 0.3, 0.6]\n",
      "[]\n",
      "[5.0]\n",
      "[15.0, 30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 4.0, 2.0, 3.6]\n",
      "[15.0, 0.1]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[0.4, 0.8, 0.4, 0.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.0]\n",
      "[]\n",
      "[7.0]\n",
      "[]\n",
      "[11.0, 14.0, 17.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[12.0]\n",
      "[0.1, 0.2, 0.5, 1.0, 0.045]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[]\n",
      "[1.2, 1.2, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8, 1.8]\n",
      "[]\n",
      "[1.0, 3.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 4.0]\n",
      "[3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0, 2.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 10.0, 3.0]\n",
      "[]\n",
      "[1.5, 1.5]\n",
      "[3.0, 20.0]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 10.0, 15.0, 5.0, 15.0, 20.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[6.0, 2.0, 12.0, 2.0]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[50.0, 50.0, 10.0, 50.0]\n",
      "[2.0, 3.5]\n",
      "[]\n",
      "[]\n",
      "[1.5, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 1.0]\n",
      "[16.0]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[2.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.07, 0.04]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[0.5, 1.0]\n",
      "[]\n",
      "[]\n",
      "[0.04, 0.04, 0.12, 0.04]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0, 6.0]\n",
      "[8.0, 6.0, 8.0, 8.0, 6.0, 8.0, 15.0]\n",
      "[3.0, 1.5, 1.5, 3.0, 1.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2, 2.5, 3.2, 2.5, 3.2, 2.5]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0, 6.0]\n",
      "[]\n",
      "[60.0, 60.0, 30.0, 60.0, 30.0, 30.0, 60.0, 60.0, 2.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 15.0, 10.0, 20.0, 10.0, 30.0]\n",
      "[1.5, 3.0, 6.0]\n",
      "[0.3, 50.0]\n",
      "[2.0]\n",
      "[]\n",
      "[0.24]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 3.0, 3.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[0.01, 0.01, 0.03, 0.06, 0.1, 0.03, 0.03, 0.06, 0.1, 0.1, 0.1, 0.06]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[25.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[36.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[3.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.7, 0.37]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 1.0, 2.0, 4.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.6, 0.8, 0.6, 0.3, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 3.0, 3.0, 2.0, 2.0]\n",
      "[2.6, 2.6]\n",
      "[]\n",
      "[]\n",
      "[13.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[1.0, 2.0, 3.0, 4.0, 4.0, 2.0, 4.0, 4.0, 4.0, 4.0, 5.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[4.0, 6.0]\n",
      "[5.0]\n",
      "[]\n",
      "[70.0, 70.0]\n",
      "[]\n",
      "[]\n",
      "[9.0, 6.0]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[6.0]\n",
      "[5.0, 5.0, 10.0, 10.0, 20.0, 20.0, 20.0, 20.0]\n",
      "[6.0]\n",
      "[]\n",
      "[100.0, 25.0, 200.0, 75.0]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0]\n",
      "[10.0, 0.24, 10.0, 0.24]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[3.14]\n",
      "[25.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[200.0]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[1.0, 3.0, 3.0, 0.35]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[5.0, 7.5, 5.0, 7.5]\n",
      "[]\n",
      "[50.0, 40.0, 50.0, 40.0, 50.0, 40.0, 0.015, 15.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0, 40.0, 14.0, 7.0, 28.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 8.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.5, 10.0, 5.0, 5.5, 0.1]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 2.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[3.0, 10.0, 10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.14, 0.14]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.4, 0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[1.2, 1.8]\n",
      "[5.33]\n",
      "[5.0, 15.0, 30.0, 5.0, 15.0, 30.0, 5.0, 15.0, 30.0]\n",
      "[]\n",
      "[0.4, 5.0]\n",
      "[]\n",
      "[32.0]\n",
      "[15.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.0, 0.0, 125.0, 5.0, 25.0, 1.0, 5.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[22.0]\n",
      "[0.15]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 10.0]\n",
      "[]\n",
      "[1.0, 3.0, 3.0, 5.0, 7.5, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 16.0]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[1.8]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 4.0, 2.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 4.0, 2.0, 8.0, 6.0, 4.0, 2.0, 6.0, 4.0, 2.0]\n",
      "[2.5, 0.5, 2.0, 0.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.0, 1.0, 2.0, 4.0, 0.0, 1.0, 2.0, 4.0, 0.0, 1.0, 2.0, 4.0, 0.0, 1.0, 2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[1.5]\n",
      "[]\n",
      "[]\n",
      "[50.0, 12.5]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[100.0, 40.0]\n",
      "[]\n",
      "[0.2, 0.2]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.25]\n",
      "[5.0, 5.0]\n",
      "[2.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 25.0, 5.0, 5.0, 25.0, 5.0, 15.0, 5.0, 25.0, 5.0]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[1.0]\n",
      "[8.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[1.0]\n",
      "[0.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0]\n",
      "[]\n",
      "[3.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[2.0, 1.5, 0.75]\n",
      "[]\n",
      "[0.5, 3.0, 0.5, 3.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 5.0, 5.0, 5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 10.0, 8.0, 10.0]\n",
      "[]\n",
      "[1.0, 50.0, 1.0, 50.0, 1.0, 50.0, 1.0, 50.0, 30.0, 0.03, 1.0, 50.0, 1.0, 50.0, 45.0, 0.03]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 120.0, 3.2, 12.8, 60.0, 120.0]\n",
      "[]\n",
      "[]\n",
      "[3.6]\n",
      "[3.0, 1.0]\n",
      "[2.0]\n",
      "[8.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 3.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 3.2]\n",
      "[0.2255]\n",
      "[6.0, 6.0, 9.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[2.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0, 10.0, 3.0, 10.0, 10.0]\n",
      "[10.0, 5.0, 35.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[6.0, 6.0, 6.0, 6.0]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[10.0]\n",
      "[20.0, 5.0, 10.0, 2.5]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[4.8]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[63.0]\n",
      "[]\n",
      "[]\n",
      "[0.045]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 25.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 1.0, 3.0, 3.0]\n",
      "[0.05]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.9]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.15]\n",
      "[2.0, 15.0, 4.0]\n",
      "[2.0, 15.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[12.0]\n",
      "[5.0]\n",
      "[1.0, 3.0, 3.0]\n",
      "[6.0]\n",
      "[3.0]\n",
      "[]\n",
      "[0.15, 0.25, 15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[100.0, 250.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[6.0, 12.0, 18.0, 2.5]\n",
      "[]\n",
      "[15.0]\n",
      "[7.5, 15.0]\n",
      "[]\n",
      "[]\n",
      "[320.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5, 0.5]\n",
      "[4.0]\n",
      "[30.0]\n",
      "[1.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 10.0, 5.0, 5.0]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.03, 0.015]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.15, 1.0]\n",
      "[50.0, 0.015, 15.0]\n",
      "[]\n",
      "[12.0, 6.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 30.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[5.0]\n",
      "[8.0, 8.0]\n",
      "[]\n",
      "[0.75, 40.0, 35.0, 40.0, 35.0, 5.0]\n",
      "[]\n",
      "[2.0, 8.0]\n",
      "[]\n",
      "[0.8]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.2, 6.0, 0.2, 6.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[2.4, 10.0, 2.4, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.2]\n",
      "[1.8]\n",
      "[5.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[2.4]\n",
      "[1.25, 1.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 0.2]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[0.08]\n",
      "[]\n",
      "[8.0, 8.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[105.0, 35.0, 70.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[1.8, 1.3]\n",
      "[]\n",
      "[3.0, 1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 2.0, 1.0, 2.0, 2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[2.0, 0.1, 0.3, 2.0, 25.0, 0.3, 2.0, 1.0, 40.0, 0.5, 0.3]\n",
      "[1.5, 1.5, 0.3]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[100.0, 200.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[0.5, 0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[4.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[20.0, 10.0, 40.0]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.3, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 30.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[0.016]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0, 4.0, 4.0, 2.0, 4.0, 4.0, 2.0, 4.0, 4.0, 2.0, 4.0, 4.0, 2.0, 4.0, 4.0, 2.0, 4.0, 4.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.57, 0.57]\n",
      "[15.0]\n",
      "[]\n",
      "[1.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[225.0, 450.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 2.0]\n",
      "[1.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0, 20.0, 20.0]\n",
      "[20.0, 30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0, 10.0]\n",
      "[0.04, 0.16, 0.08, 0.16, 0.16, 0.16]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[0.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[0.5, 0.045]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 5.0, 30.0, 0.03, 1.0, 50.0, 30.0, 0.03]\n",
      "[]\n",
      "[10.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[0.2, 0.4, 0.4, 0.4]\n",
      "[1.0, 3.0, 3.0, 1.0, 3.0, 3.0, 1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.25, 0.125]\n",
      "[]\n",
      "[24.0]\n",
      "[0.025]\n",
      "[0.025, 1.0]\n",
      "[]\n",
      "[6.0, 30.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[10.0, 5.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0, 10.0, 10.0, 20.0]\n",
      "[1.0, 3.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[110.0]\n",
      "[]\n",
      "[1.0, 1.2]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[250.0]\n",
      "[0.2, 8.0]\n",
      "[15.0]\n",
      "[]\n",
      "[20.0, 50.0]\n",
      "[1.0, 3.0]\n",
      "[100.0]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[]\n",
      "[0.03, 0.045, 0.03, 0.045, 0.03, 0.045, 0.03, 0.045]\n",
      "[]\n",
      "[10.0, 0.2, 3.0, 3.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.6, 0.45, 30.0, 0.45]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[16.0, 80.0]\n",
      "[]\n",
      "[]\n",
      "[0.3]\n",
      "[6.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[0.01, 1.0, 0.01, 1.0, 1.0, 1.0, 1.0]\n",
      "[10.0]\n",
      "[8.0]\n",
      "[6.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[3.25, 0.25, 0.75, 2.25]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8, 1.2, 1.8, 1.2]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[5.0, 10.0]\n",
      "[5.0, 5.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.1, 0.3, 0.2, 0.6, 0.5, 0.8]\n",
      "[]\n",
      "[]\n",
      "[7.0, 10.0, 15.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[3.6]\n",
      "[]\n",
      "[5.0]\n",
      "[8.0, 8.0, 6.0]\n",
      "[]\n",
      "[0.5, 0.045]\n",
      "[8.0]\n",
      "[1.0, 3.0, 3.0]\n",
      "[15.0, 15.0]\n",
      "[67.0, 200.0]\n",
      "[]\n",
      "[1.8]\n",
      "[0.075]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 80.0]\n",
      "[]\n",
      "[0.4]\n",
      "[5.0, 7.5]\n",
      "[1.8, 1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[13.33, 26.67]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.75, 2.0, 6.0]\n",
      "[0.25, 0.75, 2.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[5.0]\n",
      "[0.3]\n",
      "[10.0, 5.0, 20.0, 25.0, 10.0, 5.0, 20.0, 25.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.6, 0.6]\n",
      "[]\n",
      "[0.24]\n",
      "[25.0, 15.0, 15.0, 15.0, 15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[14.5, 9.0, 50.0, 9.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 40.0, 60.0, 30.0, 45.0, 60.0, 50.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[16.0, 16.0]\n",
      "[16.0]\n",
      "[0.2, 0.4, 0.6, 1.2]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[5.0, 5.0, 20.0]\n",
      "[15.0]\n",
      "[2.5]\n",
      "[10.0, 20.0, 40.0]\n",
      "[]\n",
      "[2.0, 2.0, 30.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.25, 1.25]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[0.25, 15.0, 45.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05, 0.2, 1.5, 2.0, 1.0, 0.05, 0.2, 0.05, 0.2, 1.5, 2.0, 1.0, 0.05, 0.2]\n",
      "[1.0]\n",
      "[15.0, 2.0, 31.0, 30.0, 4.0, 62.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 20.0]\n",
      "[]\n",
      "[1.8, 1.3]\n",
      "[40.0]\n",
      "[]\n",
      "[]\n",
      "[150.0, 50.0, 50.0, 150.0, 150.0, 50.0, 50.0, 150.0]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.4, 0.4, 0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 0.125, 4.0, 0.125, 4.0, 0.125, 4.0, 0.25, 4.0, 0.25, 4.0, 0.25]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[3.0, 1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.25]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 29.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[7.0, 7.0, 7.0]\n",
      "[]\n",
      "[30.0, 20.0]\n",
      "[0.05, 0.1, 0.05]\n",
      "[15.0]\n",
      "[]\n",
      "[3.0, 1.0, 3.0]\n",
      "[3.6]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[15.0, 6.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 6.0]\n",
      "[20.0]\n",
      "[1.8]\n",
      "[1.0, 3.0, 3.0, 1.0, 1.0, 3.0, 3.0, 3.0]\n",
      "[2.0, 2.0]\n",
      "[]\n",
      "[2.5, 5.0, 7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 4.5]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5, 7.5]\n",
      "[4.0, 0.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[1.0, 10.0, 1.0, 10.0]\n",
      "[]\n",
      "[6.0, 9.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[0.2, 0.4, 0.2, 0.05, 0.2, 0.4, 0.05, 0.4, 0.2, 0.08, 0.2, 0.4, 0.08, 0.4, 0.2, 0.1, 0.2, 0.4, 0.1, 0.4, 0.4, 0.125, 0.4, 0.2, 0.15, 0.2, 0.4, 0.15, 0.4, 0.2, 0.15, 0.2, 0.1, 0.2, 0.15, 0.2, 0.1]\n",
      "[3.0, 1.0, 3.0, 1.0, 3.0, 1.0, 3.0, 1.0]\n",
      "[4.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.07]\n",
      "[]\n",
      "[]\n",
      "[20.0, 36.0, 60.0]\n",
      "[3.25, 0.25, 0.75, 2.25]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 1.0, 3.0, 3.0, 3.0]\n",
      "[1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[25.0]\n",
      "[15.0, 1.8]\n",
      "[1.0, 0.03]\n",
      "[9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.15]\n",
      "[20.0]\n",
      "[10.0]\n",
      "[1.0]\n",
      "[]\n",
      "[2.4, 3.6, 2.4, 3.6]\n",
      "[6.0]\n",
      "[16.0]\n",
      "[]\n",
      "[10.0]\n",
      "[1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[0.25]\n",
      "[]\n",
      "[20.0, 40.0, 40.0, 20.0, 40.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 35.0]\n",
      "[65.0, 65.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0, 30.0, 15.0, 3.0, 2.0]\n",
      "[]\n",
      "[1.0, 3.0, 1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[0.9, 1.4, 0.9, 1.4, 0.9, 1.4]\n",
      "[]\n",
      "[0.3, 0.1]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[2.772]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 12.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[0.25, 0.25]\n",
      "[0.25, 0.75, 2.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[3.0, 9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0, 3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.3, 0.1, 0.3, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0, 0.03, 15.0]\n",
      "[10.0, 15.0, 10.0, 15.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[20.0, 20.0, 1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 8.0, 2.0, 20.0]\n",
      "[]\n",
      "[0.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5, 7.5, 7.5]\n",
      "[3.0, 1.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[0.5, 0.03]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[6.0]\n",
      "[0.125, 0.25, 0.5, 1.0, 1.0, 2.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[90.0]\n",
      "[3.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2]\n",
      "[1.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[0.3]\n",
      "[30.0, 30.0, 1.0, 30.0]\n",
      "[40.0, 80.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[24.0]\n",
      "[]\n",
      "[3.0, 1.0, 3.0, 1.0]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[0.1, 0.8, 0.2, 0.8, 0.4, 0.8, 0.8]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[16.0, 16.0]\n",
      "[]\n",
      "[0.03, 0.03]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[16.0, 16.0, 16.0, 16.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 0.1, 1.0, 5.0, 0.1, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.6]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[1.0, 3.0, 1.0]\n",
      "[3.6]\n",
      "[]\n",
      "[1.33, 0.8, 4.0, 2.4]\n",
      "[0.6, 1.0]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[20.0, 10.0, 10.0, 20.0]\n",
      "[4.0, 4.0]\n",
      "[30.0, 30.0]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[0.1, 0.2]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0, 16.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0, 20.0]\n",
      "[]\n",
      "[15.0]\n",
      "[3.0, 1.0, 3.0, 1.0]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[6.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[0.12]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[0.6, 1.2, 1.8, 1.8, 1.8]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.2, 0.4]\n",
      "[0.1, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8, 1.8]\n",
      "[4.0]\n",
      "[5.0, 7.5]\n",
      "[]\n",
      "[8.0, 15.0]\n",
      "[5.0]\n",
      "[15.0]\n",
      "[0.2, 0.12, 0.2, 0.12]\n",
      "[]\n",
      "[15.0, 15.0, 15.0, 15.0]\n",
      "[11.5]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.006, 0.006]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[5.0, 10.0, 15.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[200.0]\n",
      "[0.5, 0.5]\n",
      "[10.0, 10.0]\n",
      "[1.5, 1.5]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[0.2]\n",
      "[1.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[16.0]\n",
      "[10.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0, 16.0, 16.0, 16.0, 16.0, 16.0, 16.0]\n",
      "[]\n",
      "[]\n",
      "[11.0]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 60.0, 40.0, 40.0, 20.0, 60.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 30.0, 10.0]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[2.0, 1.4, 2.0]\n",
      "[1.0, 3.0, 1.0, 3.0]\n",
      "[]\n",
      "[0.25, 0.4]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[1.0, 1.0]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[50.0, 15.0, 5.0]\n",
      "[]\n",
      "[12.5, 10.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[0.02, 0.13]\n",
      "[10.0, 20.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.25]\n",
      "[]\n",
      "[]\n",
      "[3.5]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[0.04, 0.5]\n",
      "[]\n",
      "[]\n",
      "[2.5, 50.0, 2.5, 50.0]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0, 10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 5.0, 20.0]\n",
      "[]\n",
      "[1.0, 1.4, 2.08, 1.6]\n",
      "[10.0]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0]\n",
      "[6.0, 8.0, 1.0, 3.0, 4.0, 4.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0, 10.0, 20.0]\n",
      "[3.2, 2.5]\n",
      "[3.2, 2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[1.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 15.0, 30.0, 15.0, 400.0]\n",
      "[3.0]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[2.0]\n",
      "[16.0]\n",
      "[10.0]\n",
      "[2.0, 6.0, 0.75, 2.0, 0.75, 6.0, 2.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[0.3, 0.2]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[10.0, 3.0]\n",
      "[25.0, 20.0, 25.0, 20.0, 25.0, 20.0, 25.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[1.0]\n",
      "[5.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.1]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[16.0]\n",
      "[100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.12]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[0.3, 0.7]\n",
      "[0.3, 1.0, 1.0, 1.0, 0.3, 1.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[6.25, 150.0]\n",
      "[8.0, 6.0]\n",
      "[0.5]\n",
      "[8.0]\n",
      "[10.0, 5.0]\n",
      "[10.0]\n",
      "[10.0, 10.0]\n",
      "[6.4, 5.4, 6.4]\n",
      "[]\n",
      "[60.0, 50.0, 40.0, 30.0, 20.0]\n",
      "[]\n",
      "[2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[0.6, 1.0, 0.6, 2.0, 0.6, 4.0, 0.6, 6.0, 0.6, 8.0, 0.6, 0.6, 1.0, 0.6, 2.0, 0.6, 4.0, 0.6, 6.0, 0.6, 8.0, 0.6, 0.6, 1.0, 0.6, 2.0, 0.6, 4.0, 0.6, 6.0, 0.6, 8.0, 0.6]\n",
      "[0.6, 0.5, 1.2, 0.5, 0.6, 1.0, 1.2, 1.0, 0.6, 2.0, 1.2, 2.0, 0.6, 4.0, 1.2, 4.0, 0.6, 8.0, 1.2, 8.0]\n",
      "[3.0]\n",
      "[3.0, 3.0, 1.0, 3.0, 3.0, 1.0, 3.0, 1.0, 3.0, 3.0, 1.0]\n",
      "[15.0]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 3.4]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[4.0]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[0.5, 2.0]\n",
      "[]\n",
      "[35.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0, 10.0, 10.0, 10.0, 10.0, 10.0, 10.0, 10.0]\n",
      "[9.0, 6.0, 4.5, 3.0, 4.5, 3.0]\n",
      "[25.0, 50.0, 75.0]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[2.0, 3.0, 1.0, 3.0, 1.0, 3.0, 1.0]\n",
      "[7.0, 7.0]\n",
      "[0.75]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0, 20.0]\n",
      "[]\n",
      "[1.2, 0.9, 1.2, 1.2, 0.9]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[10.0]\n",
      "[]\n",
      "[1.0, 2.0, 3.0, 4.0, 5.0]\n",
      "[]\n",
      "[10.0, 209.0, 1.0, 10.0, 209.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.25]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[0.25, 0.5]\n",
      "[8.0, 6.0]\n",
      "[50.0]\n",
      "[8.0, 6.0]\n",
      "[7.5, 2.5, 7.5, 2.5]\n",
      "[15.0]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.4]\n",
      "[0.75, 0.75]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 2.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 80.0, 40.0, 80.0]\n",
      "[]\n",
      "[]\n",
      "[0.45]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[3.0]\n",
      "[]\n",
      "[1.0, 1.0, 1.0]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[3.0, 4.5, 0.85, 1.0, 1.5]\n",
      "[0.5]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[20.0, 5.0]\n",
      "[]\n",
      "[6.0, 4.0, 6.0, 4.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[7.0, 7.0, 7.0, 7.0, 7.0, 7.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[15.0]\n",
      "[]\n",
      "[15.0, 7.5]\n",
      "[]\n",
      "[16.0, 16.0, 16.0]\n",
      "[]\n",
      "[16.0, 16.0]\n",
      "[]\n",
      "[20.0, 15.0, 15.0]\n",
      "[5.0]\n",
      "[0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.3, 0.5, 2.0, 2.5, 2.0]\n",
      "[8.0]\n",
      "[]\n",
      "[50.0]\n",
      "[]\n",
      "[18.0, 9.0, 18.0, 9.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[0.3]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[20.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[15.0]\n",
      "[0.215]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 16.0, 16.0, 16.0, 16.0]\n",
      "[1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[8.0]\n",
      "[]\n",
      "[40.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[0.16, 0.16, 0.32, 0.32, 0.5]\n",
      "[3.0]\n",
      "[2.0]\n",
      "[8.0, 8.0]\n",
      "[]\n",
      "[15.0]\n",
      "[8.0]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[8.0, 6.0, 8.0]\n",
      "[1.0]\n",
      "[10.0, 10.0, 15.0, 10.0, 10.0, 15.0, 10.0, 0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 2.0]\n",
      "[10.0]\n",
      "[0.5]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[6.0, 4.0, 4.0]\n",
      "[]\n",
      "[3.6]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2]\n",
      "[3.2, 50.0, 3.2]\n",
      "[0.2, 0.4, 1.2]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[7.0, 7.0, 7.0, 10.0]\n",
      "[]\n",
      "[28.0, 56.0, 84.0]\n",
      "[0.1, 0.5, 1.0, 0.1, 0.5, 1.0]\n",
      "[]\n",
      "[75.0, 100.0]\n",
      "[]\n",
      "[6.25]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[0.025, 1.5, 0.005, 0.3]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[2.0]\n",
      "[80.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5, 7.5, 7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[3.0]\n",
      "[]\n",
      "[100.0]\n",
      "[1.0]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[6.0]\n",
      "[50.0, 20.0, 76.0, 50.0, 20.0, 76.0]\n",
      "[]\n",
      "[]\n",
      "[0.1]\n",
      "[20.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.3]\n",
      "[]\n",
      "[10.0]\n",
      "[200.0]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[3.0]\n",
      "[15.0]\n",
      "[6.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[800.0, 400.0, 400.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[3.0]\n",
      "[60.0]\n",
      "[50.0, 2.5]\n",
      "[]\n",
      "[0.15]\n",
      "[0.75, 1.0, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.12]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[0.8, 0.8, 0.8, 0.4, 0.2]\n",
      "[8.0]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[18.0, 3.0]\n",
      "[1.0, 1.0, 1.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 8.0]\n",
      "[]\n",
      "[4.0, 8.0, 2.0, 1.0, 4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[20.0, 1.0, 20.0, 1.0, 20.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 2.0, 50.0]\n",
      "[10.0]\n",
      "[0.2, 0.6]\n",
      "[15.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[0.2, 1.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[3.5]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[4.0]\n",
      "[]\n",
      "[10.0, 5.0, 15.0, 25.0, 10.0, 5.0, 25.0, 35.0, 25.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[60.0]\n",
      "[2.5, 5.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[2.0, 4.0, 8.0, 0.02, 0.03]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 6.25]\n",
      "[3.0]\n",
      "[30.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[3.0, 5.0, 3.0, 10.0, 3.0, 3.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 9.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 2.0, 15.0, 1.0, 1.0, 3.0, 1.0, 10.0, 2.0, 2.0, 15.0, 1.0, 3.0, 1.0, 10.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[35.0, 35.0]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[60.0, 60.0]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[1.5, 1.5]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[3.2, 14.5, 3.2, 14.5, 50.0, 50.0]\n",
      "[]\n",
      "[5.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[0.5, 0.2, 0.2, 0.5]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[35.0, 35.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.75, 0.5, 0.75]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[10.0, 5.0, 15.0, 10.0, 5.0]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[0.9]\n",
      "[]\n",
      "[6.0, 6.0, 6.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[1.0, 0.75]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[0.3, 1.0]\n",
      "[0.01]\n",
      "[0.5]\n",
      "[10.0, 10.0, 5.0, 3.0]\n",
      "[1.0]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0, 16.0]\n",
      "[3.0, 4.5]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.9]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[0.71, 0.71, 0.0125, 0.0125]\n",
      "[2.0, 2.0]\n",
      "[1.0, 3.0]\n",
      "[3.0, 1.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5, 5.0, 7.5, 5.0, 5.0, 7.5, 7.5, 5.0, 7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[15.0]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 20.0]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[1.0, 3.0]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[1.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[18.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[6.0, 4.0, 6.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.6, 3.6]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.045]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 2.0, 50.0, 4.5, 2.0]\n",
      "[3.0, 1.0, 3.0, 3.0, 1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.3, 9.3]\n",
      "[6.0, 6.0]\n",
      "[1.0, 0.2, 1.0, 0.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[50.0, 0.015, 15.0, 50.0, 0.015, 15.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[15.0, 1.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[0.12]\n",
      "[0.5, 2.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[0.9]\n",
      "[6.0, 1.0, 8.0]\n",
      "[]\n",
      "[1.5, 1.5, 0.5]\n",
      "[]\n",
      "[0.6]\n",
      "[15.0, 8.0, 6.0]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[2.0, 2.0]\n",
      "[]\n",
      "[5.0, 10.0, 60.0, 0.8]\n",
      "[]\n",
      "[33.0, 16.0, 8.0]\n",
      "[0.075]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.8]\n",
      "[2.0]\n",
      "[15.0, 50.0]\n",
      "[0.025]\n",
      "[0.5, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[25.0, 50.0, 75.0]\n",
      "[25.0, 6.25]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0]\n",
      "[5.0, 7.5]\n",
      "[3.0, 1.0, 3.0]\n",
      "[2.5]\n",
      "[8.0]\n",
      "[10.0]\n",
      "[]\n",
      "[8.0]\n",
      "[25.0, 6.25]\n",
      "[8.0]\n",
      "[]\n",
      "[60.0]\n",
      "[10.0, 10.0, 20.0]\n",
      "[0.3, 0.3, 0.3, 0.3]\n",
      "[10.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[0.05, 0.05]\n",
      "[]\n",
      "[8.0, 8.0]\n",
      "[2.0, 4.0, 8.0, 0.02, 0.03]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 4.0]\n",
      "[]\n",
      "[8.0]\n",
      "[12.0]\n",
      "[8.0, 4.0]\n",
      "[0.15, 0.3]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[3.0]\n",
      "[0.045]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[0.5, 0.2, 4.0]\n",
      "[]\n",
      "[4.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 8.0, 1.5, 8.0, 1.5, 8.0, 8.0]\n",
      "[]\n",
      "[50.0, 100.0, 400.0, 200.0]\n",
      "[0.2, 4.0, 0.2, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[40.0, 5.0]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0, 25.0, 25.0, 2.0, 2.0, 25.0, 25.0]\n",
      "[10.0]\n",
      "[]\n",
      "[8.0, 8.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[0.15, 0.15]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[400.0]\n",
      "[]\n",
      "[2.0, 6.0]\n",
      "[0.25, 30.0, 20.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 1.0, 1.0, 2.0, 2.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 2.0, 2.0, 2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 8.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.3, 1.0, 2.5, 1.0, 2.5, 1.0, 2.5, 1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[30.0, 1.0]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[500.0, 400.0]\n",
      "[1.0, 1.0]\n",
      "[70.0]\n",
      "[70.0]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[4.0, 2.0, 4.0, 5.0]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[2.0]\n",
      "[0.25, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 1.5, 0.5, 0.1, 2.5, 2.5, 1.5, 0.5, 0.1]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[2.0, 2.0, 2.0, 2.0, 2.0, 4.0, 4.0, 4.0, 4.0, 1.0, 1.0, 1.0, 1.0, 4.0, 4.0, 1.0, 1.0, 4.0, 4.0]\n",
      "[]\n",
      "[140.0]\n",
      "[140.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.5, 1.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[120.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 3.0, 1.0]\n",
      "[0.24, 0.03]\n",
      "[8.0, 8.0]\n",
      "[4.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[10.0]\n",
      "[2.25, 9.0]\n",
      "[0.5, 0.045]\n",
      "[10.0]\n",
      "[1.0]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[5.0, 8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.2]\n",
      "[]\n",
      "[48.0]\n",
      "[]\n",
      "[]\n",
      "[20.0, 9.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.2, 4.0, 5.0, 0.2, 4.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0]\n",
      "[15.0, 3.6]\n",
      "[]\n",
      "[1.8]\n",
      "[3.0, 3.0]\n",
      "[10.0]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[3.0, 3.0, 1.0]\n",
      "[]\n",
      "[1.66, 0.83, 0.415, 0.415, 0.83, 1.66]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[5.0]\n",
      "[0.5, 0.045]\n",
      "[1.5, 0.15, 0.02, 0.15, 0.02]\n",
      "[10.0, 15.0, 15.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[5.6]\n",
      "[5.0, 60.0, 45.0]\n",
      "[0.9, 1.8, 0.9, 1.8]\n",
      "[3.6]\n",
      "[3.0, 3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 4.5]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[0.055]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[6.4, 5.4]\n",
      "[]\n",
      "[3.6, 2.0, 6.0, 6.0]\n",
      "[0.1, 0.2, 0.025, 0.2, 0.1, 0.03, 0.3, 0.1, 0.025]\n",
      "[0.025]\n",
      "[12.0, 12.0]\n",
      "[]\n",
      "[15.0, 0.5]\n",
      "[]\n",
      "[8.0, 8.0]\n",
      "[3.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0, 6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[14.0, 50.0, 0.03, 30.0, 14.0, 50.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[45.0]\n",
      "[45.0]\n",
      "[2.4, 3.0]\n",
      "[0.1, 0.25, 0.32, 0.9]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[0.16, 15.0]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[35.0, 40.0]\n",
      "[0.16]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.6, 5.6, 5.6]\n",
      "[]\n",
      "[]\n",
      "[250.0, 250.0, 250.0]\n",
      "[0.2, 0.3, 0.4, 0.4]\n",
      "[1.0]\n",
      "[1.0]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0]\n",
      "[6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[0.9, 1.8, 1.2, 2.3, 0.6, 1.2]\n",
      "[7.5]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[6.0, 3.0, 3.0]\n",
      "[50.0, 50.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[2.6]\n",
      "[]\n",
      "[]\n",
      "[5.4, 6.4]\n",
      "[10.0]\n",
      "[]\n",
      "[0.03]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.05, 0.01]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[6.25]\n",
      "[6.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 50.0]\n",
      "[]\n",
      "[15.0, 7.5]\n",
      "[8.0, 6.0, 6.0, 8.0, 6.0, 6.0]\n",
      "[]\n",
      "[0.15, 2.0]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[7.5, 7.5]\n",
      "[1.0, 3.0]\n",
      "[0.24]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 2.5, 10.0, 5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.5, 3.0]\n",
      "[]\n",
      "[2.0, 3.0]\n",
      "[15.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[10.0, 10.0, 20.0, 10.0, 10.0, 20.0]\n",
      "[]\n",
      "[2.6]\n",
      "[5.0]\n",
      "[2.0]\n",
      "[22.0, 33.0, 44.0, 44.0, 22.0, 33.0, 44.0, 44.0]\n",
      "[2.0]\n",
      "[2.6]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 5.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[0.3, 3.0]\n",
      "[5.0, 60.0]\n",
      "[]\n",
      "[]\n",
      "[0.2]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[3.0, 3.0]\n",
      "[17.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.5, 5.0, 1.0, 50.0, 100.0, 50.0, 100.0]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[0.12]\n",
      "[0.3, 0.3, 0.3]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0, 1.0, 3.0, 1.0, 3.0]\n",
      "[]\n",
      "[9.0, 8.0, 6.4, 50.0, 100.0, 100.0]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[200.0, 400.0]\n",
      "[100.0, 25.0, 12.5]\n",
      "[25.0, 8.0, 6.0, 15.0, 8.0, 6.0, 8.0, 6.0]\n",
      "[]\n",
      "[0.1, 0.3, 0.009, 0.027]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[10.0, 10.0, 10.0, 10.0]\n",
      "[150.0, 50.0, 100.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[150.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[40.0]\n",
      "[0.006]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[1.0, 50.0, 45.0, 0.03]\n",
      "[10.0]\n",
      "[]\n",
      "[25.0, 30.0, 0.03]\n",
      "[0.5]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.3, 0.3, 0.3, 0.7, 0.3, 0.3, 0.7]\n",
      "[]\n",
      "[]\n",
      "[4.5, 15.0]\n",
      "[15.0, 15.0]\n",
      "[1.0]\n",
      "[1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[15.0, 15.0]\n",
      "[5.0]\n",
      "[80.0]\n",
      "[]\n",
      "[2.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[5.6]\n",
      "[]\n",
      "[]\n",
      "[5.0, 7.5]\n",
      "[3.0, 1.0]\n",
      "[200.0, 20.0, 10.0, 10.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[2.5, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[16.0]\n",
      "[]\n",
      "[4.0, 4.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0, 2.0, 2.0]\n",
      "[3.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.5, 0.5, 0.75, 0.02, 0.02, 0.03]\n",
      "[1.0]\n",
      "[6.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0, 0.75, 0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0, 1.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[0.5]\n",
      "[0.25]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.6, 1.0, 0.6]\n",
      "[6.0]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[3.5, 0.5, 7.0, 1.0, 7.0, 0.5]\n",
      "[7.5, 7.5, 7.5, 7.5, 7.5]\n",
      "[3.0, 3.0, 4.5, 3.0, 4.5, 6.0]\n",
      "[]\n",
      "[]\n",
      "[0.25]\n",
      "[]\n",
      "[0.3]\n",
      "[]\n",
      "[50.0]\n",
      "[4.0, 6.0]\n",
      "[]\n",
      "[2.5, 2.5, 5.0, 7.5, 10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[2.5]\n",
      "[]\n",
      "[0.25, 1.66]\n",
      "[]\n",
      "[]\n",
      "[0.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.1, 0.1, 0.1, 0.1, 0.1]\n",
      "[20.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[19.0, 19.0]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 10.0, 10.0]\n",
      "[12.5]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[10.0]\n",
      "[10.0, 5.0]\n",
      "[10.0, 10.0, 5.0, 5.0]\n",
      "[1.3, 0.65, 0.65]\n",
      "[]\n",
      "[2.0, 2.3, 2.3]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[0.2]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0, 5.0]\n",
      "[2.6]\n",
      "[2.6]\n",
      "[]\n",
      "[]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[30.0, 90.0, 0.5]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0, 2.0, 2.0, 2.0]\n",
      "[3.0, 1.0]\n",
      "[0.02]\n",
      "[]\n",
      "[0.6]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[7.5]\n",
      "[1.0]\n",
      "[]\n",
      "[75.0, 50.0]\n",
      "[15.0]\n",
      "[]\n",
      "[5.0, 5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 15.0]\n",
      "[2.5, 5.0, 7.5, 10.0, 2.5, 5.0, 7.5, 10.0]\n",
      "[8.0]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[2.0, 6.0, 2.0, 2.0, 6.0, 6.0, 6.0]\n",
      "[30.0, 30.0, 8.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0, 7.5, 5.0, 10.0, 7.5]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[0.5, 1.5]\n",
      "[10.0, 20.0, 25.0]\n",
      "[2.0, 5.0, 5.0, 5.0]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[0.3, 0.3]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[0.125, 0.25, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 2.0, 3.0]\n",
      "[7.5]\n",
      "[]\n",
      "[10.0]\n",
      "[3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[]\n",
      "[20.0, 20.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[9.3]\n",
      "[1.25]\n",
      "[0.01]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.6]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 12.0]\n",
      "[]\n",
      "[20.0]\n",
      "[0.9, 0.25, 0.4]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[0.5]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[2.5]\n",
      "[5.0]\n",
      "[2.5]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[1.0]\n",
      "[0.7]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[12.0, 12.0, 12.0]\n",
      "[]\n",
      "[1.0, 2.5]\n",
      "[]\n",
      "[5.0, 5.0, 5.0]\n",
      "[]\n",
      "[2.0, 2.0, 2.0, 2.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[7.5, 7.5]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[1.0]\n",
      "[12.0, 10.0, 20.0, 10.0, 20.0]\n",
      "[10.0, 5.0, 20.0, 10.0, 15.0, 10.0, 5.0, 20.0, 10.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[]\n",
      "[8.0, 6.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[10.0, 30.0]\n",
      "[]\n",
      "[2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[0.15, 2.0, 1.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[35.0, 15.0, 25.0, 35.0, 10.0, 25.0, 35.0, 10.0, 10.0, 5.0, 20.0, 25.0, 10.0, 5.0, 15.0]\n",
      "[]\n",
      "[1.0]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[15.0]\n",
      "[3.0]\n",
      "[0.25, 0.5, 1.0, 2.0, 0.5, 1.0, 2.0]\n",
      "[]\n",
      "[3.6]\n",
      "[35.0, 35.0]\n",
      "[]\n",
      "[7.5, 7.5]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[1.0]\n",
      "[0.5, 0.25, 0.5, 0.25, 1.0, 0.5, 1.0, 0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 0.25]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[60.0]\n",
      "[]\n",
      "[7.5]\n",
      "[6.0, 8.0]\n",
      "[]\n",
      "[1.0, 2.0]\n",
      "[45.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 3.0, 4.5, 6.0, 3.0, 4.5, 6.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[1.0, 1.5, 2.5]\n",
      "[2.0, 3.0, 3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[45.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[0.5]\n",
      "[]\n",
      "[0.03]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.4, 5.4, 4.4]\n",
      "[]\n",
      "[]\n",
      "[10.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[1.0, 3.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[1.0, 3.0]\n",
      "[1.5, 1.5, 30.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[8.0, 6.0, 6.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[50.0, 2.5, 3.2, 0.8, 50.0, 2.5, 50.0, 2.5, 3.2, 0.8, 50.0, 2.5]\n",
      "[]\n",
      "[]\n",
      "[0.3, 0.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[1.0]\n",
      "[0.3, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[0.25, 0.25]\n",
      "[]\n",
      "[]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 10.0, 60.0, 0.8]\n",
      "[0.03]\n",
      "[]\n",
      "[0.4, 0.4]\n",
      "[4.0]\n",
      "[]\n",
      "[1.5, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[2.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.9, 3.8]\n",
      "[10.0]\n",
      "[2.5]\n",
      "[3.0]\n",
      "[0.3]\n",
      "[]\n",
      "[10.0]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[5.0]\n",
      "[15.0, 15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[500.0, 1000.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 60.0, 90.0, 20.0, 20.0, 40.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 30.0, 30.0]\n",
      "[0.8]\n",
      "[8.0, 8.0, 8.0, 8.0]\n",
      "[20.0]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[25.0, 10.0, 0.02]\n",
      "[]\n",
      "[25.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[400.0, 400.0, 400.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0, 20.0]\n",
      "[10.0, 20.0, 10.0, 20.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 3.0, 1.0]\n",
      "[1.25]\n",
      "[1.0, 0.5]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[20.0]\n",
      "[1.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[5.0, 5.0, 5.0]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[3.0, 3.0]\n",
      "[]\n",
      "[0.15, 0.25, 0.35, 0.6]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[15.0, 15.0]\n",
      "[0.05]\n",
      "[0.8, 0.025, 0.025, 0.8]\n",
      "[]\n",
      "[28.0, 56.0, 84.0]\n",
      "[]\n",
      "[]\n",
      "[6.0, 20.0, 6.0]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[30.0, 1.0, 2.0, 5.5]\n",
      "[360.0, 1.0, 360.0, 1.0]\n",
      "[0.45]\n",
      "[]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[3.0, 2.0]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[1.0, 4.0]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[3.0, 1.0, 3.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[0.2, 0.5, 0.045]\n",
      "[]\n",
      "[20.0, 7.5]\n",
      "[]\n",
      "[]\n",
      "[5.4]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[0.05, 0.025, 0.01]\n",
      "[0.25]\n",
      "[15.0]\n",
      "[]\n",
      "[7.5]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[15.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[0.5, 0.5]\n",
      "[45.0]\n",
      "[]\n",
      "[1.2, 1.2, 1.2, 1.2, 1.2]\n",
      "[]\n",
      "[6.0]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.2, 1.6]\n",
      "[]\n",
      "[]\n",
      "[0.45]\n",
      "[]\n",
      "[10.0, 7.5, 10.0, 7.5]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[50.0]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[7.5]\n",
      "[2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 12.0, 12.0]\n",
      "[4.5]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0, 30.0, 30.0]\n",
      "[20.0, 100.0, 10.0, 50.0, 20.0, 100.0, 10.0, 50.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[6.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[30.0]\n",
      "[5.4, 6.0, 1.0, 1.0, 3.0, 1.0, 1.0, 6.0]\n",
      "[1.0, 8.0, 1.0, 1.0]\n",
      "[6.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[4.0]\n",
      "[200.0, 100.0, 100.0, 25.0]\n",
      "[60.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[1.0]\n",
      "[5.6]\n",
      "[6.0]\n",
      "[1.8]\n",
      "[]\n",
      "[10.0, 3.0]\n",
      "[5.2, 4.3, 4.3]\n",
      "[]\n",
      "[3.2]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 4.5]\n",
      "[50.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 10.0, 10.0]\n",
      "[35.0]\n",
      "[]\n",
      "[10.0, 10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0, 5.0, 5.0, 5.0, 3.0, 5.0, 5.0, 5.0, 5.0, 3.0, 2.5, 5.0, 5.0]\n",
      "[]\n",
      "[2.0]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[1.25]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0, 8.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[1.25, 1.25]\n",
      "[]\n",
      "[15.0]\n",
      "[0.5, 4.0]\n",
      "[]\n",
      "[10.0]\n",
      "[1.0, 3.0]\n",
      "[2.5]\n",
      "[]\n",
      "[]\n",
      "[15.0]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[0.4, 1.0]\n",
      "[]\n",
      "[0.5, 0.5]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[10.0]\n",
      "[]\n",
      "[24.0, 12.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.52]\n",
      "[6.0]\n",
      "[2.0]\n",
      "[1.0]\n",
      "[2.0]\n",
      "[20.0, 15.0]\n",
      "[]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[6.4, 6.4, 5.4, 4.4]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[3.0, 5.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[2.0, 3.0]\n",
      "[]\n",
      "[]\n",
      "[5.4]\n",
      "[8.0, 8.0, 840.0, 420.0]\n",
      "[]\n",
      "[5.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[25.0, 25.0, 25.0, 100.0]\n",
      "[15.0]\n",
      "[6.0]\n",
      "[]\n",
      "[1.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[8.0, 6.0]\n",
      "[2.0]\n",
      "[10.0, 10.0]\n",
      "[10.0]\n",
      "[9.0, 25.0, 37.5, 25.0, 37.5, 8.0, 6.4, 25.0, 37.5, 25.0, 37.5, 50.0, 25.0, 37.5]\n",
      "[]\n",
      "[]\n",
      "[3.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[10.0]\n",
      "[0.5]\n",
      "[4.8, 5.8, 4.8, 5.8, 5.8, 5.8, 5.8]\n",
      "[15.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5]\n",
      "[]\n",
      "[10.0, 5.0, 1.0, 20.0, 15.0, 1.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[13.5, 0.25]\n",
      "[]\n",
      "[5.0, 8.0, 10.0, 8.0, 8.0]\n",
      "[0.72, 5.0]\n",
      "[]\n",
      "[1.5, 1.5, 1.5]\n",
      "[7.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.4]\n",
      "[1.8]\n",
      "[10.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[2.0]\n",
      "[15.0]\n",
      "[10.0]\n",
      "[]\n",
      "[0.5]\n",
      "[6.0, 6.0]\n",
      "[]\n",
      "[2.0, 6.0, 10.0, 2.0]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[0.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0]\n",
      "[5.4, 5.4, 4.4, 3.2]\n",
      "[15.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[3.0]\n",
      "[2.0, 2.5, 3.0, 2.0, 2.5, 3.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.0]\n",
      "[0.5, 0.02, 0.25, 0.01, 0.25, 0.01, 0.05, 0.02, 0.02]\n",
      "[400.0, 400.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.5]\n",
      "[4.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[3.6]\n",
      "[20.0]\n",
      "[0.2, 0.5, 0.5]\n",
      "[]\n",
      "[]\n",
      "[2.0, 2.0]\n",
      "[3.2, 80.0, 3.2, 80.0, 3.2, 30.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[5.0]\n",
      "[2.0, 1.1, 2.0, 1.1]\n",
      "[6.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[0.32]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[20.0]\n",
      "[]\n",
      "[15.0, 10.0, 5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[6.0]\n",
      "[6.0]\n",
      "[]\n",
      "[0.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[5.4]\n",
      "[5.6]\n",
      "[2.0]\n",
      "[]\n",
      "[]\n",
      "[1.8]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[8.0, 6.0]\n",
      "[7.5]\n",
      "[2.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[10.0, 15.0, 15.0, 10.0]\n",
      "[]\n",
      "[10.0, 15.0, 6.0, 20.0]\n",
      "[6.0, 7.5]\n",
      "[5.0, 50.0]\n",
      "[5.0, 10.0, 25.0, 50.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[15.0, 30.0, 50.0, 15.0, 30.0, 50.0]\n",
      "[]\n",
      "[5.0]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[24.0, 24.0]\n",
      "[]\n",
      "[10.0, 20.0]\n",
      "[5.6]\n",
      "[]\n",
      "[20.0]\n",
      "[0.5, 0.045]\n",
      "[]\n",
      "[0.5, 0.25]\n",
      "[]\n",
      "[2.5, 2.5]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[10.0]\n",
      "[]\n",
      "[5.0, 1.5, 2.5, 14.5]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[]\n",
      "[10.0]\n",
      "[20.0, 20.0]\n",
      "[]\n",
      "[]\n",
      "[6.4]\n",
      "[]\n",
      "[]\n",
      "[0.1, 0.3, 1.0]\n",
      "[]\n",
      "[3.2]\n",
      "[10.0]\n"
     ]
    }
   ],
   "source": [
    "def get_num(x):\n",
    "    matchs = re.findall(r\"(\\d+\\.?\\d*)\\s*mg/kg\",x)\n",
    "    \n",
    "    if len(matchs) >= 1:\n",
    "        matchs = [float(i) for i in matchs]\n",
    "        return matchs\n",
    "    return matchs\n",
    "    \n",
    "def mg_select(value):\n",
    "    if type(value) == str:\n",
    "        if 'mg/' in value:\n",
    "            # print(get_num(value))\n",
    "            return get_num(value)\n",
    "        else:\n",
    "            return None\n",
    "    elif type(value) == list:\n",
    "        lis = []\n",
    "        for i in value:\n",
    "            if 'mg/' in i:\n",
    "                lis.extend(get_num(i))\n",
    "        if len(lis) > 0:\n",
    "            # print(lis)\n",
    "            return lis\n",
    "        else:\n",
    "            return None\n",
    "    return None\n",
    "\n",
    "temp = dose['dose_description'].apply(mg_select).dropna()\n",
    "# temp_2 = dose_2['dose_description'].apply(mg_select)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "绝对值分布"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "lis = []\n",
    "for i in temp.dropna().index:\n",
    "    if temp[i] == False:\n",
    "        continue\n",
    "    if len(temp[i]) == 1:\n",
    "        lis.append((i, temp[i][0]))\n",
    "        continue\n",
    "    else:\n",
    "        for j in temp[i]:\n",
    "            lis.append((i, j))\n",
    "\n",
    "absoult_dose = pd.DataFrame(lis, columns=['nctid', 'dose'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count    6209.000000\n",
       "mean       13.194185\n",
       "std        39.202270\n",
       "min         0.000000\n",
       "25%         1.500000\n",
       "50%         5.000000\n",
       "75%        10.000000\n",
       "max      1000.000000\n",
       "Name: dose, dtype: float64"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = absoult_dose['dose']\n",
    "data.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 800x400 with 0 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8, 4))\n",
    "data.hist(bins=50)\n",
    "plt.title('Data Distribution')\n",
    "plt.xlabel('Absoult Value(mg/kg)')\n",
    "plt.ylabel('Frequency')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[   0.   20.   40.   60.   80.  100.  120.  140.  160.  180.  200.  220.\n",
      "  240.  260.  280.  300.  320.  340.  360.  380.  400.  420.  440.  460.\n",
      "  480.  500.  520.  540.  560.  580.  600.  620.  640.  660.  680.  700.\n",
      "  720.  740.  760.  780.  800.  820.  840.  860.  880.  900.  920.  940.\n",
      "  960.  980. 1000.]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "hist, bin_edges = np.histogram(data, bins=50)\n",
    "max_bin_index = np.argmax(hist)\n",
    "max_bin_start = bin_edges[max_bin_index]\n",
    "max_bin_end = bin_edges[max_bin_index + 1]\n",
    "mode_bin_data = data[(data >= max_bin_start) & (data < max_bin_end)]\n",
    "print(bin_edges)\n",
    "plt.figure(figsize=(8, 4))\n",
    "mode_bin_data.hist(bins=50)\n",
    "plt.title('Data Distribution')\n",
    "plt.xlabel('Absoult Value(mg/kg)')\n",
    "plt.ylabel('Frequency')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 800x400 with 0 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8, 4))\n",
    "data.plot(kind='box')\n",
    "plt.title('Box Plot of Data')\n",
    "plt.ylabel('Absoult Value')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of outliers: 670\n",
      "Outliers: [50.0, 40.0, 30.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 40.0, 40.0, 60.0, 60.0, 500.0, 750.0, 40.0, 100.0, 100.0, 45.0, 60.0, 60.0, 60.0, 60.0, 60.0, 50.0, 200.0, 24.0, 60.0, 28.0, 33.0, 175.0, 175.0, 90.0, 50.0, 50.0, 50.0, 50.0, 60.0, 75.0, 100.0, 50.0, 50.0, 25.0, 40.0, 60.0, 60.0, 30.0, 60.0, 120.0, 50.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 500.0, 100.0, 500.0, 60.0, 120.0, 60.0, 120.0, 24.0, 100.0, 50.0, 60.0, 60.0, 24.0, 25.0, 29.0, 30.0, 34.0, 110.0, 110.0, 120.0, 60.0, 50.0, 50.0, 50.0, 50.0, 50.0, 80.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 60.0, 30.0, 60.0, 30.0, 40.0, 80.0, 40.0, 35.0, 30.0, 40.0, 50.0, 60.0, 30.0, 60.0, 90.0, 40.78, 60.0, 100.0, 27.0, 240.0, 75.0, 30.0, 30.0, 30.0, 60.0, 50.0, 30.0, 50.0, 30.0, 40.0, 30.0, 30.0, 30.0, 60.0, 30.0, 50.0, 50.0, 50.0, 60.0, 40.0, 80.0, 40.0, 50.0, 30.0, 40.0, 40.0, 40.0, 40.0, 60.0, 160.0, 60.0, 40.0, 50.0, 40.0, 80.0, 40.0, 80.0, 100.0, 50.0, 28.0, 60.0, 90.0, 25.0, 25.0, 25.0, 25.0, 60.0, 45.0, 45.0, 25.0, 200.0, 80.0, 200.0, 80.0, 25.0, 60.0, 60.0, 60.0, 30.0, 60.0, 60.0, 60.0, 60.0, 35.0, 25.0, 25.0, 30.0, 30.0, 35.0, 35.0, 40.0, 40.0, 45.0, 45.0, 50.0, 50.0, 55.0, 55.0, 50.0, 30.0, 30.0, 45.0, 40.0, 55.0, 60.0, 60.0, 30.0, 60.0, 66.0, 50.0, 40.0, 60.0, 80.0, 25.0, 120.0, 60.0, 150.0, 50.0, 100.0, 60.0, 55.0, 65.0, 150.0, 50.0, 50.0, 25.0, 50.0, 33.3, 100.0, 35.0, 60.0, 100.0, 50.0, 400.0, 400.0, 70.0, 70.0, 30.0, 100.0, 60.0, 30.0, 30.0, 60.0, 60.0, 30.0, 30.0, 50.0, 50.0, 50.0, 60.0, 60.0, 30.0, 60.0, 30.0, 30.0, 60.0, 60.0, 60.0, 60.0, 30.0, 50.0, 25.0, 36.0, 30.0, 70.0, 70.0, 100.0, 25.0, 200.0, 75.0, 30.0, 25.0, 200.0, 50.0, 40.0, 50.0, 40.0, 50.0, 40.0, 40.0, 28.0, 30.0, 30.0, 30.0, 30.0, 32.0, 125.0, 25.0, 30.0, 50.0, 100.0, 40.0, 25.0, 25.0, 25.0, 30.0, 50.0, 50.0, 50.0, 50.0, 30.0, 50.0, 50.0, 45.0, 60.0, 120.0, 60.0, 120.0, 35.0, 63.0, 25.0, 100.0, 250.0, 320.0, 30.0, 50.0, 30.0, 30.0, 40.0, 35.0, 40.0, 35.0, 105.0, 35.0, 70.0, 35.0, 25.0, 40.0, 100.0, 200.0, 100.0, 50.0, 40.0, 30.0, 30.0, 225.0, 450.0, 30.0, 50.0, 30.0, 50.0, 30.0, 24.0, 30.0, 35.0, 110.0, 250.0, 50.0, 100.0, 30.0, 80.0, 67.0, 200.0, 40.0, 80.0, 26.67, 25.0, 25.0, 25.0, 50.0, 50.0, 40.0, 40.0, 60.0, 30.0, 45.0, 60.0, 50.0, 50.0, 40.0, 30.0, 45.0, 31.0, 30.0, 62.0, 40.0, 150.0, 50.0, 50.0, 150.0, 150.0, 50.0, 50.0, 150.0, 30.0, 29.0, 100.0, 30.0, 36.0, 60.0, 25.0, 40.0, 40.0, 40.0, 40.0, 35.0, 65.0, 65.0, 30.0, 50.0, 90.0, 30.0, 30.0, 30.0, 40.0, 80.0, 24.0, 30.0, 30.0, 60.0, 200.0, 60.0, 40.0, 40.0, 60.0, 40.0, 30.0, 50.0, 50.0, 50.0, 30.0, 400.0, 25.0, 25.0, 25.0, 25.0, 30.0, 40.0, 100.0, 150.0, 60.0, 50.0, 40.0, 30.0, 35.0, 35.0, 25.0, 50.0, 75.0, 209.0, 209.0, 50.0, 40.0, 80.0, 40.0, 80.0, 50.0, 50.0, 40.0, 50.0, 28.0, 56.0, 84.0, 75.0, 100.0, 80.0, 100.0, 50.0, 76.0, 50.0, 76.0, 35.0, 200.0, 30.0, 800.0, 400.0, 400.0, 60.0, 50.0, 50.0, 100.0, 25.0, 25.0, 35.0, 25.0, 35.0, 60.0, 30.0, 50.0, 35.0, 35.0, 60.0, 60.0, 50.0, 50.0, 35.0, 35.0, 50.0, 60.0, 50.0, 50.0, 60.0, 60.0, 33.0, 50.0, 25.0, 50.0, 75.0, 25.0, 40.0, 25.0, 60.0, 50.0, 100.0, 400.0, 200.0, 40.0, 25.0, 25.0, 25.0, 25.0, 400.0, 30.0, 30.0, 50.0, 30.0, 500.0, 400.0, 70.0, 70.0, 140.0, 140.0, 120.0, 48.0, 60.0, 45.0, 30.0, 30.0, 50.0, 30.0, 50.0, 45.0, 45.0, 35.0, 40.0, 250.0, 250.0, 250.0, 50.0, 50.0, 30.0, 50.0, 33.0, 44.0, 44.0, 33.0, 44.0, 44.0, 40.0, 60.0, 30.0, 50.0, 100.0, 50.0, 100.0, 50.0, 100.0, 100.0, 200.0, 400.0, 100.0, 25.0, 25.0, 150.0, 50.0, 100.0, 150.0, 40.0, 50.0, 45.0, 25.0, 30.0, 80.0, 200.0, 50.0, 30.0, 30.0, 90.0, 75.0, 50.0, 30.0, 30.0, 25.0, 50.0, 30.0, 35.0, 25.0, 35.0, 25.0, 35.0, 25.0, 35.0, 35.0, 30.0, 30.0, 60.0, 45.0, 45.0, 40.0, 30.0, 50.0, 50.0, 50.0, 50.0, 30.0, 60.0, 500.0, 1000.0, 30.0, 60.0, 90.0, 40.0, 30.0, 30.0, 25.0, 25.0, 400.0, 400.0, 400.0, 28.0, 56.0, 84.0, 30.0, 360.0, 360.0, 45.0, 50.0, 30.0, 30.0, 100.0, 50.0, 100.0, 50.0, 30.0, 200.0, 100.0, 100.0, 25.0, 60.0, 50.0, 35.0, 24.0, 840.0, 420.0, 25.0, 25.0, 25.0, 100.0, 25.0, 37.5, 25.0, 37.5, 25.0, 37.5, 25.0, 37.5, 50.0, 25.0, 37.5, 400.0, 400.0, 80.0, 80.0, 30.0, 50.0, 25.0, 50.0, 30.0, 50.0, 30.0, 50.0, 24.0, 24.0]\n",
      "['Standard dosing paclitaxel: 80 mg/m2 QW intravenously)', 'administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses']\n",
      "['Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).']\n",
      "['80 mg/kg AAT inhaled', 'Placebo inhaled']\n",
      "['single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.', 'single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.', 'single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.']\n",
      "['Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .\\r\\nTitration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).\\r\\nAfter titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.\\r\\nDuring forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP.', 'Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).\\r\\nTitration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).\\r\\nAfter titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.\\r\\nDuring forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP.']\n",
      "['low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3', 'low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3']\n",
      "['Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells', 'Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow']\n",
      "['Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.']\n",
      "['Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2', 'Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2']\n",
      "['Saline administered IV for 12 hours', 'MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours', 'MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours']\n",
      "['Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv', 'Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration', 'Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).\\r\\nFludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.\\r\\nBone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.\\r\\nTacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.\\r\\nMycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).', 'Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).\\r\\nFludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.\\r\\nTacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.\\r\\nMycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).']\n",
      "['Maximum of 1800 mg/day or 63 mg/kg/day']\n",
      "['6MW3211 injection, 45mg/kg, Q2W']\n",
      "['All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.']\n",
      "['patients will receive oral 1000 mg of curcumin capsules daily in addition to their standard treatment for three months.\\r\\nStandard treatment includes: oral MMF initial dose of 1200 mg/m2/day, no more than 2000 m g/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day\\r\\nsecond regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids']\n",
      "['Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide']\n",
      "['IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]', 'IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]']\n",
      "['Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.']\n",
      "['Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:\\r\\nBevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;\\r\\nIrinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;\\r\\nLeucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;\\r\\nFloxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.']\n",
      "['Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)', 'Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)', 'Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)', 'Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)']\n",
      "['P-rATG days (always starting on Day -12 to -10)\\r\\nHyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6\\r\\nThiotepa (5mg/kg/day x 2 day) Day -5 to -4\\r\\nCyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2\\r\\nGCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements.', 'P-rATG days (Appendix A - always starting on Day -12 to -10)\\r\\nBusulfan -Day -9 to -7\\r\\nInitial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5\\r\\nFludarabine (25mg/m2/day x 5 days) Day -6 to -2\\r\\nGCSF Day +7']\n",
      "['All subjects will be given the lower (10 mg/kg bw, bid) to higher dose (30 mg/kg bw, bid) for 52 weeks, according to the administration plan.\\r\\nThe dosage form is tablets.']\n",
      "['Sterile water will be packaged identically to the active comparator.\\r\\nEach patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs.', 'Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.\\r\\nThe maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:\\r\\nIf the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins\\r\\nIf the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated\\r\\nIf the systolic BP decrease rapidly more than 25% over 15 minutes\\r\\nIf the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate.']\n",
      "['RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment.', \"WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + ethambutol (EMB) 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion.\"]\n",
      "['Deferiprone, 25 to 30 mg/kg per day, oral use']\n",
      "['60 mg/kg azithromycin ER (Extended Release)arm', '30 mg/kg azithromycin IR (Immediate Release) arm']\n",
      "['Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg', '10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg', '10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg', '0.9 % Sodium chloride infusion']\n",
      "['Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively', 'Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively']\n",
      "['Participants will receive intravenous (i.v.) infusion of 10 milligrams per kilograms (mg/kg) NNC6019-0001 every 4 weeks (Q4W) added to standard of care until week 52.', 'Participants will receive i.v. infusion of 60 mg/kg NNC6019-0001 Q4W added to standard of care until week 52.', 'Participants will receive i.v. infusion of placebo (NNC6019-0001) Q4W added to standard of care until week 52.']\n",
      "['Study Drug given IV every 28 days at 24mg/kg', 'Placebo']\n",
      "['Deuremidevir Hydrobromide for Suspension will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.', 'Placebo will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.']\n",
      "['Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2\\r\\nCyclophosphamide 14.5 mg/kg/day IV on Days -6, -5\\r\\nTotal Body Irradiation (TBI) 200cGy on Day -1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)\\r\\nCyclophosphamide 50mg/kg/day IV on Days -2,-1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)\\r\\nFludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Cyclophosphamide 50mg/kg/day IV on Days -5,-4\\r\\nTotal Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.']\n",
      "[\"Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\"]\n",
      "['Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Cyclophosphamide 50mg/kg (days +3, +4)']\n",
      "['10 mg/kg/day Intravenous inositol 5%', '40 mg/kg/day Intravenous inositol 5%', '80 mg/kg/day Intravenous inositol 5%', 'Glucose 5% given in volumes equal to that of the comparator drug']\n",
      "['BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.\\r\\nStandard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.\\r\\nStandard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.\\r\\nStandard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)']\n",
      "['Cannabidiol oral solution (40 milligram/kilogram/day [40 mg/kg/day]) divided into two daily doses with a standard meal', 'Matching placebo solution divided into two daily doses with a standard meal']\n",
      "['Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.']\n",
      "['Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).', 'Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)']\n",
      "['Sanfetrinem cilexetil 1.6g will be given orally 12 hourly for 14 consecutive days.', 'Rifampicin 35 mg/kg will be given orally once daily for 14 consecutive days.', 'Sanfetrinem cilexetil 3.2 g will be given orally daily for 14 consecutive days.', 'Sanfetrinem cilexetil 800 mg will be given orally 12 hourly for 14 consecutive days.', 'Sanfetrinem cilexetil 800 mg will be given orally 8 hourly for 14 consecutive days.', 'Sanfetrinem cilexetil 1.6 g plus amoxicillin/clavulanic acid 250 mg/125 mg will be given orally 12 hourly for 14 consecutive days.', 'Sanfetrinem cilexetil 1.6 g will be given orally 12 hourly plus rifampicin 35 mg/kg orally once daily for 14 consecutive days.']\n",
      "['IV every 3-weeks (Q3W) and placebo (normal saline)', 'IV every 4-weeks (Q4W) and placebo (normal saline)', '60 mg/kg IV once weekly (QW) and placebo (normal saline)']\n",
      "['Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.']\n",
      "['Cytoreductive treatment: (preferentially) FC (2-4 cycles)\\r\\nMobilization: Dexa-BEAM + G-CSF (1-2 cycles)\\r\\nMyeloablation:\\r\\nfractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)\\r\\nautologous peripheral blood stem cell transplantation (PBSCT) (d 0)']\n",
      "['Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .']\n",
      "['Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.', 'Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.', 'Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.', 'Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.', 'Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.', 'Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).', 'Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).', 'Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.']\n",
      "['15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.', '15 patients will receive 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.', '15 patients will receive 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.']\n",
      "['Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.', 'Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.']\n",
      "['Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.', 'Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.']\n",
      "['Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).', 'Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses). Note: This arm is now closed.', 'Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).', 'Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses). Note: This arm is now closed.']\n",
      "['FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.', 'FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.']\n",
      "['Dose 1 : 100 mg/kg of Betaine', 'Dose 2 : 250 mg/kg of Betaine']\n",
      "['patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes']\n",
      "['Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).', 'In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).']\n",
      "['Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.', 'Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.']\n",
      "['Standard Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants without prior treatment pembrolizumab or nivolumab Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)', 'Standard Chemo Prep Regimen Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants previously treated with pembrolizumab or nivolumab.\\r\\nStandard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)', 'Decreased Chemo Prep Regimen+Retreat. Young TIL+High Dose Interleukin-2, Decreased Chemo Preparative Regimen. Young TIL+High Dose Interleukin-2, Standard Chemo (Retreat). Lower dose preparative regimen + Young TIL Cells. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days. Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 300 mg/m^2 IV over 60 minutes. Young TIL: Day 0: Cells will be infused IV. Retreatment: Standard Chemo Prep Regimen. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide: 60 mg/kg/day X 2 days IV. Young TIL: Day 0: Cells will be infused IV.', 'Decreased Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2 Lower Dose preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 30 mg/kg IV over 60 minutes for 2 days.\\r\\nYoung TIL: Day 0: Cells will be infused intravenously (IV)', 'Standard Chemo Prep Regimen(SCPR)+Retreat. Young TIL+High Dose(HD) Interleukin-2, SCPR. Young TIL+HD Interleukin-2, SC(Retreat). SCPR+Young TIL Cells retreatment with SCPR+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kgIV every eight hours (+/-1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back(IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL:Day 0: Cells will be infused IV. Retreatment with standard preparative regimen+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL: Day 0:Cells will be infused IV. Pembrolizumab:2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).']\n",
      "['The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.']\n",
      "['Patients in arm A will receive doses of 10 mg/kg of Abatacept', 'Patients in arm B will receive doses of 20 mg/kg of Abatacept', 'Patients in arm C will receive doses of 25 mg/kg of Abatacept']\n",
      "['All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.']\n",
      "['Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.', 'Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.']\n",
      "['Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days']\n",
      "['Treatment with cyclophosphamide 50 mg/kg/d x 1 days.', 'Treatment with cyclophosphamide 50 mg/kg/d x 2 days.', 'Treatment with cyclophosphamide 50 mg/kg/d x 3 days.']\n",
      "['66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.']\n",
      "['Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.', 'Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.']\n",
      "['Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.\\r\\nStep 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.\\r\\nVRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.\\r\\nStep 3: SOC oral ART regimen for approximately 48 weeks.']\n",
      "['60 mg/kg/day']\n",
      "['The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.', 'Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.']\n",
      "['KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles']\n",
      "['Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W']\n",
      "['Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.', 'Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.', 'Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.\\r\\nPirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician.', 'Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.\\r\\nPirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician.']\n",
      "['PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.\\r\\nCapecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks\\r\\nPART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration.']\n",
      "['Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00']\n",
      "['Single dose intravenous vinblastine (6mg/m2) in bolous.', 'Patient will recieve oral hydroxiurea at a dose of 50mg/kg/day until response or administration of induction chemotherapy']\n",
      "['60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously', '1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously']\n",
      "['Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection\\r\\nDrug: melphalan 200 mg/kg over 2 days\\r\\nProcedure/Surgery: autologous peripheral blood stem cell transplantation\\r\\nautologous peripheral blood stem cell transplantation']\n",
      "['Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.', 'Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.', 'Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.']\n",
      "['Evorpacept (ALX148) 45 mg/kg IV and pembrolizumab 200 mg IV given every 3 weeks.', 'Pembrolizumab 200 mg IV given every 3 weeks.']\n",
      "['10 mg/kg BW, 8 weekly doses for 8-week treatment period', '25 mg/kg BW, 4 biweekly doses for 8-week treatment period']\n",
      "['2:1 in favour of UDCA', 'UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.']\n",
      "[\"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.\\r\\nTable 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg\\r\\n*Max dose not to exceed 2700mg/day (1350mg BID)\"]\n",
      "['Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.', 'Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.\\r\\nTreatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks.', 'Treatment Period: Cannabidiol Oral Solution 10 mg/kg/day divided BID for 4 weeks.']\n",
      "['Participants will receive 35 milligrams (mg) decitabine/100 mg cedazuridine as a fixed dose combination (FDC) tablet, orally, once daily (QD) on Days 1-5 of each 28-day cycle in combination with magrolimab, intravenous (IV) infusion of 1 milligrams per kilogram (mg/kg) on Days 1 and 4, 15 mg/kg on Day 8, 30 mg/kg on Days 11, 15, 22, 29, 36, 43, and 50, followed by a maintenance dose of 30 mg/kg on Day 57 and every 14 days thereafter until toxicity, progressive disease, withdrawal, death or end of study (approximately 44 months).']\n",
      "['This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.', 'This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.']\n",
      "['Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)', 'Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours']\n",
      "['Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.', 'Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.', 'Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.', 'Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.']\n",
      "['divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks']\n",
      "['Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).\\r\\nPhase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).\\r\\nPhase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days']\n",
      "[\"Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.\", \"Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.\", \"Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.\", 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.', 'Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.']\n",
      "['Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.\\r\\nCefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present\\r\\nRanitidine 5 mg/kg IV, q.d. for 2 days\\r\\nAmoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.', 'Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.\\r\\nCefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.\\r\\nRanitidine 5 mg/kg IV, q.d. for 2 days.\\r\\nAmoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.']\n",
      "['Saline dose', 'Low Dose Ketamine (.20 mg/kg)', 'High Dose Ketamine (.50 mg/kg)']\n",
      "['. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days', 'group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.']\n",
      "[\"Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29.\", \"Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29.\"]\n",
      "['Placebo plus cognitive behavioral therapy', 'Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy']\n",
      "[\"Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.\", \"The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.\"]\n",
      "['Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours', 'Group 2 : \"Ketoprofen quarter dose\" (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours.', 'Group 3 : \"Ketoprofen half-dose\" (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours.', 'Group 4 : \"Ketoprofen full dose\" (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours']\n",
      "['PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).']\n",
      "['Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.\\r\\nCells for infusion are prepared using the CliniMACS system.']\n",
      "['The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).']\n",
      "['Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg cefiderocol and participants ≥34 kg will receive 2000 mg.', 'Participants will receive cefiderocol administered via IV every 8 hours for an expected 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.', 'Participants will receive standard of care treatment according to local standards.']\n",
      "['Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)', 'Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)', 'Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)', 'Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)']\n",
      "['All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.\\r\\nParticipants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days.']\n",
      "['Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.']\n",
      "['patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min', 'patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min']\n",
      "['Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks', 'Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks', 'Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment']\n",
      "['320 mg/kg', 'Normal saline IV infusion']\n",
      "['Placebo', '60 mg/kg was given on Days 0, 7, 14', '90 mg/kg was given on Days 0, 7, 14']\n",
      "['50 mg/kg eteplirsen for 28 weeks\\r\\n30 mg/kg eteplirsen for 28 weeks']\n",
      "['Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0\\r\\nAldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)\\r\\nFludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)\\r\\nCyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6', 'Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0\\r\\nAldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)\\r\\nFludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)\\r\\nCyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6']\n",
      "['Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['6MW3211injection,30mg/kg,Q2W']\n",
      "['At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit.', 'At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).', 'At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).']\n",
      "['Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.', 'Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).']\n",
      "['anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter\\r\\nRituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;\\r\\nFor adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).\\r\\nTacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.']\n",
      "['Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.', 'Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.', 'For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.']\n",
      "['30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.']\n",
      "['Patients Receive:\\r\\nPatients receive:\\r\\nBusulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.']\n",
      "['ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months', 'ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF']\n",
      "['Plerixafor 160mg/kg/dose by IV on days 5-8\\r\\nFilgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.']\n",
      "['Given on Day 1 of each 21 day cycle, in the following order of administration:\\r\\n200 mg IV pembrolizumab* (maximum of 2 years (approximately 35 cycles)\\r\\n45 mg/kg IV ALX148\\r\\n30 mg/m^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)*\\r\\n*standard of care']\n",
      "['Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.', 'High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.', 'Placebo group: Oral administration of tablets for 24 weeks, BID after meal']\n",
      "['Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.', '5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline']\n",
      "['Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.']\n",
      "['4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）\\r\\n4.2.2 Unrelated donor and haploidentical donor\\r\\n1) ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）', '4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d\\r\\n4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d']\n",
      "['D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months', 'ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months']\n",
      "[\"Arm A - Intervention arm (Immunotherapy and Chemotherapy)\\r\\nNivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks\\r\\nPlatinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion.\\r\\nCarboplatin dosed at AUC 5, and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous\", 'Arm B - control arm (Immunotherapy only)\\r\\nNivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks']\n",
      "['Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.', 'Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28 and 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.', 'Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.', 'Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.', 'Participants will receive i.v. bimagrumab 30 mg/kg at baseline, and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.', 'Participants will receive i.v. bimagrumab 30 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg per the dose escalation schedule.']\n",
      "['Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.']\n",
      "['Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.', 'Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0']\n",
      "['L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID).', 'Standard dose (100mg/kg IV TID).', 'Low dose (25mg/kg IV TID).']\n",
      "['Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.', \"Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).\"]\n",
      "['Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.', 'Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.', 'Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.']\n",
      "['Group A: Subjects with Multiple Myeloma\\r\\nConditioning regimen, over a 7 day period, includes:\\r\\nMelphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion\\r\\nGroup B: Subjects with Lymphoma\\r\\nConditioning regimen, over a 7 day period, includes: (BEAC)\\r\\nBCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant']\n",
      "['5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for >/= 21 days or per discretion of enrolling physician.']\n",
      "['Patients receive a single 6 mg/kg dose of oxfendazole administered orally.', 'Patients receive a single 15 mg/kg dose of oxfendazole administered orally.', 'Patients receive a single 30 mg/kg dose of oxfendazole administered orally.', 'Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.', 'Patients receive a single 400 mg/kg dose of albendazole administered orally.']\n",
      "['Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration', 'Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly', 'Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly']\n",
      "['Deferoxamine 32 Milligram Per Kilogram (mg/kg)', 'Deferoxamine 48 mg/kg', 'normal saline']\n",
      "['Deferasirox daily oral dose between 5-40 mg/kg/day']\n",
      "['Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.', 'Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.', 'Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.', 'Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).']\n",
      "['Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:\\r\\nFludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions', 'Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:\\r\\nBusulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2']\n",
      "['General anesthesia is induced in the lidocaine group with intravenous lidocaine 1.5mg/kg for ten minutes, followed by continuous injection of lidocaine 1.5mg/kg.h. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most).', 'The lidocaine is replaced by identical volumes and rates of 0.9% saline. At the end of the operation, the patient controlled intravenous analgesia without lidocaine is used.']\n",
      "['20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day', '50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week', '\"DFO to ICL\" (patients who switched from DFO to deferasirox in extension)', '\"ICL to DFO\" (patients who switched from deferasirox to DFO in extension)']\n",
      "['Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.']\n",
      "[\"In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.\", 'In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg']\n",
      "['50 mg/kg/day orally twice daily for 24 weeks']\n",
      "['PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks', 'PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks', 'Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks']\n",
      "['Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.', \"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).\\r\\nFenofibrate 160 mg per day. To be taken once per day for 6 weeks.\", \"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).\\r\\nFenofibrate 160 mg per day. To be taken once per day for 6 weeks.\"]\n",
      "[\"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.\\r\\nClobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant.\"]\n",
      "['Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:\\r\\nNonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.\\r\\nCyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.\\r\\nCohort 1 = unselected TIL', 'Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:\\r\\nNonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.\\r\\nCyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.\\r\\nCohort 2 = CD4+ depleted (selected) TIL', 'Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):\\r\\nNonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.\\r\\nCyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.\\r\\nCohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation', 'Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:\\r\\nNonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.\\r\\nCyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.\\r\\nCohort 4 = unselected TIL - it is the SAME as cohort 1', 'Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:\\r\\nNonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.\\r\\nCyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.\\r\\nCohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2']\n",
      "['Conditioning regimen containing treosulfan 30-42 g/m2, fludarabine 150 mg/mg, thymoglobulin 5 mg/kg and thiotepa 10 mg/kg or melphalan 140 mg/m2\\r\\nGVHD prophylaxis regimen for matched unrelated (MUD) and matched related donors (MRD):\\r\\nCyclophosphamide (PTCY) 25 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5\\r\\nGVHD prophylaxis regimen for mismatched related donor (MMRD):\\r\\nCyclophosphamide (PTCY) 50 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5']\n",
      "['A single dose of 140 mg/kg of VPA plus standard of care', 'A single dose of isotonic saline solution plus standard of care']\n",
      "['Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.\\r\\nThen they will undergo an Autologous Hematopoietic Stem Cell Transplantation.']\n",
      "['Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.']\n",
      "['200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours', '50ml every 6 hours for 96 hours']\n",
      "['Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.']\n",
      "['Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.']\n",
      "['with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days']\n",
      "['Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.', 'Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.', 'Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.']\n",
      "['Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d']\n",
      "['Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.', 'Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).', 'Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.', 'Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.']\n",
      "['6MW3211 injection, 30mg/kg']\n",
      "['High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen', 'High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen']\n",
      "['Rezafungin: Weekly intravenous infusion with a loading dose of 400 mg over 1 hour (±10 minutes) on Day 1 followed by maintenance doses of 200 mg over 1 hour (±10 minutes) on Day 8 and Day 15.\\r\\nFrom Day 1 to Day 7, co-trimoxazole will also be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.\\r\\nFor participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day', 'From Day 1 to Day 21, co-trimoxazole will be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.\\r\\nFor participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day']\n",
      "['MgSO4\\r\\n1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.\\r\\nMonitoring and Protective measures:\\r\\nBefore and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.']\n",
      "['Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC', 'Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate']\n",
      "['Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.']\n",
      "['Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.']\n",
      "['Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.', 'Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.', 'Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.', 'Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.', 'Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.', 'Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.']\n",
      "['BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.\\r\\nCycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21.']\n",
      "['100 mg/kg magnesium', '100 mg/kg 0.9 % saline']\n",
      "['Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.']\n",
      "['Conditioning:\\r\\nfludarabine 180 mg/m2 busulfan 8-14 mg/kg per os\\r\\nGVHD prophylaxis:\\r\\ncyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35', 'Conditioning:\\r\\nfludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2\\r\\nGVHD prophylaxis:\\r\\ncyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150']\n",
      "['High Dose Arm\\r\\nWash-out then 7 days of:\\r\\nArg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA', 'Low Dose Arm\\r\\nWash-out followed by 7 days of:\\r\\nArg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA']\n",
      "['consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.']\n",
      "['Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks', 'Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks', 'Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks', 'Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm']\n",
      "['Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.']\n",
      "['Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.']\n",
      "['Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.']\n",
      "['Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks', 'Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks']\n",
      "[\"Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.\"]\n",
      "['Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.', 'Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..', 'Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.', 'Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.', 'Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.', 'Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.']\n",
      "['SP-420, 28 mg/kg, three times weekly for 48 weeks', 'SP-420, 56 mg/kg, three times weekly for 48 weeks', 'SP-420, 84 mg/kg, three times weekly for 48 weeks']\n",
      "['Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.', 'Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.', \"Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.\"]\n",
      "['25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days', '50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days', '75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days']\n",
      "['Participants receive 25mg/kg HLX22 IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy', 'Participants receive 15mg/kg HLX22 IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy', 'Participants receive placebo IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy']\n",
      "['Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days', 'Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days']\n",
      "['Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg of cefiderocol and participants ≥34 kg will receive 2000 mg.', 'Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.']\n",
      "['They will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then an intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.', 'They will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.']\n",
      "['Busulfan/Cyclophosphamide, \"standard\" conditioning regimen as a control group. including Bu3.2mg/kg -5~-3d; Cy 80mg/kg，-2~-1d。 or alternative Bu/Cy regimen, Bu3.2mg/kg -9~-7d；Flu 30mg/m2 -6~-4d；Ara-C 2g/m2 -6~-4d；Cy 80mg/kg -3~-2d。', 'using MCBC as conditioning regimen, Mel 60mg/ m2 -9~-8d, Cladribine 5 mg/m2 -9~-5d, Bu3.2mg/kg -5~-3d； Cy 30mg/kg -2~-1 d']\n",
      "['Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.', 'Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.', 'Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.']\n",
      "['All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses\\r\\nAll patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles\\r\\nThe first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab\\r\\nThe schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)', 'All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses\\r\\nAll patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles.']\n",
      "['NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype \"A\" serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg..']\n",
      "['Oral Glutathione oral powder at 65mg/kg/day', 'Placebo oral powder at 65mg/kg/day']\n",
      "['All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).']\n",
      "['BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.\\r\\nAvonex once-weekly intramuscular (IM) injection up to Week 84.', 'BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'Placebo once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.']\n",
      "['In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.', 'In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.']\n",
      "['Subjects will receive rhu-pGSN 24 mg/kg once, followed by 5 daily doses of 12 mg/kg based on actual body weight in addition to standard care .', 'Subjects will receive 6 doses of normal-saline placebo in volumes equivalent to subjects given rhu-pGSN in addition to standard care.']\n",
      "['4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks', 'Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks']\n",
      "['BCD-100 mg/kg Q3W']\n",
      "['Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.', 'Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.']\n",
      "['Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.']\n",
      "['25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days']\n",
      "['Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.']\n",
      "['Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant']\n",
      "['Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol', 'Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg', 'Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg', 'Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg', 'HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol']\n",
      "['In case of bleeding and:\\r\\nCT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;\\r\\nMCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;\\r\\nCT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg.']\n",
      "['Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.', 'Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.']\n",
      "['N-acetyl cysteine will be administered as follows: A loading dose of 50 mg/kg will be started as a 1-hour infusion before surgical incision, and will be followed by a maintenance dose of 50 mg/kg administered over 4 hours.']\n",
      "['Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs', 'Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles']\n",
      "['In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.', 'In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.']\n",
      "['MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.']\n",
      "['Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.']\n",
      "['Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.', 'Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.']\n",
      "['2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity', '2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity', '2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.']\n",
      "['Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]', 'Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient']\n",
      "['Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.', 'Single dose of Nivolumab 480 mg fixed dose\\r\\nReduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.\\r\\nSecond dose of Nivolumab 480 mg fixed dose (at least 4 weeks from the first dose)', 'FMT loading dose given via colonoscopy\\r\\nFMT 12 oral capsules as maintenance - given 2 times\\r\\nSingle dose of Ipilimumab 1mg/kg up to 100 mg\\r\\nReduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.']\n",
      "['2 doses of rituximab 375 mg/m^2 (Maximum 500mg/day)at 6 months intervals', 'MMF 20~30mg/kg/day，BID']\n",
      "['Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.']\n",
      "['Oral SSP-004184AQ taken once daily for 48 weeks', 'Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.', 'A single dose given in the initial pharmacokinetic phase.']\n",
      "['SP-420 initially at 28 mg/kg', 'SP -20 initially at 56 mg/kg', 'SP-420 initially at 84 mg/kg']\n",
      "['standard treatment: Irrua regimen\\r\\n100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)\\r\\n25 mg/kg days 2-7\\r\\n12.5 mg/kg days 8-10', 'Oral favipiravir\\r\\nDay 1 2400mg(H0)-2400mg(H8)-1200mg(H16)\\r\\nDay 2-10 1200mg twice daily (BD)']\n",
      "[\"The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.\"]\n",
      "['Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).']\n",
      "['cytarabine 2g/m2 bid Days 4-7', 'AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7', 'AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7']\n",
      "['Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.', 'Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.']\n",
      "['Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).', 'Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).']\n",
      "['This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).']\n",
      "['Patients were randomized into experimental and control groups. For the experimental patients, the initial combination therapy consisted rhTPO at an initial does of 150U/kg once daily subcutaneously for 28 days and IVIg 400mg/kg per day for 5 days. If the platelet count was in the range of 30 to 50 × 10^9/L, the combination therapy was repeated. To reduce the risk for thrombocytosis, patients received maintenance therapy consisting rhTPO at a dose of 150U/kg per day if the platelet count rose above 50 × 10^9/L, and treatment discontinued when platelet counts exceeded 100 × 10^9/L. After delivery, the treatment consisted rhTPO 150U/kg per day, and maintained the dose if the platelet count exceeded 30 × 10^9/L. In addition, IVIg 400mg/kg per day for 5 days was added if the platelet count could not maintain above 30 × 10^9/L. If patients did not achieve 30 × 10^9/L within 4 weeks treatment was also discontinued.', 'Patients would be treated with IVIg 400mg/kg per day for 5 days monthly. And treatment discontinued when platelet counts exceeded 100 × 10^9/L.']\n",
      "['Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.']\n",
      "['Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg', 'Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg']\n",
      "['Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1. Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#9; and x5 days with vaccination #10. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10)']\n",
      "['Pre-transplant conditioning regimen:\\r\\nThiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF\\r\\nPost haploidentical stem cell transplant participants:\\r\\nCyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.']\n",
      "['Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.', 'Participants will receive placebo intravenously once a week for 12 weeks.']\n",
      "['Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0']\n",
      "[\"Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician\", \"Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician\"]\n",
      "['Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 40 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.', 'Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.', 'Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.', 'Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days']\n",
      "['Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.']\n",
      "['Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4', 'Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8', '4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12']\n",
      "['Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:\\r\\nDay 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.\\r\\nDay 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).\\r\\nThere will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles.']\n",
      "['Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.', 'Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.']\n",
      "['Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.', 'Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.']\n",
      "['Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL', 'Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL', 'Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL', 'Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL', 'Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.']\n",
      "['Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days']\n",
      "['L-serine white or almost white crystalline powder or colourless crystal formulation which will be dissolved in water and administered orally.\\r\\nThe dose will be weight based: 400mg/kg/day (total daily dose).', 'Dextrose monohydrate powder: monohydrate form of crystalline D-glucose (dextrose) consisting of odourless, multi-granular white crystals.\\r\\nThe dose will be weight based: 400mg/kg/day (total daily dose).']\n",
      "['Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.', 'Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose']\n",
      "['fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days\\r\\ncyclophosphamide-60 mg/kg/day x 2 days intravenous\\r\\nAnti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.\\r\\naldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)', 'fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days\\r\\ncyclophosphamide-60 mg/kg/day x 2 days intravenous\\r\\nAnti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes\\r\\naldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)']\n",
      "['Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0.', 'Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.', 'Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0.']\n",
      "['10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.', '10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.']\n",
      "[\"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).\\r\\nParticipants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.\\r\\nDosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early.\"]\n",
      "['N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs', 'equivalent volume over the same period.']\n",
      "['The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.\\r\\nGVHD Prevention Treatment:\\r\\nCyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.\\r\\nTacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.\\r\\nMycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days.']\n",
      "['will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day).', 'will receive dexamethasone 0.5mg/kg IV.', 'will received placebo 10 ml normal saline IV.']\n",
      "['Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor']\n",
      "['Participants to receive:\\r\\nCyclophosphamide 25 mg/kg IV over 1 hour on Day 3 and Day 4 following transplant\\r\\nAbatacept 10 mg/kg IV on Day 5, Day 14, Day 28, and Day 56 following transplant\\r\\nTacrolimus 0.02 mg/kg IV by continuous infusion, starting on Day 5 following transplant. May switch to oral administration when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Tacrolimus treatment is continued until Day 60 and then tapered over a period of 4 weeks in the absence of GvHD.']\n",
      "['Patients in enrolled in Regimen A will receive the following:\\r\\nTotal Body Irradiation (TBI), hyper-fractionated to a dose of 1320 cGy depending on age, stage of disease and requirement of general anesthesia with lung shielding\\r\\nThiotepa, 5 mg/kg/day x 2 days via IV infusion over 4 hours daily or 10 mg/kg on one day\\r\\nCyclophosphamide, 60 mg/kg/day x 2 days via IV infusion over 2 hours daily (or if cyclophosphamide is contraindicated, fludarabine at 25 mg/m^2 x 5 days may be substituted)', 'Patients in enrolled in Regimen B will receive the following:\\r\\nBusulfan, IV 0.8 mg/kg q6hours x 10 or 12 doses over 3 days, depending on the disease\\r\\nMelphalan, 70 mg/m^2/day x 2 days via IV infusion over 30 minutes daily\\r\\nFludarabine, 25 mg/m^2/day x 5 days via IV infusion over 30 minutes daily']\n",
      "['Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy']\n",
      "['Drug excipient', '20mg/kg/day deferiprone', '30mg/kg/day Deferiprone']\n",
      "['Evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.', 'Pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.']\n",
      "['Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)']\n",
      "['Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).']\n",
      "['Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours', 'Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours']\n",
      "['Patients with localized disease will receive six cycles of the combination as \"maintenance\" therapy following standard chemotherapy.\\r\\nCycles 4-6 will include:\\r\\nIfosfamide 2,800 mg/m2/day on days 1-5\\r\\nEtoposide 100 mg/m2/day on days 1-5\\r\\nCycle 7 will include :\\r\\nCyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day\\r\\nDoxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day\\r\\nVincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)\\r\\nCycles 8-13 will include:\\r\\nIrinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously\\r\\nTemozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously', 'Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.\\r\\nCycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:\\r\\nIrinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously\\r\\nTemozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously\\r\\nCycles 6, 9, and 12 will include:\\r\\nIfosfamide 2,800 mg/m2/day on days 1-5\\r\\nEtoposide 100 mg/m2/day on days 1-5\\r\\nCycle 15 will include:\\r\\nCyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day\\r\\nDoxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day\\r\\nVincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)']\n",
      "['Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.']\n",
      "['Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).', 'Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg']\n",
      "['This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.\\r\\nAll patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.\\r\\nAfter the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.\\r\\nClinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent.']\n",
      "['Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).']\n",
      "['Study Drug given IV every 28 days at 24mg/kg', 'Placebo']\n",
      "['7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.', '7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.']\n",
      "['Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.', 'FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.']\n",
      "['Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.']\n",
      "['Stereotactic radiation therapy (SBRT (8GyX3)) will be delivered to gross tumor volume (GTV) +3mm, followed by Pembrolizumab 200 mg IV and Evorpacept 45 mg/kg IV every three weeks x 2 cycles followed by surgical resection of primary tumor and neck dissection.']\n",
      "['After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w']\n",
      "['patients receive 6 mg/kg oxfendazole once', 'patients receive 30 mg/kg oxfendazole once', 'patients receive 6 mg/kg oxfendazole three times', 'patients receive 400 mg albendazole once']\n",
      "['Target dose 20 mg/kg Docosahexaenoic acid', 'Target dose 36 mg/kg Docosahexaenoic acid', 'Target dose 60 mg/kg Docosahexaenoic acid', 'Soybean oil']\n",
      "['Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours', 'Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours']\n",
      "['100 mg/kg T.I.D 3x a day IV or PO', 'Saline or sugar pill']\n",
      "['Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)', 'Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.']\n",
      "['rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)\\r\\nAND\\r\\npyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)\\r\\nfixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)']\n",
      "['Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.\\r\\nPatients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.\\r\\nMMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.', 'Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.\\r\\nPatients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.\\r\\nMMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.', 'Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.\\r\\nSirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.\\r\\nMMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.']\n",
      "['Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.']\n",
      "['A single loading dose of 25 mg/kg followed by a maintenance dose of:\\r\\nPostmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly', 'Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly']\n",
      "['Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection', '2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection', '1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells']\n",
      "['Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.']\n",
      "['Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks', 'Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days']\n",
      "['Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .', 'Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .']\n",
      "['Avalglucosidase alfa, 20 mg/kg intravenous (IV) infusion every other week (qow) for 25 weeks in the Primary Analysis Period (PAP), followed by same treatment from Week 26 up to Week 371 in extension treatment period (ETP).', 'Avalglucosidase alfa 40 mg/kg IV infusion qow for 25 weeks in the PAP, followed by same treatment from Week 26 up to Week 371 in ETP.', 'After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received avalglucosidase alfa 40 mg/kg (the highest tolerated dose) IV infusion qow for 25 weeks in PAP, followed by same treatment from Week 26 up to Week 371 in ETP.', 'After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose [between 20 mg/kg qow and 40 mg/kg weekly as per physician] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.']\n",
      "['Patients with AML and MDS:\\r\\nDays -6 through -3: Busulfan q 5-6h IV q24h x 4 days\\r\\nDays -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV\\r\\nFor patients with ALL and lymphoblastic lymphoma:\\r\\nDays -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV\\r\\nDays -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days\\r\\nAll patients Day 0: Infuse unmanipulated bone marrow\\r\\nDay +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV\\r\\nDay +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day\\r\\nDay +30: Assess chimerism and disease status in bone marrow\\r\\nDay +35: Discontinue MMF\\r\\nDay +60: Assess chimerism and disease status in bone marrow\\r\\nDay 180: Discontinue tacrolimus']\n",
      "['Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.\\r\\nDrug to be given in combination of Busulfan, Campath and Fludarabine', 'Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.', 'Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath', 'No cyclophosphamide given with Busulfan, Fludarabine and Campath']\n",
      "['Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days']\n",
      "['Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.', 'Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.']\n",
      "['Intervention: Drug: AGuIX® + WBRT\\r\\nOther Names:\\r\\nGadolinium-chelated polysiloxane based nanoparticles\\r\\n3 intravenous injections at 100mg/kg\\r\\nD0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)\\r\\nFr1: AGuIX® injection before the first radiation session\\r\\nFr6: AGuIX® injection before the sixth radiation session\\r\\n30 Gy in 10 fractions of 3 Gy over 2-3 weeks']\n",
      "['Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12']\n",
      "['Hormone Receptor(HR) negative, Human Epidermal Growth Factor Receptor 2(HER2 )negative breast cancer Drug: Utidelone in combination with carboplatin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin ,Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'HR positive, HER2 negative, Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH)non-amplification breast cancer Drug: Utidelone in combination with Epirubicin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Epirubicin 75mg/m2 was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'Drug: Utidelone in combination with carboplatin, trastuzumab and pertuzumab Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total. Trastuzumab 8mg/kg iv in first cycle on day 1, then 8mg/kg in the rest cycles; pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles.\\r\\nOne treatment cycle is 21 days, and there are 6 cycles in total.']\n",
      "['A single dose of 140 mg/kg of VPA plus standard of care', 'A single dose of isotonic saline solution plus standard of care']\n",
      "['These patients receive a placebo infusion of D5W prior to and after surgery', 'These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.']\n",
      "['Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['D-serine 30 mg/kg', 'D-serine 60 mg/kg', 'D-serine 120 mg/kg']\n",
      "['Deferiprone oral solution 20 mg/kg/day', 'Deferiprone oral solution 40 mg/kg/day']\n",
      "['Thalidomide:\\r\\nOral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.\\r\\nTemozolomide:\\r\\nOral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.\\r\\nPatients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression']\n",
      "['Patients receive:\\r\\nBusulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3\\r\\nFludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (90 mg/m2 total dose) IV on days -7 to -5\\r\\nTotal body irradiation (TBI) (1200 cGy total dose) on days -4 to -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (120-180 mg/m2 total dose) IV on days -6 to -2\\r\\nBusulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (120-180 mg/m2 total dose) IV on days -7 to -3\\r\\nMelphalan (100-140 mg/m2) IV on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nCyclophosphamide (29-50 mg/kg) IV on days -6 and -5\\r\\nTBI (200 cGy) on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nBusulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3\\r\\nCyclophosphamide (100 mg/kg total dose) IV on days -2 and -1\\r\\nPatients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nCyclophosphamide (100 mg/kg total dose) IV on days -5 and -4\\r\\nTBI (1200 cGy total dose) on days -3, -2 and -1\\r\\nPatients receive a BM graft infusion from a mismatched unrelated donor on Day 0.']\n",
      "['Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.', 'Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.', 'Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.']\n",
      "['IV Ketamine .25mg/kg', '25mg Diphenhydramine']\n",
      "['Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.', 'Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.']\n",
      "['Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.', 'Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.']\n",
      "['busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4', 'busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4']\n",
      "['Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes', 'Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes', 'Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.', 'Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes']\n",
      "['The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.', 'Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.', 'Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.']\n",
      "['Treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or Absolute Neutrophil Count (ANC) <4000', 'Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day']\n",
      "['Paclitaxel and carboplatin', 'Paclitaxel, carboplatin and Mapatumumab 10 mg/kg', 'Paclitaxel, carboplatin and Mapatumumab 30 mg/kg']\n",
      "['(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5']\n",
      "['Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and immediately after exposure', 'rhu-pGSN 24 mg/kg IV immediately prior to hyperbaric chamber exposure, and sterile normal saline 0.9% IV immediately after exposure', 'Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and rhu-pGSN 24 mg/kg IV immediately after exposure']\n",
      "['All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).']\n",
      "['Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.\\r\\nThe starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day.', 'Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.']\n",
      "['Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.', 'One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.']\n",
      "['Participants will receive vitamin C in addition to active comparator treatment:\\r\\nInpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;\\r\\nPlus Active Comparator treatment:\\r\\nHydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days', 'Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days']\n",
      "['All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.']\n",
      "['50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.', '50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.', '50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.']\n",
      "[\"Participants received the first intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) 120 milligrams per kilogram (mg/kg), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8 (second dose was not mandatory and was given at the principal investigator's [PI] discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.\", \"Participants received IV infusions of 0.9% normal saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 (Day 8 was not mandatory and was given at the PI's discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.\"]\n",
      "[\"Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.\", \"Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29\"]\n",
      "['Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day', 'Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.', 'Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide']\n",
      "['Patients randomized to Control group will receive placebo (D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study.', 'Patients randomized to Study group will receive fomepizole (diluted in D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study. If randomized to Study group, the participant will receive fomepizole in a fixed dose relative to acetylcysteine. The fixed ratio is acetylcysteine 10 : 1 fomepizole. In the first 20-21 hours (2 vs. 3-bag regimen), a total of 30 mg/kg fomepizole is delivered.']\n",
      "['7.1.1 HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought (see 7.2 for definition of response) (Maximum of 4 dose levels) (7.1.2):']\n",
      "['Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.', 'Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.']\n",
      "['The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.']\n",
      "['Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.', 'Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.']\n",
      "['150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline', '150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline', '150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.', '150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.']\n",
      "['Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours', 'Normal saline (240mL) intravenous infusion over 12 hours']\n",
      "[\"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).\\r\\nPrednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\ncyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\", \"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).\\r\\nPrednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\nmycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\", \"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\nLeflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.\\r\\nAngiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\"]\n",
      "['Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.']\n",
      "[\"We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.\", \"We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.\"]\n",
      "['Meropenem 6g IV over 6 hours plus amoxicillin/CA', 'Ertapenem 1g IM plus amoxicillin/CA', 'Meropenem 3g over 1 hour twice daily plus amoxicillin/CA', 'Ertapenem 1g IV plus amoxicillin/CA', 'Amoxicillin; CA', 'Rifampicin 35mg/kg plus amoxicillin/CA', 'Meropenem 6g or 4g IV over 60 minutes plus amoxicillin/CA', 'Rifafour e-275']\n",
      "['Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2']\n",
      "['Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).', 'Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)']\n",
      "['Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.', 'Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.']\n",
      "['1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.']\n",
      "['Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.']\n",
      "['Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an \"add-on\" therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.\\r\\nThe dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours.', 'Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an \"add-on\" therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.\\r\\nThe placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm).']\n",
      "['Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.\\r\\nGroup A has been closed to new patient entry as of January 14, 2016.', 'Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.', 'Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.', 'Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.']\n",
      "['Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.']\n",
      "['Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).']\n",
      "['Intravenous injection of 0,25 mg/kg Indocyanine Green']\n",
      "['Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.']\n",
      "['Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).', 'Standard of care anti-TB therapy as described in Arm 1,\\r\\nPlus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days).', 'Standard of care anti-TB therapy as described in Arm 1,\\r\\nPlus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),\\r\\nPlus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)']\n",
      "['- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.', '- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.']\n",
      "['SURFAXIN (lucinactant) at 175 mg/kg', 'SURFAXIN (lucinactant) at 90 mg/kg', 'Sham air using 3.0 mL/kg volume of air']\n",
      "['Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.']\n",
      "['Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.', 'Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.', 'Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.']\n"
     ]
    }
   ],
   "source": [
    "# 计算Q1和Q3及IQR\n",
    "Q1 = data.quantile(0.25)\n",
    "Q3 = data.quantile(0.75)\n",
    "IQR = Q3 - Q1\n",
    "\n",
    "# 定义离群点的界限\n",
    "lower_bound = Q1 - 1.5 * IQR\n",
    "upper_bound = Q3 + 1.5 * IQR\n",
    "\n",
    "# 计算离群点的个数\n",
    "outliers = data[(data < lower_bound) | (data > upper_bound)]\n",
    "num_outliers = outliers.count()\n",
    "\n",
    "print(\"Number of outliers:\", num_outliers)\n",
    "print(\"Outliers:\", outliers.tolist())\n",
    "\n",
    "# 检查离群点\n",
    "outliers_nctid = absoult_dose['nctid'][(absoult_dose['dose'] < lower_bound) | (absoult_dose['dose'] > upper_bound)]\n",
    "outliers_nctid = set(outliers_nctid.to_list())\n",
    "for nctid in outliers_nctid:\n",
    "    print(dose['dose_description'][nctid])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "差值分布"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "38.0 [50.0, 12.0, 40.0]\n",
      "['D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months', 'ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months']\n",
      "250.0 [500.0, 750.0]\n",
      "['Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.', 'Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.']\n",
      "400.0 [500.0, 100.0, 500.0]\n",
      "['High Dose Arm\\r\\nWash-out then 7 days of:\\r\\nArg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA', 'Low Dose Arm\\r\\nWash-out followed by 7 days of:\\r\\nArg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA']\n",
      "500.0 [500.0, 1000.0]\n",
      "['Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks', 'Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks']\n",
      "832.0 [8.0, 8.0, 840.0, 420.0]\n",
      "['Hormone Receptor(HR) negative, Human Epidermal Growth Factor Receptor 2(HER2 )negative breast cancer Drug: Utidelone in combination with carboplatin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin ,Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'HR positive, HER2 negative, Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH)non-amplification breast cancer Drug: Utidelone in combination with Epirubicin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Epirubicin 75mg/m2 was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'Drug: Utidelone in combination with carboplatin, trastuzumab and pertuzumab Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total. Trastuzumab 8mg/kg iv in first cycle on day 1, then 8mg/kg in the rest cycles; pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles.\\r\\nOne treatment cycle is 21 days, and there are 6 cycles in total.']\n"
     ]
    }
   ],
   "source": [
    "maxedge = 0\n",
    "lis = []\n",
    "for i in temp.dropna().index:\n",
    "    if temp[i] == False:\n",
    "        continue\n",
    "    if len(temp[i]) == 1:\n",
    "        lis.append((i, temp[i][0]))\n",
    "        continue\n",
    "    elif len(temp[i]) == 0:\n",
    "        continue\n",
    "    else:\n",
    "        lis.append((i, max(temp[i])- min(temp[i])))\n",
    "        if (max(temp[i])- min(temp[i])) > maxedge:\n",
    "            maxedge = max(temp[i])- min(temp[i])\n",
    "            print(maxedge, temp[i])\n",
    "            print(dose.loc[i, 'dose_description'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.DataFrame(lis, columns=['nctid', 'maxedge']).set_index('nctid').to_csv('drug-dose-prediction/output_maxedge.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>dose_description</th>\n",
       "      <th>phase</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ntcid</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00000249</th>\n",
       "      <td>[Subject inhaled 20% N2O for 40 minutes with c...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000250</th>\n",
       "      <td>[Subjects will immerse forearm in lukewarm wat...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000251</th>\n",
       "      <td>[Subjects inhale 30% N2O, Subjects inhale 0.2%...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000252</th>\n",
       "      <td>[Subjects will inhale 0% N2O, Subjects will in...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00000271</th>\n",
       "      <td>[Participants were treated with desipramine, u...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263491</th>\n",
       "      <td>[If participants show that they have no MRD, p...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263543</th>\n",
       "      <td>[SG will be administered on Days 1 and 8 of co...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263959</th>\n",
       "      <td>[Patiants on stable nucleos(t)ide analog (NA) ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264141</th>\n",
       "      <td>[Nasal spray with nitric oxide releasing solut...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264310</th>\n",
       "      <td>[8 study subjects will receive placebo once da...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>35983 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              dose_description    phase\n",
       "ntcid                                                                  \n",
       "NCT00000249  [Subject inhaled 20% N2O for 40 minutes with c...  Phase 2\n",
       "NCT00000250  [Subjects will immerse forearm in lukewarm wat...  Phase 2\n",
       "NCT00000251  [Subjects inhale 30% N2O, Subjects inhale 0.2%...  Phase 2\n",
       "NCT00000252  [Subjects will inhale 0% N2O, Subjects will in...  Phase 2\n",
       "NCT00000271  [Participants were treated with desipramine, u...  Phase 2\n",
       "...                                                        ...      ...\n",
       "NCT06263491  [If participants show that they have no MRD, p...  Phase 2\n",
       "NCT06263543  [SG will be administered on Days 1 and 8 of co...  Phase 2\n",
       "NCT06263959  [Patiants on stable nucleos(t)ide analog (NA) ...  Phase 2\n",
       "NCT06264141  [Nasal spray with nitric oxide releasing solut...  Phase 2\n",
       "NCT06264310  [8 study subjects will receive placebo once da...  Phase 2\n",
       "\n",
       "[35983 rows x 2 columns]"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dose"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>maxedge</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nctid</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT00001626</th>\n",
       "      <td>38.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00001832</th>\n",
       "      <td>30.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00001962</th>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00001964</th>\n",
       "      <td>28.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT00003838</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06251492</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06253650</th>\n",
       "      <td>6.4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06255977</th>\n",
       "      <td>0.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06261359</th>\n",
       "      <td>3.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06263543</th>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2664 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             maxedge\n",
       "nctid               \n",
       "NCT00001626     38.0\n",
       "NCT00001832     30.0\n",
       "NCT00001962      1.0\n",
       "NCT00001964     28.0\n",
       "NCT00003838      0.0\n",
       "...              ...\n",
       "NCT06251492      0.0\n",
       "NCT06253650      6.4\n",
       "NCT06255977      0.9\n",
       "NCT06261359      3.2\n",
       "NCT06263543     10.0\n",
       "\n",
       "[2664 rows x 1 columns]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "maxedge = pd.read_csv('drug-dose-prediction/output_maxedge.csv', index_col=0)\n",
    "maxedge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count    2664.000000\n",
       "mean       12.101052\n",
       "std        34.622193\n",
       "min         0.000000\n",
       "25%         0.900000\n",
       "50%         3.857500\n",
       "75%        10.000000\n",
       "max       832.000000\n",
       "Name: maxedge, dtype: float64"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "maxedge['maxedge'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = maxedge['maxedge']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of outliers: 267\n",
      "Outliers: [38.0, 30.0, 28.0, 250.0, 39.0, 59.0, 40.0, 184.0, 60.0, 32.975, 155.0, 85.0, 30.0, 50.0, 60.0, 96.0, 50.0, 25.0, 40.0, 90.0, 50.0, 400.0, 60.0, 90.0, 50.0, 112.5, 60.0, 50.0, 80.0, 60.0, 27.0, 60.0, 70.0, 35.0, 40.0, 30.0, 40.31, 40.0, 240.0, 60.0, 29.0, 48.0, 40.0, 30.0, 49.2, 50.0, 60.0, 60.0, 40.0, 30.0, 48.0, 150.0, 60.0, 45.0, 70.0, 40.0, 100.0, 50.0, 27.97, 59.2, 90.0, 60.0, 195.0, 25.0, 50.0, 60.0, 30.0, 45.0, 35.0, 55.0, 59.4, 66.0, 50.0, 40.0, 60.0, 100.0, 100.0, 45.0, 91.7, 60.0, 100.0, 49.985, 69.933, 97.0, 60.0, 30.0, 40.0, 58.0, 25.0, 49.7, 25.0, 36.0, 30.0, 175.0, 30.0, 25.0, 200.0, 49.985, 33.0, 30.0, 25.0, 32.0, 125.0, 37.5, 60.0, 30.0, 49.97, 116.8, 30.0, 63.0, 150.0, 320.0, 30.0, 49.985, 39.25, 70.0, 39.9, 100.0, 50.0, 30.0, 30.0, 225.0, 50.0, 49.97, 24.0, 24.0, 30.0, 110.0, 250.0, 30.0, 100.0, 29.55, 64.0, 133.0, 40.0, 41.0, 30.0, 30.0, 28.0, 44.75, 60.0, 40.0, 100.0, 30.0, 95.5, 40.0, 25.0, 30.0, 28.0, 49.97, 90.0, 29.0, 40.0, 24.0, 60.0, 200.0, 40.0, 45.0, 47.5, 394.0, 100.0, 143.75, 40.0, 50.0, 208.0, 50.0, 40.0, 50.0, 50.0, 40.0, 46.8, 56.0, 25.0, 80.0, 100.0, 56.0, 200.0, 30.0, 400.0, 60.0, 47.5, 48.0, 100.0, 30.0, 60.0, 46.8, 48.0, 60.0, 49.985, 60.0, 59.2, 25.0, 35.0, 50.0, 40.0, 60.0, 350.0, 35.0, 400.0, 29.75, 29.0, 100.0, 70.0, 70.0, 140.0, 140.0, 120.0, 48.0, 55.0, 30.0, 30.0, 49.97, 45.0, 45.0, 30.0, 44.0, 35.0, 55.0, 30.0, 99.0, 93.6, 200.0, 87.5, 100.0, 150.0, 40.0, 49.97, 29.97, 80.0, 190.0, 50.0, 30.0, 89.5, 25.0, 50.0, 30.0, 30.0, 30.0, 60.0, 45.0, 45.0, 30.0, 28.5, 49.2, 30.0, 59.2, 500.0, 70.0, 24.98, 56.0, 29.0, 359.0, 45.0, 50.0, 90.0, 30.0, 175.0, 60.0, 40.0, 35.0, 832.0, 75.0, 43.6, 76.8, 45.0, 45.0, 35.0]\n",
      "['320 mg/kg', 'Normal saline IV infusion']\n",
      "['Placebo', '60 mg/kg was given on Days 0, 7, 14', '90 mg/kg was given on Days 0, 7, 14']\n",
      "['Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs', 'Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles']\n",
      "['Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .', 'Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .']\n",
      "['Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.', 'In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.']\n",
      "['Patients with AML and MDS:\\r\\nDays -6 through -3: Busulfan q 5-6h IV q24h x 4 days\\r\\nDays -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV\\r\\nFor patients with ALL and lymphoblastic lymphoma:\\r\\nDays -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV\\r\\nDays -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days\\r\\nAll patients Day 0: Infuse unmanipulated bone marrow\\r\\nDay +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV\\r\\nDay +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day\\r\\nDay +30: Assess chimerism and disease status in bone marrow\\r\\nDay +35: Discontinue MMF\\r\\nDay +60: Assess chimerism and disease status in bone marrow\\r\\nDay 180: Discontinue tacrolimus']\n",
      "['Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).']\n",
      "['6MW3211injection,30mg/kg,Q2W']\n",
      "['At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit.', 'At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).', 'At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (\"compassionate use\") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient\\'s interest.\\r\\nFor Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).']\n",
      "['MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.']\n",
      "['80 mg/kg AAT inhaled', 'Placebo inhaled']\n",
      "['single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.', 'single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.', 'single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.']\n",
      "['Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.\\r\\nDrug to be given in combination of Busulfan, Campath and Fludarabine', 'Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.', 'Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath', 'No cyclophosphamide given with Busulfan, Fludarabine and Campath']\n",
      "['Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.', 'Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.']\n",
      "['Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.']\n",
      "['2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity', '2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity', '2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.']\n",
      "['Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.', 'Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).']\n",
      "['Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]', 'Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient']\n",
      "['anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter\\r\\nRituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;\\r\\nFor adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).\\r\\nTacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.']\n",
      "['Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.', 'Single dose of Nivolumab 480 mg fixed dose\\r\\nReduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.\\r\\nSecond dose of Nivolumab 480 mg fixed dose (at least 4 weeks from the first dose)', 'FMT loading dose given via colonoscopy\\r\\nFMT 12 oral capsules as maintenance - given 2 times\\r\\nSingle dose of Ipilimumab 1mg/kg up to 100 mg\\r\\nReduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..\\r\\nPreparation and administration of TIL\\r\\nBolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.']\n",
      "['Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.', 'Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.', 'For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.']\n",
      "['Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.']\n",
      "['Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days']\n",
      "['2 doses of rituximab 375 mg/m^2 (Maximum 500mg/day)at 6 months intervals', 'MMF 20~30mg/kg/day，BID']\n",
      "['Patients Receive:\\r\\nPatients receive:\\r\\nBusulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.', 'Patients receive:\\r\\nFludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.\\r\\nPatients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.\\r\\nFirst 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.']\n",
      "['ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months', 'ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF']\n",
      "['Oral SSP-004184AQ taken once daily for 48 weeks', 'Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.', 'A single dose given in the initial pharmacokinetic phase.']\n",
      "['low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3', 'low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3']\n",
      "['Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells', 'Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow']\n",
      "['SP-420 initially at 28 mg/kg', 'SP -20 initially at 56 mg/kg', 'SP-420 initially at 84 mg/kg']\n",
      "['standard treatment: Irrua regimen\\r\\n100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)\\r\\n25 mg/kg days 2-7\\r\\n12.5 mg/kg days 8-10', 'Oral favipiravir\\r\\nDay 1 2400mg(H0)-2400mg(H8)-1200mg(H16)\\r\\nDay 2-10 1200mg twice daily (BD)']\n",
      "['Plerixafor 160mg/kg/dose by IV on days 5-8\\r\\nFilgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.']\n",
      "['Intervention: Drug: AGuIX® + WBRT\\r\\nOther Names:\\r\\nGadolinium-chelated polysiloxane based nanoparticles\\r\\n3 intravenous injections at 100mg/kg\\r\\nD0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)\\r\\nFr1: AGuIX® injection before the first radiation session\\r\\nFr6: AGuIX® injection before the sixth radiation session\\r\\n30 Gy in 10 fractions of 3 Gy over 2-3 weeks']\n",
      "['Saline administered IV for 12 hours', 'MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours', 'MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours']\n",
      "['Given on Day 1 of each 21 day cycle, in the following order of administration:\\r\\n200 mg IV pembrolizumab* (maximum of 2 years (approximately 35 cycles)\\r\\n45 mg/kg IV ALX148\\r\\n30 mg/m^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)*\\r\\n*standard of care']\n",
      "['Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12']\n",
      "['Hormone Receptor(HR) negative, Human Epidermal Growth Factor Receptor 2(HER2 )negative breast cancer Drug: Utidelone in combination with carboplatin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin ,Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'HR positive, HER2 negative, Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH)non-amplification breast cancer Drug: Utidelone in combination with Epirubicin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Epirubicin 75mg/m2 was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.', 'Drug: Utidelone in combination with carboplatin, trastuzumab and pertuzumab Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total. Trastuzumab 8mg/kg iv in first cycle on day 1, then 8mg/kg in the rest cycles; pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles.\\r\\nOne treatment cycle is 21 days, and there are 6 cycles in total.']\n",
      "['Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv', 'Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration', 'Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['A single dose of 140 mg/kg of VPA plus standard of care', 'A single dose of isotonic saline solution plus standard of care']\n",
      "[\"The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.\"]\n",
      "['Maximum of 1800 mg/day or 63 mg/kg/day']\n",
      "['Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.', '5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline']\n",
      "['Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).\\r\\nFludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.\\r\\nBone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.\\r\\nTacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.\\r\\nMycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).', 'Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).\\r\\nFludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.\\r\\nTacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.\\r\\nMycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).']\n",
      "['All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.']\n",
      "['cytarabine 2g/m2 bid Days 4-7', 'AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7', 'AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7']\n",
      "['6MW3211 injection, 45mg/kg, Q2W']\n",
      "['4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）\\r\\n4.2.2 Unrelated donor and haploidentical donor\\r\\n1) ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）', '4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d\\r\\n4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d']\n",
      "['patients will receive oral 1000 mg of curcumin capsules daily in addition to their standard treatment for three months.\\r\\nStandard treatment includes: oral MMF initial dose of 1200 mg/m2/day, no more than 2000 m g/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day\\r\\nsecond regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids']\n",
      "['D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months', 'ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months']\n",
      "['These patients receive a placebo infusion of D5W prior to and after surgery', 'These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.']\n",
      "['Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide']\n",
      "[\"Arm A - Intervention arm (Immunotherapy and Chemotherapy)\\r\\nNivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks\\r\\nPlatinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion.\\r\\nCarboplatin dosed at AUC 5, and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous\", 'Arm B - control arm (Immunotherapy only)\\r\\nNivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks']\n",
      "['Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['D-serine 30 mg/kg', 'D-serine 60 mg/kg', 'D-serine 120 mg/kg']\n",
      "['Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.', 'Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.']\n",
      "['Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.']\n",
      "['Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.']\n",
      "['Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).', 'Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).']\n",
      "['Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:\\r\\nBevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;\\r\\nIrinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;\\r\\nLeucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;\\r\\nFloxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.']\n",
      "['This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).']\n",
      "['Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)', 'Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)', 'Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)', 'Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)']\n",
      "['P-rATG days (always starting on Day -12 to -10)\\r\\nHyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6\\r\\nThiotepa (5mg/kg/day x 2 day) Day -5 to -4\\r\\nCyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2\\r\\nGCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements.', 'P-rATG days (Appendix A - always starting on Day -12 to -10)\\r\\nBusulfan -Day -9 to -7\\r\\nInitial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5\\r\\nFludarabine (25mg/m2/day x 5 days) Day -6 to -2\\r\\nGCSF Day +7']\n",
      "['L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID).', 'Standard dose (100mg/kg IV TID).', 'Low dose (25mg/kg IV TID).']\n",
      "['Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.']\n",
      "['Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.', \"Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).\"]\n",
      "['Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1. Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#9; and x5 days with vaccination #10. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10)']\n",
      "['Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.', 'Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.', 'Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.']\n",
      "['Group A: Subjects with Multiple Myeloma\\r\\nConditioning regimen, over a 7 day period, includes:\\r\\nMelphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion\\r\\nGroup B: Subjects with Lymphoma\\r\\nConditioning regimen, over a 7 day period, includes: (BEAC)\\r\\nBCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant']\n",
      "['Pre-transplant conditioning regimen:\\r\\nThiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF\\r\\nPost haploidentical stem cell transplant participants:\\r\\nCyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.']\n",
      "['Patients receive:\\r\\nBusulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3\\r\\nFludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nPatients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (90 mg/m2 total dose) IV on days -7 to -5\\r\\nTotal body irradiation (TBI) (1200 cGy total dose) on days -4 to -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (120-180 mg/m2 total dose) IV on days -6 to -2\\r\\nBusulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (120-180 mg/m2 total dose) IV on days -7 to -3\\r\\nMelphalan (100-140 mg/m2) IV on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nFludarabine (150 mg/m2 total dose) IV on days -6 to -2\\r\\nCyclophosphamide (29-50 mg/kg) IV on days -6 and -5\\r\\nTBI (200 cGy) on day -1\\r\\nPatients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nBusulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3\\r\\nCyclophosphamide (100 mg/kg total dose) IV on days -2 and -1\\r\\nPatients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0.', 'Patients receive:\\r\\nCyclophosphamide (100 mg/kg total dose) IV on days -5 and -4\\r\\nTBI (1200 cGy total dose) on days -3, -2 and -1\\r\\nPatients receive a BM graft infusion from a mismatched unrelated donor on Day 0.']\n",
      "['Patients receive a single 6 mg/kg dose of oxfendazole administered orally.', 'Patients receive a single 15 mg/kg dose of oxfendazole administered orally.', 'Patients receive a single 30 mg/kg dose of oxfendazole administered orally.', 'Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.', 'Patients receive a single 400 mg/kg dose of albendazole administered orally.']\n",
      "['IV Ketamine .25mg/kg', '25mg Diphenhydramine']\n",
      "['Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.', 'Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.', 'Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.']\n",
      "['Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.', 'Participants will receive placebo intravenously once a week for 12 weeks.']\n",
      "['Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0']\n",
      "['Sterile water will be packaged identically to the active comparator.\\r\\nEach patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs.', 'Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.\\r\\nThe maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:\\r\\nIf the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins\\r\\nIf the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated\\r\\nIf the systolic BP decrease rapidly more than 25% over 15 minutes\\r\\nIf the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate.']\n",
      "['Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration', 'Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration']\n",
      "['Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.', 'Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.']\n",
      "['Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.']\n",
      "['Deferoxamine 32 Milligram Per Kilogram (mg/kg)', 'Deferoxamine 48 mg/kg', 'normal saline']\n",
      "['RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment.', \"WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + ethambutol (EMB) 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion.\"]\n",
      "['Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4', 'Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8', '4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12']\n",
      "['Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.', 'Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.']\n",
      "['Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.', 'Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.']\n",
      "['Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL', 'Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL', 'Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL', 'Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL', 'Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.']\n",
      "['Stereotactic radiation therapy (SBRT (8GyX3)) will be delivered to gross tumor volume (GTV) +3mm, followed by Pembrolizumab 200 mg IV and Evorpacept 45 mg/kg IV every three weeks x 2 cycles followed by surgical resection of primary tumor and neck dissection.']\n",
      "['Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.', 'Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.']\n",
      "['Deferasirox daily oral dose between 5-40 mg/kg/day']\n",
      "['Deferiprone, 25 to 30 mg/kg per day, oral use']\n",
      "['Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days']\n",
      "['busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4', 'busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4']\n",
      "['Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.', 'Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.', 'Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.', 'Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).']\n",
      "['60 mg/kg azithromycin ER (Extended Release)arm', '30 mg/kg azithromycin IR (Immediate Release) arm']\n",
      "['Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg', '10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg', '10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg', '0.9 % Sodium chloride infusion']\n",
      "['Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.', 'Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose']\n",
      "['Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0.', 'Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.', 'Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.\\r\\nStem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0.']\n",
      "['Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:\\r\\nFludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions', 'Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:\\r\\nBusulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2']\n",
      "['Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively', 'Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively']\n",
      "['Participants will receive intravenous (i.v.) infusion of 10 milligrams per kilograms (mg/kg) NNC6019-0001 every 4 weeks (Q4W) added to standard of care until week 52.', 'Participants will receive i.v. infusion of 60 mg/kg NNC6019-0001 Q4W added to standard of care until week 52.', 'Participants will receive i.v. infusion of placebo (NNC6019-0001) Q4W added to standard of care until week 52.']\n",
      "['General anesthesia is induced in the lidocaine group with intravenous lidocaine 1.5mg/kg for ten minutes, followed by continuous injection of lidocaine 1.5mg/kg.h. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most).', 'The lidocaine is replaced by identical volumes and rates of 0.9% saline. At the end of the operation, the patient controlled intravenous analgesia without lidocaine is used.']\n",
      "['Study Drug given IV every 28 days at 24mg/kg', 'Placebo']\n",
      "['20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day', '50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week', '\"DFO to ICL\" (patients who switched from DFO to deferasirox in extension)', '\"ICL to DFO\" (patients who switched from deferasirox to DFO in extension)']\n",
      "['10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.', '10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.']\n",
      "['Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes', 'Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes', 'Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.', 'Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes']\n",
      "['Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.']\n",
      "['Deuremidevir Hydrobromide for Suspension will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.', 'Placebo will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.']\n",
      "['Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2\\r\\nCyclophosphamide 14.5 mg/kg/day IV on Days -6, -5\\r\\nTotal Body Irradiation (TBI) 200cGy on Day -1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)\\r\\nCyclophosphamide 50mg/kg/day IV on Days -2,-1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)\\r\\nFludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.', 'Cyclophosphamide 50mg/kg/day IV on Days -5,-4\\r\\nTotal Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1\\r\\nInfusion of non-T-cell depleted bone marrow on Day 0\\r\\nAlthough a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above.']\n",
      "['Treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or Absolute Neutrophil Count (ANC) <4000', 'Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day']\n",
      "['50 mg/kg/day orally twice daily for 24 weeks']\n",
      "['(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5']\n",
      "['Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.', \"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).\\r\\nFenofibrate 160 mg per day. To be taken once per day for 6 weeks.\", \"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).\\r\\nFenofibrate 160 mg per day. To be taken once per day for 6 weeks.\"]\n",
      "[\"Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\", \"Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.\"]\n",
      "['N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs', 'equivalent volume over the same period.']\n",
      "['The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.\\r\\nGVHD Prevention Treatment:\\r\\nCyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.\\r\\nTacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.\\r\\nMycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days.']\n",
      "['will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day).', 'will receive dexamethasone 0.5mg/kg IV.', 'will received placebo 10 ml normal saline IV.']\n",
      "['Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Cyclophosphamide 50mg/kg (days +3, +4)']\n",
      "['Conditioning regimen containing treosulfan 30-42 g/m2, fludarabine 150 mg/mg, thymoglobulin 5 mg/kg and thiotepa 10 mg/kg or melphalan 140 mg/m2\\r\\nGVHD prophylaxis regimen for matched unrelated (MUD) and matched related donors (MRD):\\r\\nCyclophosphamide (PTCY) 25 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5\\r\\nGVHD prophylaxis regimen for mismatched related donor (MMRD):\\r\\nCyclophosphamide (PTCY) 50 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5']\n",
      "['10 mg/kg/day Intravenous inositol 5%', '40 mg/kg/day Intravenous inositol 5%', '80 mg/kg/day Intravenous inositol 5%', 'Glucose 5% given in volumes equal to that of the comparator drug']\n",
      "['A single dose of 140 mg/kg of VPA plus standard of care', 'A single dose of isotonic saline solution plus standard of care']\n",
      "['BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.\\r\\nStandard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.\\r\\nStandard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.\\r\\nStandard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)']\n",
      "['Cannabidiol oral solution (40 milligram/kilogram/day [40 mg/kg/day]) divided into two daily doses with a standard meal', 'Matching placebo solution divided into two daily doses with a standard meal']\n",
      "['Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.']\n",
      "['Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).', 'Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)']\n",
      "['Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.\\r\\nThen they will undergo an Autologous Hematopoietic Stem Cell Transplantation.']\n",
      "['Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.']\n",
      "['200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours', '50ml every 6 hours for 96 hours']\n",
      "['Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor']\n",
      "['IV every 3-weeks (Q3W) and placebo (normal saline)', 'IV every 4-weeks (Q4W) and placebo (normal saline)', '60 mg/kg IV once weekly (QW) and placebo (normal saline)']\n",
      "['Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.']\n",
      "['Cytoreductive treatment: (preferentially) FC (2-4 cycles)\\r\\nMobilization: Dexa-BEAM + G-CSF (1-2 cycles)\\r\\nMyeloablation:\\r\\nfractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)\\r\\nautologous peripheral blood stem cell transplantation (PBSCT) (d 0)']\n",
      "['All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).']\n",
      "['Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.']\n",
      "['Participants to receive:\\r\\nCyclophosphamide 25 mg/kg IV over 1 hour on Day 3 and Day 4 following transplant\\r\\nAbatacept 10 mg/kg IV on Day 5, Day 14, Day 28, and Day 56 following transplant\\r\\nTacrolimus 0.02 mg/kg IV by continuous infusion, starting on Day 5 following transplant. May switch to oral administration when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Tacrolimus treatment is continued until Day 60 and then tapered over a period of 4 weeks in the absence of GvHD.']\n",
      "['Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .']\n",
      "['Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.', 'Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.', 'Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.', 'Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.', 'Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.', 'Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).', 'Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).', 'Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.']\n",
      "['Patients in enrolled in Regimen A will receive the following:\\r\\nTotal Body Irradiation (TBI), hyper-fractionated to a dose of 1320 cGy depending on age, stage of disease and requirement of general anesthesia with lung shielding\\r\\nThiotepa, 5 mg/kg/day x 2 days via IV infusion over 4 hours daily or 10 mg/kg on one day\\r\\nCyclophosphamide, 60 mg/kg/day x 2 days via IV infusion over 2 hours daily (or if cyclophosphamide is contraindicated, fludarabine at 25 mg/m^2 x 5 days may be substituted)', 'Patients in enrolled in Regimen B will receive the following:\\r\\nBusulfan, IV 0.8 mg/kg q6hours x 10 or 12 doses over 3 days, depending on the disease\\r\\nMelphalan, 70 mg/m^2/day x 2 days via IV infusion over 30 minutes daily\\r\\nFludarabine, 25 mg/m^2/day x 5 days via IV infusion over 30 minutes daily']\n",
      "['Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.\\r\\nThe starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day.', 'Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.']\n",
      "['15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.', '15 patients will receive 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.', '15 patients will receive 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.']\n",
      "['Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.', 'Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.']\n",
      "['Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.', 'Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.', 'Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.']\n",
      "['Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.', 'Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.']\n",
      "['Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.', 'Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).', 'Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.', 'Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.']\n",
      "['Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).', 'Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses). Note: This arm is now closed.', 'Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).', 'Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses). Note: This arm is now closed.']\n",
      "['Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.', 'One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.']\n",
      "['FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.', 'FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.']\n",
      "['Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d']\n",
      "['Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy']\n",
      "['6MW3211 injection, 30mg/kg']\n",
      "['Rezafungin: Weekly intravenous infusion with a loading dose of 400 mg over 1 hour (±10 minutes) on Day 1 followed by maintenance doses of 200 mg over 1 hour (±10 minutes) on Day 8 and Day 15.\\r\\nFrom Day 1 to Day 7, co-trimoxazole will also be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.\\r\\nFor participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day', 'From Day 1 to Day 21, co-trimoxazole will be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.\\r\\nFor participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day']\n",
      "['Dose 1 : 100 mg/kg of Betaine', 'Dose 2 : 250 mg/kg of Betaine']\n",
      "['Participants will receive vitamin C in addition to active comparator treatment:\\r\\nInpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;\\r\\nPlus Active Comparator treatment:\\r\\nHydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days', 'Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days']\n",
      "['Evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.', 'Pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.']\n",
      "['patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes']\n",
      "['Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).', 'In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).']\n",
      "['Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC', 'Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate']\n",
      "['Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.']\n",
      "['Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)']\n",
      "['Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.']\n",
      "['Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.', 'Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.']\n",
      "['All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.']\n",
      "['Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.', 'Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.', 'Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.', 'Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.', 'Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.', 'Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.', 'Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.']\n",
      "['BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.\\r\\nCycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21.']\n",
      "['Standard Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants without prior treatment pembrolizumab or nivolumab Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)', 'Standard Chemo Prep Regimen Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants previously treated with pembrolizumab or nivolumab.\\r\\nStandard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)', 'Decreased Chemo Prep Regimen+Retreat. Young TIL+High Dose Interleukin-2, Decreased Chemo Preparative Regimen. Young TIL+High Dose Interleukin-2, Standard Chemo (Retreat). Lower dose preparative regimen + Young TIL Cells. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days. Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 300 mg/m^2 IV over 60 minutes. Young TIL: Day 0: Cells will be infused IV. Retreatment: Standard Chemo Prep Regimen. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide: 60 mg/kg/day X 2 days IV. Young TIL: Day 0: Cells will be infused IV.', 'Decreased Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2 Lower Dose preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).\\r\\nFludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 30 mg/kg IV over 60 minutes for 2 days.\\r\\nYoung TIL: Day 0: Cells will be infused intravenously (IV)', 'Standard Chemo Prep Regimen(SCPR)+Retreat. Young TIL+High Dose(HD) Interleukin-2, SCPR. Young TIL+HD Interleukin-2, SC(Retreat). SCPR+Young TIL Cells retreatment with SCPR+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kgIV every eight hours (+/-1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back(IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL:Day 0: Cells will be infused IV. Retreatment with standard preparative regimen+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL: Day 0:Cells will be infused IV. Pembrolizumab:2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).']\n",
      "['Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).']\n",
      "['Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours', 'Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours']\n",
      "['Patients with localized disease will receive six cycles of the combination as \"maintenance\" therapy following standard chemotherapy.\\r\\nCycles 4-6 will include:\\r\\nIfosfamide 2,800 mg/m2/day on days 1-5\\r\\nEtoposide 100 mg/m2/day on days 1-5\\r\\nCycle 7 will include :\\r\\nCyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day\\r\\nDoxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day\\r\\nVincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)\\r\\nCycles 8-13 will include:\\r\\nIrinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously\\r\\nTemozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously', 'Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.\\r\\nCycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:\\r\\nIrinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously\\r\\nTemozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously\\r\\nCycles 6, 9, and 12 will include:\\r\\nIfosfamide 2,800 mg/m2/day on days 1-5\\r\\nEtoposide 100 mg/m2/day on days 1-5\\r\\nCycle 15 will include:\\r\\nCyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day\\r\\nDoxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day\\r\\nVincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)']\n",
      "['The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.']\n",
      "[\"Participants received the first intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) 120 milligrams per kilogram (mg/kg), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8 (second dose was not mandatory and was given at the principal investigator's [PI] discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.\", \"Participants received IV infusions of 0.9% normal saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 (Day 8 was not mandatory and was given at the PI's discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.\"]\n",
      "['Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.']\n",
      "['Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.']\n",
      "['All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.']\n",
      "[\"Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.\", \"Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29\"]\n",
      "['Conditioning:\\r\\nfludarabine 180 mg/m2 busulfan 8-14 mg/kg per os\\r\\nGVHD prophylaxis:\\r\\ncyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35', 'Conditioning:\\r\\nfludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2\\r\\nGVHD prophylaxis:\\r\\ncyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150']\n",
      "['High Dose Arm\\r\\nWash-out then 7 days of:\\r\\nArg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA', 'Low Dose Arm\\r\\nWash-out followed by 7 days of:\\r\\nArg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA']\n",
      "['Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day', 'Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.', 'Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide']\n",
      "['Patients randomized to Control group will receive placebo (D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study.', 'Patients randomized to Study group will receive fomepizole (diluted in D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study. If randomized to Study group, the participant will receive fomepizole in a fixed dose relative to acetylcysteine. The fixed ratio is acetylcysteine 10 : 1 fomepizole. In the first 20-21 hours (2 vs. 3-bag regimen), a total of 30 mg/kg fomepizole is delivered.']\n",
      "['Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).', 'Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg']\n",
      "['Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks', 'Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks', 'Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks', 'Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm']\n",
      "['7.1.1 HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought (see 7.2 for definition of response) (Maximum of 4 dose levels) (7.1.2):']\n",
      "['Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.']\n",
      "['This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.\\r\\nAll patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.\\r\\nAfter the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.\\r\\nClinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent.']\n",
      "['Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.']\n",
      "['Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.']\n",
      "['66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.']\n",
      "['Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.', 'Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.']\n",
      "['The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.']\n",
      "['Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks', 'Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks']\n",
      "['Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).']\n",
      "['Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.\\r\\nStep 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.\\r\\nVRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.\\r\\nStep 3: SOC oral ART regimen for approximately 48 weeks.']\n",
      "['150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline', '150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline', '150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.', '150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.']\n",
      "['Study Drug given IV every 28 days at 24mg/kg', 'Placebo']\n",
      "['60 mg/kg/day']\n",
      "['7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.', '7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.', '7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.']\n",
      "['The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.', 'Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.']\n",
      "['Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours', 'Normal saline (240mL) intravenous infusion over 12 hours']\n",
      "['Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.']\n",
      "['Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W']\n",
      "['Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.', 'Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..', 'Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.', 'Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.', 'Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.', 'Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.']\n",
      "['PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.\\r\\nCapecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks\\r\\nPART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration.']\n",
      "[\"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).\\r\\nPrednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\ncyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\", \"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).\\r\\nPrednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\nmycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\", \"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.\\r\\nLeflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.\\r\\nAngiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.\"]\n",
      "['KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles']\n",
      "['Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.', 'Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.', \"Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.\"]\n",
      "['25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days', '50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days', '75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days']\n",
      "['Single dose intravenous vinblastine (6mg/m2) in bolous.', 'Patient will recieve oral hydroxiurea at a dose of 50mg/kg/day until response or administration of induction chemotherapy']\n",
      "['SP-420, 28 mg/kg, three times weekly for 48 weeks', 'SP-420, 56 mg/kg, three times weekly for 48 weeks', 'SP-420, 84 mg/kg, three times weekly for 48 weeks']\n",
      "['Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days', 'Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days']\n",
      "['Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg of cefiderocol and participants ≥34 kg will receive 2000 mg.', 'Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.']\n",
      "['60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously', '1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously']\n",
      "['Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection\\r\\nDrug: melphalan 200 mg/kg over 2 days\\r\\nProcedure/Surgery: autologous peripheral blood stem cell transplantation\\r\\nautologous peripheral blood stem cell transplantation']\n",
      "['Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.', 'Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.', 'Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.']\n",
      "['After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w']\n",
      "['Evorpacept (ALX148) 45 mg/kg IV and pembrolizumab 200 mg IV given every 3 weeks.', 'Pembrolizumab 200 mg IV given every 3 weeks.']\n",
      "['patients receive 6 mg/kg oxfendazole once', 'patients receive 30 mg/kg oxfendazole once', 'patients receive 6 mg/kg oxfendazole three times', 'patients receive 400 mg albendazole once']\n",
      "['Busulfan/Cyclophosphamide, \"standard\" conditioning regimen as a control group. including Bu3.2mg/kg -5~-3d; Cy 80mg/kg，-2~-1d。 or alternative Bu/Cy regimen, Bu3.2mg/kg -9~-7d；Flu 30mg/m2 -6~-4d；Ara-C 2g/m2 -6~-4d；Cy 80mg/kg -3~-2d。', 'using MCBC as conditioning regimen, Mel 60mg/ m2 -9~-8d, Cladribine 5 mg/m2 -9~-5d, Bu3.2mg/kg -5~-3d； Cy 30mg/kg -2~-1 d']\n",
      "['Target dose 20 mg/kg Docosahexaenoic acid', 'Target dose 36 mg/kg Docosahexaenoic acid', 'Target dose 60 mg/kg Docosahexaenoic acid', 'Soybean oil']\n",
      "['Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.', 'Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.', 'Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.']\n",
      "['2:1 in favour of UDCA', 'UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.']\n",
      "['Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.']\n",
      "[\"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.\\r\\nTable 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg\\r\\n*Max dose not to exceed 2700mg/day (1350mg BID)\"]\n",
      "['Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours', 'Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours']\n",
      "['100 mg/kg T.I.D 3x a day IV or PO', 'Saline or sugar pill']\n",
      "['All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses\\r\\nAll patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles\\r\\nThe first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab\\r\\nThe schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)', 'All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses\\r\\nAll patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles.']\n",
      "['Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)', 'Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.']\n",
      "['This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.', 'This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.']\n",
      "['NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype \"A\" serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg..']\n",
      "['Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.\\r\\nPatients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.\\r\\nMMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.', 'Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.\\r\\nPatients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.\\r\\nMMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.', 'Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.\\r\\nSirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.\\r\\nMMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS.']\n",
      "['Meropenem 6g IV over 6 hours plus amoxicillin/CA', 'Ertapenem 1g IM plus amoxicillin/CA', 'Meropenem 3g over 1 hour twice daily plus amoxicillin/CA', 'Ertapenem 1g IV plus amoxicillin/CA', 'Amoxicillin; CA', 'Rifampicin 35mg/kg plus amoxicillin/CA', 'Meropenem 6g or 4g IV over 60 minutes plus amoxicillin/CA', 'Rifafour e-275']\n",
      "['Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2']\n",
      "['Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)', 'Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours']\n",
      "['divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks']\n",
      "['Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.', 'Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.']\n",
      "['Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).\\r\\nPhase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).\\r\\nPhase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days', 'Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days']\n",
      "['1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.']\n",
      "['Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.']\n",
      "['Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an \"add-on\" therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.\\r\\nThe dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours.', 'Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an \"add-on\" therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.\\r\\nThe placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm).']\n",
      "['Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.']\n",
      "['All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).']\n",
      "['Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).']\n",
      "['BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.\\r\\nAvonex once-weekly intramuscular (IM) injection up to Week 84.', 'BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.', 'Placebo once every 4 weeks IV infusion up to Week 72.\\r\\nAvonex once-weekly IM injection up to Week 84.']\n",
      "['Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.\\r\\nCefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present\\r\\nRanitidine 5 mg/kg IV, q.d. for 2 days\\r\\nAmoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.', 'Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.\\r\\nCefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.\\r\\nRanitidine 5 mg/kg IV, q.d. for 2 days.\\r\\nAmoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.']\n",
      "['Saline dose', 'Low Dose Ketamine (.20 mg/kg)', 'High Dose Ketamine (.50 mg/kg)']\n",
      "['In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.', 'In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.']\n",
      "['. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days', 'group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.']\n",
      "[\"Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29.\", \"Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29.\"]\n",
      "['4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks', 'Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks']\n",
      "['Placebo plus cognitive behavioral therapy', 'Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy']\n",
      "['BCD-100 mg/kg Q3W']\n",
      "['Intravenous injection of 0,25 mg/kg Indocyanine Green']\n",
      "['Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours', 'Group 2 : \"Ketoprofen quarter dose\" (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours.', 'Group 3 : \"Ketoprofen half-dose\" (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours.', 'Group 4 : \"Ketoprofen full dose\" (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours']\n",
      "['Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.']\n",
      "['PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).']\n",
      "['Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.\\r\\nCells for infusion are prepared using the CliniMACS system.']\n",
      "['25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days']\n",
      "['The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).']\n",
      "['Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.']\n",
      "['Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).', 'Standard of care anti-TB therapy as described in Arm 1,\\r\\nPlus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days).', 'Standard of care anti-TB therapy as described in Arm 1,\\r\\nPlus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),\\r\\nPlus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)']\n",
      "['Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg cefiderocol and participants ≥34 kg will receive 2000 mg.', 'Participants will receive cefiderocol administered via IV every 8 hours for an expected 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.', 'Participants will receive standard of care treatment according to local standards.']\n",
      "['Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant']\n",
      "['- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.', '- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.']\n",
      "['All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.\\r\\nParticipants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days.']\n",
      "['SURFAXIN (lucinactant) at 175 mg/kg', 'SURFAXIN (lucinactant) at 90 mg/kg', 'Sham air using 3.0 mL/kg volume of air']\n",
      "['In case of bleeding and:\\r\\nCT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;\\r\\nMCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;\\r\\nCT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg.']\n",
      "['Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.']\n",
      "['Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.', 'Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.', 'Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.']\n",
      "['Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks', 'Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks', 'Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment']\n",
      "['Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.']\n"
     ]
    }
   ],
   "source": [
    "# 计算Q1和Q3及IQR\n",
    "Q1 = data.quantile(0.25)\n",
    "Q3 = data.quantile(0.75)\n",
    "IQR = Q3 - Q1\n",
    "\n",
    "# 定义离群点的界限\n",
    "lower_bound = Q1 - 1.5 * IQR\n",
    "upper_bound = Q3 + 1.5 * IQR\n",
    "\n",
    "# 计算离群点的个数\n",
    "outliers = data[(data < lower_bound) | (data > upper_bound)]\n",
    "num_outliers = outliers.count()\n",
    "\n",
    "print(\"Number of outliers:\", num_outliers)\n",
    "print(\"Outliers:\", outliers.tolist())\n",
    "\n",
    "# 检查离群点\n",
    "outliers_nctid = maxedge[(maxedge['maxedge'] < lower_bound) | (maxedge['maxedge'] > upper_bound)].index\n",
    "for nctid in set(list(outliers_nctid)):\n",
    "    print(dose['dose_description'][nctid])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8, 4))\n",
    "maxedge['maxedge'].hist(bins=50)\n",
    "plt.title('Data Distribution')\n",
    "plt.xlabel('Value(mg)')\n",
    "plt.ylabel('Frequency')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[  0.    16.64  33.28  49.92  66.56  83.2   99.84 116.48 133.12 149.76\n",
      " 166.4  183.04 199.68 216.32 232.96 249.6  266.24 282.88 299.52 316.16\n",
      " 332.8  349.44 366.08 382.72 399.36 416.   432.64 449.28 465.92 482.56\n",
      " 499.2  515.84 532.48 549.12 565.76 582.4  599.04 615.68 632.32 648.96\n",
      " 665.6  682.24 698.88 715.52 732.16 748.8  765.44 782.08 798.72 815.36\n",
      " 832.  ]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "hist, bin_edges = np.histogram(data, bins=50)\n",
    "max_bin_index = np.argmax(hist)\n",
    "max_bin_start = bin_edges[max_bin_index]\n",
    "max_bin_end = bin_edges[max_bin_index + 1]\n",
    "mode_bin_data = data[(data >= max_bin_start) & (data < max_bin_end)]\n",
    "print(bin_edges)\n",
    "plt.figure(figsize=(8, 4))\n",
    "mode_bin_data.hist(bins=50)\n",
    "plt.title('Data Distribution')\n",
    "plt.xlabel('Value(mg/kg)')\n",
    "plt.ylabel('Frequency')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8, 4))\n",
    "maxedge['maxedge'].plot(kind='box')\n",
    "plt.title('Box Plot of Data')\n",
    "plt.ylabel('Value')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "def drug_hit_smiles(drug, drug2smiles):\n",
    "\t\"\"\"\n",
    "\t\theuristics\n",
    "\t\"\"\"\n",
    "\tif drug in drug2smiles:\n",
    "\t\treturn drug2smiles[drug]\n",
    "\tfor word in drug.split():\n",
    "\t\tif len(word)>=7 and word in drug2smiles:\n",
    "\t\t\tprint(\"drug hit: \", drug, '&', word)\n",
    "\t\t\treturn drug2smiles[word]\n",
    "\treturn None \t\n",
    "\n",
    "def xml2smiles(xml_file):\n",
    "\ttree = ET.parse(xml_file)\n",
    "\troot = tree.getroot()\n",
    "\tpkl_file = \"../data/drug2smiles.pkl\"\n",
    "\tdrug2smiles = pickle.load(open(pkl_file, 'rb'))\n",
    "\n",
    "\tinterventions = [i for i in root.findall('intervention')]\n",
    "\tdrugs = [i.find('intervention_name').text.lower() for i in interventions \\\n",
    "\t\t\t\t\t\t\t\t\t\t\t\t\t\tif i.find('intervention_type').text=='Drug']\n",
    "\tsmiles_lst = []\n",
    "\tfor drug in drugs:\n",
    "\t\tsmiles = drug_hit_smiles(drug, drug2smiles)\n",
    "\t\tif smiles is not None: \n",
    "\t\t\t\t\t# drug_hit += 1\n",
    "\t\t\tsmiles_lst.append(smiles)\n",
    "\t\telse:\n",
    "\t\t\tprint(\"unfounded drug: \", drug)\n",
    "\treturn smiles_lst"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "smile_list = []\n",
    "\n",
    "with open(\"../../data/all_xml\", \"r\") as file:\n",
    "    for xml_path in tqdm(file):\n",
    "        xml_path = f\"../../{xml_path.strip()}\"\n",
    "        \n",
    "        # NCT00000150 <- raw_data/NCT0000xxxx/NCT00000150.xml\n",
    "        nct_id = re.search(r\"/([^/]+)\\.xml$\", xml_path).group(1)\n",
    "        \n",
    "        smile = xmlfile2text(xml_path)\n",
    "\n",
    "        smile_list.append((nct_id, smile))\n",
    "\n",
    "smile_df = pd.DataFrame(smile_list, columns=['ntcid', 'smile'])\n",
    "smile_df = smile_df.set_index('ntcid')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
